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There are well established links between abnormal fetal kidney development and increased risk of 
developing chronic kidney disease (CKD), hypertension and cardiovascular disease later in life. 
Abnormal fetal growth may adversely impact kidney development and in particular, the number 
and quality of the functional units of the kidney known as nephrons. We need a better 
understanding of how an adverse intrauterine environment may alter nephrogenesis. Currently 
there is no sensitive, non-invasive, in-vivo method for assessing fetal kidney growth to assess the 
number and quality of fetal nephrons. This thesis used a novel ultrasound measurement of the 
fetal renal parenchyma along with fetal renal artery Doppler measurements to evaluate fetal renal 
growth and provide an indirect estimate of nephron number. The effects of growth restriction, 
overgrowth and diabetes on the developing kidneys was explored. The main aim of this thesis was 
to assess fetal renal parenchymal development and fetal renal blood flow through serial ultrasound 
measurements of pregnant women demonstrating either normal or abnormal fetal growth and 
determine if abnormal fetal growth impacts fetal renal parenchymal growth.  
Methods 
A prospective, longitudinal, observational study was conducted among a cohort of mixed-risk 
pregnant women at the Townsville University Hospital, Australia. Serial ultrasound measurements 
were performed approximately every four weeks between 16 to 40 weeks gestational age and 
multiple novel fetal renal measurements were taken as well as routine fetal measurements. Using 
mixed effects modelling, the normal range of fetal renal parenchymal thickness and fetal renal 
artery blood flow were established. Subsequently, the fetal renal parenchymal thickness and fetal 
renal artery Doppler flow were compared between different groups of pregnant women to analyse 
the effects of growth restriction, overgrowth and diabetes on the developing kidneys using mixed 
xi 
effects modelling. An ANOVA model was used to evaluate intra and interobserver reliability of 
the fetal renal measurements and fetal renal Doppler traces.  
Results 
In all, 155 participants were recruited. Seven participants were excluded, six for fetal or 
chromosomal abnormality and one who did not attend any ultrasound appointments. This resulted 
in 148 participants remaining in the study. Standard charts of the normal ranges of fetal renal 
parenchymal thickness, kidney length and kidney volume, and fetal renal artery resistivity index 
(RI) and pulsatility index (PI) were developed from a group of low-risk pregnant women (N = 72). 
The intraclass correlation coefficient (ICC) for the fetal renal parenchymal measurements was 
excellent for both intraobserver reliability (ICC = 0.97) and interobserver reliability (ICC = 0.96). 
For the fetal renal artery RI and PI, the reliability was moderate for the intraobserver (RI = 0.66, 
PI = 0.88) and poor for the interobserver reliability (RI = 0.11, PI = -0.56). 
Thirty fetal growth restricted (FGR) fetuses were compared to 102 appropriate for gestational age 
(AGA) fetuses. The fetal renal parenchymal thickness was seen to be thinner in the growth 
restricted fetuses (likelihood ratio (LR) = 21.06, p =<0.0001) and their renal parenchyma had a 
slower growth trajectory. In fetuses with the same head circumference, a growth restricted fetus 
was more likely to have a thinner renal parenchyma than an AGA fetus. No significant difference 
was seen in the RI (p = 0.182) or PI (p = 0.554) of the fetal renal arteries between the FGR and 
AGA groups.  
Sixteen pregnancies resulted in infants who were large for gestational age (LGA). The fetal renal 
parenchymal thickness for these fetuses were compared to 102 AGA fetuses. The LGA group had 
fetal renal parenchyma that was significantly thicker than the AGA group (LR = 6.1, p = 0.013), 
however, the renal parenchymal thickness was proportional to the overall size of the fetus. No 
xii 
significant difference was seen in the RI (p = 0.403) or PI (p = 0.956) of the fetal renal arteries 
between the LGA and AGA groups. 
Finally, the renal parenchymal thickness of a group of 55 women with diabetes in pregnancy (46 
with gestational diabetes and 9 with pregestational diabetes) were compared to a control group of 
low-risk pregnant women (N = 72). The fetal renal parenchyma was significantly thicker in the 
fetuses of mothers with gestational diabetes than the fetuses in the control group (LR = 4.8, p = 
0.029), however, the renal parenchymal thickness was proportionate to the overall size of the fetus. 
In the pregestational diabetes group the fetal renal parenchyma was not significantly thicker than 
those in the control group even though these fetuses were significantly larger. Therefore, in 
contrast to the fetuses of mothers with gestational diabetes, the renal parenchyma of fetuses of 
mothers with pregestational diabetes was thinner than expected considering the overall size of the 
fetus. 
Conclusions 
Measurement of the fetal renal parenchyma is an easy to perform, non-invasive single 
measurement to evaluate changes in fetal kidney growth and indirectly estimate nephron 
endowment. The charts of the normal ranges of fetal renal parenchymal thickness can be utilised 
in clinical practice together with established measurements of renal size. Alterations from these 
normal ranges may be utilised to improve the identification of infants at a higher risk of future 
kidney disease and hypertension. The fetal renal parenchymal thickness could be combined with 
other markers to assist in the diagnosis of renal parenchymal pathologies. Monitoring and support 
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Chapter. 1 Introduction and Background 
1.1 Chronic Kidney Disease 
Globally, chronic kidney disease (CKD) is an important, under recognised and neglected chronic 
disease.1-3 Additionally, CKD has strong associations, if not causative pathogenesis with other 
major diseases, such as hypertension, cardiovascular disease and diabetes, which is often 
underestimated.1, 4 Deaths from kidney disease continue to escalate globally with an increase in 
deaths of 41% from 1990 to 2017.3 In recent Australian data, 1 in 9 deaths have CKD as a primary 
and/or associated cause of death.5 CKD is a condition of the kidney which is diagnosed when 
abnormal biomarkers of kidney function or damage that persists for three or more months.5 CKD 
arises from a multitude of pathological processes that adversely impact the kidney. A reduction in 
the functional units of the kidney (nephrons) results in hyperfiltration of the remaining nephrons 
followed in time by glomerular hypertension and hypertrophy, proteinuria and the progressive 
advancement of CKD.6 Patients with CKD typically present with hypertension, proteinuria and a 
progressive decline in glomerular filtration rates (GFR). The pathological insults that give rise to 
CKD may also occur in-utero, in infancy or childhood, and acute kidney injury in childhood has 
been shown to precede the chronic sequelae of CKD.7, 8 
Abnormalities in normal fetal growth, such as fetal growth restriction and preterm birth, have been 
shown to have a profound effect on the development of the fetal kidney.9, 10 An adverse 
intrauterine environment may therefore result in a reduced nephron number and an increased risk 
of developing CKD later in life.11-13 Consequently, the normal development of the fetal kidneys is 
crucial to an individual’s long-term health outcomes. Expert advice suggests acting early to 
optimise fetal and child health to prevent the development of CKD and hypertension.2, 14, 15 This 
firstly requires understanding and recognition of CKD risk factors so that preventative strategies 
can be implemented to reduce these risks.   
2 
1.2 Kidney Anatomy and Physiology 
The kidneys play an essential role in keeping a human body functioning with over 180 litres of 
blood filtered by the kidneys per day.16 The two bean-shaped organs extract waste from the blood, 
balance body fluids, form urine and maintain a stable extracellular environment to support the 
function of all body cells.17 Kidneys maintain the water and electrolyte balance by controlling the 
excretion of substances such as water, sodium, potassium, chloride, calcium, magnesium, 
phosphate and by managing acid-base status.17 Via the renin-angiotensin-aldosterone system, the 
kidneys also modulate blood pressure.16 Each kidney is normally supplied by one main renal artery, 
which arises from the lower aorta.18 The three main internal parts of the kidney are the renal cortex, 
medulla and pelvis17 (Fig 1.1). 
 
Figure 1.1 The three main internal parts of the kidney – renal cortex, renal medulla and 
renal pelvis17. The renal parenchyma refers to the combined cortex and medulla. Source: 
Adapted from Image by Balik from Pixabay https://pixabay.com/illustrations/kidney-
cross-section-medical-organ-2183443/. 
3 
1.3 Kidney Development and Nephrogenesis 
The human kidney develops through three successive embryonic stages. Transient development 
and regression of the primary (pronephros) and secondary (mesonephros) occurs between day 23 
and day 112 of life.19 These primitive fetal kidneys serve as temporary excretory organs. The 
definitive, tertiary fetal kidney is the metanephros and this matures into the fully functional 
permanent kidney. The metanephros begins developing in the fifth week and leads to the 
formation of nephrons through a process known as nephrogenesis.19, 20 
Nephrons are the functional units within the kidney. Each nephron is comprised of a glomerulus, 
proximal tubule, loop of Henle and distal tube. Their role is to filter blood, reabsorb water, excrete 
waste and perform some endocrine functions.20, 21 New nephrons are formed through successive 
branching of the ureteral bud, with concentric layers of nephrons proceeding outwards. Hence, 
the newest nephrons are in the outer layer and any disruption to nephrogenesis results in fewer 
layers of nephrons.12, 22 Fetal kidneys are unlike most other fetal organs in that the maximum cell 
proliferation occurs in the third trimester. Nephrogenesis continues up until 34 to 36 weeks 
gestation with approximately 60% of nephrons formed in the third trimester.23 An autopsy study 
of a small number of term infants, demonstrated there were four to five glomerular layers around 
22 weeks gestational age, with the formation of another new glowerular layer every four weeks, 
layering out towards the outer cortex.24 Once nephrogenesis is complete, no new nephrons are 
formed, providing the maximum number of nephrons an individual will have at this point in 
life.23,24 It is therefore essential that appropriate nephrogenesis is supported in-utero, as the number 
and quality of nephrons directly influences kidney function throughout life.25  
A normal healthy kidney contains around one million nephrons, however, autopsy studies of 
human kidneys demonstrate a wide variation of between 200,000 to over 2.5 million nephrons per 
kidney.10, 26, 27 This wide range in nephron number is attributed primarily to uterine environmental 
factors during nephrogenesis, as well as genetic factors.2 After birth, exposure to a variety of 
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different stressors, such as renal infections, smoking, drugs and poor nutrition along with the loss 
of renal function that occurs with increasing age lead to a further reduction in nephron 
endowment.28 These secondary insults on those individuals with an already depleted nephron 
number is what exacerbates the occurrence of renal disease (Fig 1.2).14, 28, 29 The main determinant 
of life-long nephron number and kidney function is nephrogenesis in-utero. Insults during 
intrauterine life and the first few weeks of life can induce lasting structural and functional changes 
not just to the kidneys but, to many aspects of the developing fetus. This process is termed 





Figure 1.2 Demonstration of how the intrauterine environment can influence nephron 
number at birth which is then followed by insults to the kidney over the life course that 
can lead to further reductions in nephron number and possibly chronic kidney disease. 
Source: D. Brennan. 
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1.4 Developmental Origins of Health and Disease 
Barker and colleagues, in the late 80’s, first proposed the hypothesis that adult diseases could have 
origins in an adverse environment in-utero and in early life.31 This concept later became known as 
developmental origins of health and disease and is now well established and accepted.32, 33 The 
basis of the concept is that during the human body’s development, its structure and function are 
vulnerable and permanently programmed by intra-uterine and early post-natal environment.30, 31 
Barker et al. initially identified that increased rates of cardiovascular disease and chronic bronchitis 
were associated with a low birth weight.31 Since then an adverse intrauterine environment has been 
associated with many other chronic conditions such as hypertension, obesity, type 2 diabetes and 
CKD.34, 35 Barker suggested that the early environment can be thought of as the trigger for 
branching pathways for the development of diseases. These pathways in turn determine each 
individual’s susceptibility to future health consequences.34 
Studies have now demonstrated that an adverse intrauterine environment is associated with CKD 
and hypertension.11, 36 Compromised intrauterine conditions are thought to effect fetal kidney 
evolution resulting in a reduced nephron endowment which, can later in life, result in essential 
hypertension and reduced kidney function.14, 37, 38 There is strong evidence that fetal growth 
restriction can impact on kidney development, however less evidence is available to demonstrate 
the relationship between fetal overgrowth or diabetes during pregnancy and kidney growth and 
development.9, 10, 15, 38-40 
1.5 Fetal Growth 
The growth of a fetus is determined by genetic factors and the uterine environment.41 Maternal 
health status prior to and during pregnancy is also an important determinant of fetal growth and 
well-being.42, 43 Nutrition and oxygen are delivered to the fetus via the placenta.44 Consequently, 
anything that affects the placental function or interferes with this supply may impact on fetal 
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growth. Abnormal growth may be restrictive, such as is seen in placental insufficiency which results 
in a slowing of fetal growth, or may result in an acceleration of fetal growth as a result of an 
increase in placental transfer, such as occurs in pregnancies complicated by diabetes and the 
associated pathologically increased glucose availability.41  
1.6 Fetal Growth Restriction 
Fetal growth restriction (FGR) is defined as growth of a fetus below its genetically determined 
growth potential.45, 46 FGR is a major cause of morbidity and mortality and is also believed to lead 
to a predisposition for a range of diseases later in life.34, 45, 46 The pathogenesis of FGR is 
multifactorial and includes placental, maternal and fetal causes (Fig 1.3). FGR is usually due to 
utero-placental causes with a restriction in oxygen and nutrient supply to the fetus, resulting in 
chronic hypoxia and under nutrition.46, 47 The fetus compensates for hypoxia by centralising the 
fetal circulation via preferentially shunting blood, rich in nutrients and oxygen, away from organs 
such as the kidneys and bowel towards more essential organs such as the heart, brain and 
adrenals.47 The difficulty in studies involving FGR is based on the lack of a gold standard for its 




Figure 1.3 A variety of placental, maternal and fetal factors can individually, or in 
combination, cause fetal growth restriction46, 47. Source: D. Brennan. 
8 
1.7 Defining Fetal Growth Restriction and Small for Gestational Age 
Previously, fetal weight centile cut-offs, such as an estimated fetal weight below the 10th centile or 
5th centile were commonly used to identify FGR, however this simplistic approach is not accurate 
or ideal.49 The term small for gestational age (SGA) is used to refer to a constitutionally small, but 
healthy fetus and FGR for a fetus that is pathologically small.  Difficultly arises when differentiating 
between these two groups.  There is also a group of fetuses that will be in the normal weight range 
at birth but are, in fact, growth restricted because they did not reach their potential size. The single 
largest risk of stillbirth is FGR; however, 50% of stillbirths are within the normal weight range.50 
In addition to measuring fetal biometry, Doppler assessment of maternal and fetal blood flow is 
being utilised to identify pregnancies at risk of FGR, affected by FGR or to identify fetal 
compensation or decompensation in the presence of FGR and placental insufficiency.45, 49, 51, 52 
Presently, there is no definitive measure to distinguish FGR from SGA fetuses.45, 48  
In an attempt to obtain an international consensus on the identification of FGR, a Delphi survey 
was conducted internationally among 45 experts in fetal growth disorders and was published in 
2016.53 Early FGR was defined as growth restriction identified prior to 32 weeks gestation and late 
FGR as identified from 32 weeks and greater. For this thesis the criteria for classification of FGR 




Classification of fetal growth restriction (FGR)  
Early FGR: Gestational Age < 32 weeks Late FGR: Gestational Age ≥ 32 weeks 
• AC or EFW < 3rd centile or UA - AEDF • AC or EFW < 3rd centile 
Or Or at least two of the following 
• AC or EFW < 10th centile combined with  • AC or EFW < 10th centile 
• Uterine artery - PI > 95th centile and/or • AC or EFW crossing centiles > 2 quartiles 
• UA-PI > 95th centile • CPR < 5th centile or UA-PI > 95th centile 
Note: AC, abdominal circumference; AEDF, absent end diastolic flow; CPR, cerebroplacental ratio; EFW, 
estimated fetal weight; FGR, fetal growth restriction; PI, pulsatility index; UA, umbilical artery. (based on 
Gordijn et al.53). 
 
1.8 Fetal Growth Restriction and Kidney Development 
Low birth weight, preterm birth and FGR are all intricately linked.54, 55 Low birth weight may be 
due to FGR or preterm birth or a combination of both and FGR is associated with both 
spontaneous and iatrogenic preterm birth.55, 56 Both FGR and preterm birth can adversely impact 
kidney development and often both occur together, increasing the risk of renal insults.38 There is 
strong evidence that a low birth weight is associated with an increased risk of CKD and 
hypertension later in life and these increased risks are assumed to be due to depleted layers of 
nephrons. 9, 34, 37, 57, 58 True nephron number, however, can currently only be determined at autopsy. 
Human autopsy studies have demonstrated reduced nephron numbers in those born with a low 
birth weight compared to a normal birth weight, with one study reporting a 20% reduction in 
nephron numbers in low birth weight infants.9, 10, 26, 28 An autopsy study investigating preterm 
infants, some of which were also growth restricted, observed that up to 13% of the glomeruli 
within the nephrons were abnormally formed.25 Animal models have also established other factors 
such as low protein intake, maternal chronic diseases, relative vitamin A deficiency and 
administration of steroids late in the pregnancy can result in FGR and impaired nephrogenesis, 
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resulting in a reduction in nephron numbers.59-62 A low birth weight has been demonstrated to be 
a significant factor in final nephron number and quality, however, this has not yet been confirmed 
in vivo as presently we do not have an accurate non-invasive method to estimate nephron numbers 
during development. 
Most studies on the effect of low birth weight on kidney development and future CKD and 
hypertension have not separately analysed low birth weight due to either FGR or to preterm 
birth.37, 38 Studies usually use the standard definition of low birth weight as newborns weighing less 
than 2,500 grams.63 Many neonates may not reach the standard definition of low birth weight, but 
they did however, experience FGR and they would not be included in the studies. Further studies 
are required to define specifically the role FGR and preterm birth has on nephrogenesis, as one 
occurs in-utero and one occurs after birth. 
1.9 Fetal Overgrowth 
Large for gestational age (LGA) is most commonly defined as having an estimated fetal weight 
(EFW) greater than the 90th centile and macrosomia as a birth weight greater than 4,000 grams.64 
The use of the term LGA is preferred over macrosomia as macrosomia is only concerned with 
birth weight and does not factor in gestational age.41 For this thesis neonates were classified as 
LGA if their birth weight was greater than the 90th centile using the Hadlock et al. fetal weight 
charts.65 The main risk factors for fetal overgrowth are obesity, maternal weight gain and 
pregestational and gestational diabetes mellitus.41, 66 Almost half the women in Australia who gave 
birth in 2018 were overweight or obese; 21% were obese (BMI ≥30), 26% were overweight (BMI 
of 25.5 – 29.9), 49.5% were within the normal weight range (BMI of 18.5 – 24.9), whilst the 
remaining women were underweight (BMI <18.5).67 Fetal overgrowth is a serious condition that 
is associated with increased risks to the mother and infant, such as instrumental delivery, 
emergency caesarean section, shoulder dystocia and trauma to the birth canal.64, 68 
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1.10 Fetal Overgrowth and Kidney Development 
There is mounting evidence of the long-term health risks for infants born LGA, such as obesity 
and metabolic syndromes.69-71 These conditions are both strong risk factors for CKD and 
hypertension.72, 73 Furthermore, there are emerging indications that a high birth weight may be 
associated with CKD and hypertension.40, 71 The findings are more equivocal than those studies 
investigating low birth weight and kidney disease. In one study a high birth weight was associated 
with an increased risk of hypertension in children, but a decreased risk in adulthood.40 Another 
study found no significant increase in kidney disease in children less than 21 years of age who were 
born LGA74 Considering, however, that the causes of a high birth weight are thought to have 
programming effects on the fetus and that there is an increased likelihood of obesity and metabolic 
syndromes for these infants, further research is warranted to attempt to understand the variations 
in the data. Additionally, fetal overgrowth, when related to maternal hyperglycaemia, appears to 
be associated with an increased risk of proteinuria and kidney disease later in life and this requires 
further investigation.40, 71 
1.11 Diabetes in Pregnancy 
Diabetes in pregnancy is a significant and increasingly common complication of pregnancy which 
is exacerbated by an increasing prevalence of obesity and increasing maternal age of pregnant 
women.75, 76 Gestational diabetes mellitus is diabetes that is first identified during pregnancy and 
pregestational diabetes denotes diabetes mellitus (usually type 1 or type 2 diabetes) that exists prior 
to pregnancy.76 In Australia, in 2018, around 40,000 (13.5%) of pregnant women had gestational 
diabetes and around 2,500 (0.8%) had pregestational diabetes.67 
During pregnancy, increased maternal insulin resistance facilitates adequate transfer of the essential 
nutrient glucose to the fetus.76, 77 However, this does predispose the mother to maternal 
hyperglycaemia which results in abnormally high circulating levels of glucose.75, 76 Maternal 
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hyperglycaemia  is associated with increased adverse maternal and neonatal outcomes, such as a 
birth weight above the 90th centile, preterm delivery and birth trauma.75, 78 In 2008, the 
Hyperglycemia and Adverse Pregnancy Outcomes (HAPO) study reported that even minor 
degrees of hyperglycaemia during pregnancy were associated with adverse outcomes.78 These 
findings resulted in reclassification of the criteria for the diagnosis of gestational diabetes which 
were adopted by the Australasian Diabetes in Pregnancy Society (ADIPS) in late 2014.79, 80 For this 
thesis, the diagnosis of gestational diabetes was based on the ADIPS guidelines which are 
consistent with the International Association of the Diabetes and Pregnancy Study Groups 
(IADPSG) guidelines and are outlined in Table 1.2.79, 80 
Table 1.2  
Criteria for the diagnosis of gestational diabetes based on ADIPS guidelines79 
 Glucose measure Blood glucose level 
Diagnosis of gestational 
diabetes if one or more 
criteria are met 
Fasting overnight ≥ 5.1mmol/L 
1 hr - following 75g oral glucose load ≥ 10.0mmol/L 
2hr – following 75g oral glucose load ≥ 8.5mmol/L 
 
Maternal glucose can easily cross the placenta, however, insulin does not. Therefore, if the mother 
is hyperglycaemic, the fetus must secrete additional insulin.81 Fetal hyperglycaemia and 
hyperinsulinaemia can result in: 
• Increased urine production, which may lead to increased liquor (polyhydramnios); 
• Increased fat deposition, which may lead to a LGA fetus and increased birth weight; 
• Polycythaemia; and 
• Neonatal hypoglycaemia, jaundice, hypocalcaemia and hypomagnesemia.76 
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Complications are directly related to circulating glucose levels, with higher glucose levels associated 
with higher risks of adverse outcomes.77, 78 Consequently, pregnant women with gestational 
diabetes have less complications than those who are affected with pregestational diabetes.77 
Adverse effects can be reduced by treatment - the better controlled the hyperglycaemia is, the 
lower the risk of adverse outcomes.78, 82 
1.12 Diabetes in Pregnancy and Kidneys 
Hyperglycaemia can also be teratogenic to the fetus, particularly at conception and during 
embryogenesis.81 With regards to the developing kidneys, one study demonstrated a three-fold 
increase in renal dysgenesis and agenesis in fetuses of mothers with diabetes.83 However, this study 
did not elucidate the type, duration, or treatment of diabetes. Another study found infants of 
mothers with pregestational diabetes were 7.5 times more likely to be born with renal dysgenesis 
or agenesis and infants of mothers with gestational diabetes had a 1.3 times increased risk of 
obstructive renal pathology.74 Animal models have also demonstrated that maternal 
hyperglycaemia may be associated with a reduced nephron number, diminished glomerular 
filtration, microalbuminuria and hypertension in later life.84, 85 Again, the mechanisms and etiology 
of maternal hyperglycaemia and any increased risks in kidney disease and hypertension in humans 
remained to be elucidated. However, there is consensus that maternal hyperglycaemia affects 
nephron endowment and quality.39 
1.13 Antenatal Ultrasound Imaging 
Antenatal ultrasound uses high frequency sound waves to image the developing fetus and the 
surrounding maternal structures.86 Ultrasound is a non-invasive, safe, relatively inexpensive and 
widely available imaging modality.87 Images are produced in real-time which enables assessment of 
fetal movement, heart motion and blood flow. The last decade has seen dramatic advances in 
ultrasound resolution, computer processing power, volumetric imaging and extended and 
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improved colour and spectral Doppler applications.86-88 Ultrasound is the principal imaging 
modality in pregnancy, which enables prenatal diagnosis of many fetal abnormalities and facilitates 
ideal prenatal management.86, 89 
Ultrasound is the primary imaging modality for evaluating fetal kidneys. Kidney size can be 
measured non-invasively and efficiently with ultrasound.86 We initially conducted a systematic 
review of the evaluation of fetal kidney growth using ultrasound.90 This full systematic review is 
presented in Chapter 2. In summary, after reviewing the studies it was found that there were some 
normal ranges of kidney length, transverse (TS) and antero-posterior (AP) diameters, and 2D and 
3D kidney volumes. There were, however, few large, good quality, longitudinal studies. Fetal 
kidney length was demonstrated to not be a good indicator of kidney growth with no significant 
difference in kidney length seen between growth restricted fetuses and appropriately grown 
fetuses. In contrast, the TS and AP diameters of the fetal kidneys were reduced in growth restricted 
fetuses, indicating the kidney maintained its length however was “thinner”. There are few studies 
investigating abnormal fetal growth and associated kidney growth. A few small studies assessed 
FGR on fetal kidney growth, but, no single study was found on the effect of fetal overgrowth on 
kidney growth and only one study on the effect of diabetes in pregnancies on fetal kidney 
volumes.90  
Antenatal ultrasound reliably diagnoses obstructive renal abnormalities such as hydronephrosis, 
hydroureter and bladder outlet obstruction, whereas it is much less reliable at diagnosing 
parenchymal pathologies such as renal dysplasia, polycystic kidney disease, and tuberous 
sclerosis.91, 92 In part this is due to a lack of effective criteria to aid diagnosis. Reviewing the 
literature highlighted the need to discover more accurate in-vivo methods to estimate nephron 
number and assess fetal kidney growth which could be used to detect changes in kidney 
development and function under altered fetal conditions. 
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1.14 Estimation of Nephron Number 
In order to further examine the mechanisms and timing of effects that influence future kidney 
health and blood pressure, an accurate, in-vivo, non-invasive method to estimate nephron number 
is required.2, 15 At present, the only accurate method of calculating human nephron number is 
during an autopsy.14 It is essential to have a good understanding of fetal kidney development under 
normal and abnormal fetal conditions and what can effect the number and quality of nephrons. 
This led to the investigations in this thesis measuring the functional renal mass which contains the 
layers of nephrons and is known as the renal parenchyma. 
1.15 Renal Parenchymal Thickness 
Measuring the renal parenchyma with ultrasound is a novel method to assess fetal kidney 
development and possibly provide an indirect estimate of nephron number. There are currently 
no studies in the literature to date that have utilised this measurement to assess growth of the fetal 
kidneys under compromised intrauterine conditions. The renal parenchyma consists of the renal 
cortex and medullary pyramids (Fig 1.4).93 Ultrasound technology has improved tremendously over 
the last ten years and current machines can produce very high-quality images of the fetal kidneys.86 
Ultrasound assessment and measurement of the fetal renal parenchyma could potentially be a more 
reliable criteria of kidney development and estimate of nephron number than what is currently 
available. We have previously conducted studies on term neonates and the findings indicated that 
renal parenchymal thickness may be a more reliable investigative method to define normal and 
abnormal kidney development.94 
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Figure 1.4 Ultrasound image of kidney (left) with measurement of the renal parenchymal 
thickness (red line). Line drawing of kidney (right) demonstrating the renal parenchymal 
thickness measurement (red line). Source: Ultrasound image -Townsville University 
Hospital, line drawing – D. Brennan. 
 
By measuring the renal parenchyma, instead of the entire kidney volume or size, only the important 
functional part of the kidney containing the nephrons is analysed. The collecting system of the 
kidney is not included. For example, in the setting of fetal renal dilatation of the collecting system 
(hydronephrosis), a kidney length or a 2D or 3D kidney volume would result in a significant 
overestimation of the volume of kidney tissue, due to the enlargement of the collecting system 
with fluid.95 The renal parenchyma itself may be thinner than normal and the kidney could have 
impaired function (Fig 1.5). Further investigations are therefore needed into the potential of renal 
parenchymal thickness as a marker of nephron endowment and its role in improving the diagnosis 




Figure 1.5 One-week old neonate with normal right kidney without hydronephrosis and a 
parenchymal thickness of 10.8mm and left kidney with hydronephrosis and parenchymal 
thickness of 6.5mm. Source: Townsville University Hospital.  
1.16 Fetal Kidney Function 
Fetal kidney function is difficult to assess non-invasively in-utero. FGR, caused by placental 
insufficiency, can result in chronic hypoxaemia with redistribution of oxygenated blood away from 
organs, such as the kidneys, to more essential organs.46, 47 By analysing the fetal renal arteries with 
Doppler mode, a few studies have demonstrated an elevation in the resistance of blood flow to 
the kidneys of growth restricted fetuses.97-99  Changes in kidney perfusion may influence urine 
output as urine production rate has been shown to be reduced in FGR fetuses in observational 
human studies and in animal models.59, 100-102 Amniotic fluid volume does have some relationship 
with fetal kidney function, however, there is currently no well-established non-invasive method to 
assess fetal kidney function.44, 103, 104 Analysing renal parenchymal thickness together with fetal renal 
artery Dopplers and amniotic fluid levels may provide more accurate information on fetal kidney 
growth and function.  
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1.17 Purpose of This Thesis 
The purpose of this thesis is to evaluate the use of antenatal ultrasound to measure the fetal renal 
parenchyma and to investigate if this measurement can be used as an indirect estimate of nephron 
endowment. The fetal artery blood flow will also be explored. These measurements will then be 
applied to gain a better appreciation of kidney development and function in the normally and 
abnormally grown fetus and in diabetes in pregnancy. The results could help identify factors that 
adversely affect kidney development. Subsequently, public health interventions and education 
programs could be implemented to try and address those factors that might be modifiable. A low 
nephron number at birth does not necessarily lead to hypertension and chronic kidney disease but, 
renders the kidney vulnerable to disease later in life.11, 39 It is necessary to optimise fetal nephron 
number and quality at birth to try and reduce susceptibility to CKD and hypertension in later life. 
To achieve this, we firstly need a non-invasive method to estimate nephron number. 
1.17.1 Overall aim 
The overall aim of this thesis was to assess the fetal renal parenchymal growth through serial 
ultrasound measurements of a pregnant population and determine if abnormal fetal growth or 
diabetes in pregnancy impacts fetal renal parenchymal thickness. 
1.17.2 Hypothesis 
Abnormal fetal growth adversely affects fetal renal parenchymal growth. 
Aim 1  
Conduct a systematic review of the use of antenatal ultrasound to evaluate fetal kidney growth. 






Determine the normal ranges for fetal renal parenchymal thickness, kidney length and kidney 
volume between 16- to 38-weeks gestational age from a group of low-risk pregnancies and to 
assess the reliability of these measurements. This aim is addressed in Chapter 4. 
Aim 3 
Determine the normal ranges for fetal renal artery resistivity index (RI) and pulsatility index (PI) 
between 16- to 38-weeks gestational age from a group of low-risk pregnancies and to assess the 
reliability of these measurements. This aim is addressed in Chapter 5. 
Aim 4 
Evaluate the effects of FGR on the growth of the fetal renal parenchyma and renal artery blood 
flow. This aim is addressed in Chapter 6. 
Aim 5 
Evaluate the effects of fetal overgrowth on the growth of the fetal renal parenchyma and renal 
artery blood flow. This aim is addressed in Chapter 7. 
Aim 6 
Evaluate the effects of diabetes in pregnancy on the growth of the fetal renal parenchyma. This 




This thesis contains published papers, and as such, the different papers may contain similar 
concepts and methods. The original papers contained different styles, spelling and referencing 
depending on the journal. Generally, the style, spelling and referencing has been reformatted to fit 
the overall style of this thesis. 
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To determine the role of ultrasound imaging in evaluating fetal kidney growth.  
Methods 
MEDLINE, CINAHL and EMBASE databases were electronically searched for studies between 
1996 and January 2017 and limited to English language. Studies were included if they reported on 
an ultrasound technique to assess fetal kidney growth and they were not a case report or case series. 
There was independent selection of studies by two reviewers in consensus with one other reviewer. 
Data were extracted by one reviewer in consensus with two other reviewers. 
Results 
A total of 1,785 articles were identified. The full text of 39 of these were assessed for eligibility for 
inclusion. Twenty-eight studies were then included in the review. Standard two-dimensional fetal 
renal (2D) measurements are easy to perform, however, this review identified that most studies 
had some methodological limitations. The disadvantage with 2D and three dimensional (3D) fetal 
renal volumes are that they include the entire kidney and good reproducibility of 3D volumes has 
not yet been demonstrated. Currently there is limited research on fetal kidney growth in the setting 
of abnormal fetal growth. Research focusing directly on fetal kidney parenchyma and blood flow 
is scarce.  
Conclusions 
Some nomograms of 2D and 3D fetal kidney size and volume have been developed. Kidney length 
is the most popular single fetal kidney measurement; however, it does not seem to be a good 
indicator of growth. In IUGR fetuses, kidney length remained similar to appropriately grown 
fetuses whereas AP and TS dimensions were significantly decreased. New ultrasound techniques 
focusing on the parenchyma of the kidney and perfusion to the kidney should be explored as they 
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may provide more meaningful information on kidney development in the fetus and future kidney 
function.  
2.2 Introduction  
It is well established that an adverse intrauterine environment can affect fetal kidney development 
resulting in possible hypertension and chronic kidney disease later in life.1, 2 Intrauterine growth 
restriction (IUGR) can result in significant reductions in nephron number3, which may ultimately 
result in decreased renal function.4 Although most studies concentrate on IUGR and low birth 
weight infants, overgrowth or large for gestational age (LGA) are also emerging as factors that can 
disrupt normal fetal kidney development and increase risks for hypertension and chronic kidney 
disease.5 The normal development of the fetal kidneys can be crucial to an individual’s long-term 
health outcomes. 
The human kidney develops through three successive embryonic stages. Transient development 
and regression of the primary (pronephros) and secondary (mesonephros) fetal kidneys occurs 
between day 23 and day 112.6 These primitive fetal kidneys have no impact on fetal renal function. 
The definitive, tertiary fetal kidney is the metanephros and this is the permanent functional kidney. 
It begins developing on day 30 leading to the formation of nephrons – the functional units within 
the kidney.6, 7 Fetal kidneys are unlike most other organs in that the maximum cell proliferation 
occurs in the third trimester. Nephrogenesis continues up until 34 to 36 weeks gestation with 
approximately 60% of nephrons formed in the third trimester.8 
Assessment of the fetal kidneys is an essential part of an obstetric ultrasound. Accurate information 
regarding kidney size is crucial to identifying kidney abnormalities and detecting changes in fetal 
kidney growth. Ultrasound imaging is safe, cost effective and widely available to evaluate fetal 
kidney size, echotexture and perfusion. A variety of two and three-dimensional ultrasound 
techniques have emerged and advanced to evaluate kidney development. The aim of this review 
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was to systematically review the literature to determine what role ultrasound plays in evaluating 
fetal kidney growth. Current ultrasound imaging techniques and accuracy will be reviewed. 
2.3 Method 
A systematic review of observational studies was conducted using a protocol designed a priori and 
following the PRISMA guidelines for systematic reviews. Author SB developed and conducted the 
search strategy using medical subject headings (MeSH) and keywords and this was reviewed by 
author YK (Appendix 1). MEDLINE (Ovid), CINAHL and EMBASE electronic databases were 
electronically searched in August 2016 and again in January 2017, for publications from the year 
1996 onwards. The literature search was limited to the English language. The reference lists of 
relevant articles were hand-searched for additional relevant studies. 
Human observational ultrasound studies that were not a case report or case series were included. 
Only studies reporting on an ultrasound technique assessing fetal kidney growth were included. 
Studies that only assessed fetal pelvic renal dilatation were excluded.  
Only studies published from the last 20 years (from 1996) were included as it was felt that the 
significant advances in ultrasound techniques and improvements in diagnosis and definition in 
prenatal imaging made these older studies less relevant. Also excluded were unpublished studies, 
non-peer-reviewed, conference abstracts, letters to the editor and opinion articles. If data from a 
single study population was reported more than once, the publication containing the most 
complete information was included. 
Study selection was performed in two sequential steps, firstly assessing articles by title and abstract 
and secondly by full text of the article. Two reviewers (SB and YK) independently screened the 
titles and abstracts of all identified citations and potentially eligible studies were selected. The full 
text of these potentially eligible studies was screened by the same two reviewers. Any discrepancies 
between the reviewers were resolved by consultation with a third reviewer (DW). 
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A data extraction sheet was developed. Only pre-specified outcomes of interest in the review were 
collected. Review author SB extracted the data from the studies and the second review author YK 
checked the extracted data. Any disagreements were resolved by discussion with a third reviewer 
(DW). Figure 2.1 outlines study selection process. A narrative synthesis, including tables, was done 
on the extracted data to explain and summarise the characteristics and findings of the included 
studies. 
2.4 Results 
A total of 1,785 articles were identified and after review of the title and abstract, the full text of 39 
of these were assessed for eligibility for inclusion (Figure 2.1). Four papers from the Generation 
R study reported the same renal data9-12 and therefore these data were only considered once using 
the paper by Verburg et al.9 as it contained the most relevant and complete data assessing fetal 
kidney measurements. Finally, 28 studies were reviewed. 
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Figure 2.1 Study selection process. 
Relevant characteristics of these included studies are presented in Tables 2.1, 2.2 and 2.3. Most 
studies were prospective in design with only 2 of the 28 studies being retrospective.13, 14 A cross-
sectional design was utilised by 21 studies while 7 studies had a longitudinal design. Selected studies 
were divided into three groups depending on the ultrasound technique used to assess the kidneys. 
Some studies reported on more than one ultrasound technique (Tables 2.1, 2.2, and 2.3).  
Generally, the study time and duration, how participants were recruited, and missing participants 
and data was poorly reported. Calculation of estimated gestational age (GA) was most commonly 
achieved using the last normal menstrual period (LNMP) correlated with a first or early second 
trimester ultrasound (18 studies).13-30 Six studies used ultrasound dating only9, 31-35, one used only 
an accurate LNMP36 and three did not report how GA was determined.37-39 
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Table 2.1  
























UK P/Long Singleton 
preg AGA & 
SGA 
AGA = 50 
SGA = 37 





TA, 2D, No 
operators NR 
KL, TS, AP & 
circumference 
SGA different growth to AGA. 
AGA acceleration of growth 26-34 
weeks (critical period) not seen in SGA. 
No difference in KL. 
Rosati et 
al. 199615 




489 LNMP & 
US 
11 – 16 
wks 
Once TV, 2D, 2 
operators 
KL, TS, AP, 
circumference 
& KC/AC 
Normal fetal kidney size in early 
pregnancy. There was linear growth of 




UK P/CS Singleton 
preg AGA & 
SGA 
AGA=129 
SGA = 90 
10-12 wks 
US 
22 – 38 
wks 
Once TA, 2D, 1 
operator 
KL, TS, AP & 
circumference 
Between AGA & SGA – no difference in 
KL, significant difference in TS & AP 
from 26 weeks. SGA resulted in long 




USA P/CS Normal AGA 
singleton preg 
100 NR 18 – 39 
wks 
Once TA, 2D, 4 
operators  
KL, TS, AP, 2D 
volume, EFW 
Provides normal fetal kidney size 
relative to both GA & EFW. Constant 
ratio between KL to weight. Ratio of KL 


























P/CS Normal AGA 
singleton preg 
793 LNMP & 
BPD & FL 
16 – 40 
wks 
Once TA, 2D, No 
operators NR 
 KL, BPD & FL 
Good correlation between KL, BPD & 





Italy P/CS Normal AGA 
singleton preg 
807 LNMP 11 – 16 
wks 




BPD/KL plotted against GA for early 
pregnancy & appears constant through 
11-16wks. 
Zalel et al. 
200217 
Israel P/CS Normal AGA 
singleton preg 
269 LNMP & 
CRL 
13 – 22 
wks 
Once TV, TA, 2D, 1 
operator 
KL 




Belgium P/CS Normal AGA 
singleton preg 
25 LNMP & 
CRL 8-10 
weeks 
23 & 32 
wks 
Twice (23 
weeks & 32 
weeks) 
TA, 2D, 1 
operator 
KL, TS, AP & 
2D volume 
Thinner neonates at birth have smaller 
kidneys relative to body size. Mean 
KV/EFW ratio did not significantly 
change between 23 and 32 weeks. KL 
not related to birthweight & ponderal 
index, however, TS & AP related 
positively to both. 
Konje et 
al. 200219 
UK P/Long Normal AGA 
singleton preg 
73 LNMP & 
CRL 





TA, 2D, 2 
operators 
KL, BPD, HC, 
AC & FL 
























UK P/CS Normal AGA 
singleton preg 
661 LNMP & 
US 18-
20weeks 
14 – 42 
wks 
Once TA, 2D, No 
operators NR 
KL, TS, AP, 2D 
volume 




USA P/CS Singleton 
preg IUGR & 
SGA 
AGA = 43 
IUGR = 34 
LNMP & 
CRL or 2nd 
US 
27 – 41 
wks 
Once TA, 2D, 2 
operators 
KL, TS, AP, 
circumference 
& 2D volume 
Renal artery 
Doppler 
Kidney volume in IUGR fetuses was 
31% less than in AGA fetuses & 15% 
less when adjusted for fetal weight. No 
difference in renal artery blood flow 
AGA vs SGA. 
Lampl et 
al. 200522 











19 - NR Every week 
from 19 
weeks 
TA, 2D, 1 
operator 
KL, TS, AP, 2D 
volume 
Recorded birth outcomes for 6 
smokers & 21 non-smokers this was 
insufficient for meaningful results. 
Smoke exposed fetal kidneys were 
thicker in 2nd trimester and then 











































Once TA, 2D, 3 
operators 
KL, TS, AP, 2D 
volume, EFW, 
UA, MCA & 
UA/MCA ratio 
Normal ranges of KL, TS, AP & 2D 
volume for 28 to 34wks. Maternal 
weight & height positively associated 
with kidney volume. Kidney volume is 
positively associated with all growth 
characteristics & amniotic fluid. 
Umbilical artery RI’s & CPR negatively 






P/Long Normal AGA 
singleton preg 






by 2 weeks 
TA, 2D, 1 
operator 
KL, TS, AP, 2D 
volume 
Normal ranges of KL, TS, AP & 2D 
volume for 16 to 42 weeks. 
Neves et 
al. 201333 




















TA, 2D, 1 
operator 
KL, TS, AP, 2D 
volume 
Significant difference between groups. 
Median kidney volume of 
hyperglycaemic group > 75th percentile 
for normoglycaemic group. Maternal 
hyperglycaemia is associated with fetal 




Iran P/CS Normal AGA 
singleton preg 





Once TA, 2D, 2 
operators 
KL, BPD, HC, 
AC, FL 
KL, AC, FL & HC had a linear & strong 
correlation with GA. Best GA predictor 


























UK P/CS Normal AGA 
singleton preg 
South Asian & 








32 + 3 
days to 
34 + 4 
days 
Once TA, 2D, 4 
sonographers 





After adjusting for GA, all renal 
dimensions for South Asians were 
significantly smaller than for White 
British. Proportion reduction greatest 
for TS the AP. Kidney volume reduced 
with adjusted BW, kidney volume still 
higher in White British. Findings may 
partly explain the increased risk of 
adult chronic kidney disease in South 
Asians. 
 
Note: AC, abdominal circumference; AGA, appropriate-for-gestational age; AP, anterio-posterior; BPD, biparietal diameter; Btw, between; BW, birth weight; CPR, 
cerebroplacental ratio; CS, cross-sectional; CRL, crown rump length; EFW, estimated fetal weight; FL, femur length; GA, gestational age; HC, head circumference; IUGR, 
intrauterine growth restriction; KC, kidney circumference; KL, kidney length; LNMP, last normal menstrual period; Long, longitudinal; NR, not recorded; P, prospective; 







Table 2.2  



















Summary of Reported 
Findings 
Yu et al. 
200024 













Good correlation between GA and kidney 













Once TA, 2D & 3D, 1 
operator 
2D calculated 




Normal ranges of 3D kidney volumes. 
Due to limitations of 3D volumes this study 
found the constant for volume to be 

















20 wks to 
birth 









Normal ranges of 3D kidney volumes. 
Significant difference found between their 
study and two others (24, 25).   
They were doubtful about reproducibility of 






































Once TA, 3D, 1 
operator but 






Using 3D kidney volumes, the best screening 
criteria for detection of a growth restricted 
fetus is the 10th percentile – sensitivity = 
96.4%, specificity = 95.9%, PPV = 75%, NPV = 


























Strong correlation between GA and kidney 
volume. 
Normal ranges of 3D kidney volumes using 
VOCAL. 
Kidney volume highly correlated with other 








213 CRL  20 -40 
wks 








Note: AGA, appropriate-for-gestational age; CS, cross-sectional; CRL, crown rump length; GA, gestational age; IUGR, intrauterine growth restriction; LNMP, last normal 
















































2nd & 3rd 
trimesters 
Once TA, 2D, No operators 
NR 
Assess for renal 
medullary 
hyperechogenicity  
KL & BPD /KL ratio 
IUGR fetuses divided into those with 
hyperechoic kidneys and those 
without. 
Normal nomogram BPD/KL 
correlated with GA. Significant 
difference btw KL of normal fetuses 
and IUGR fetuses with hyperechoic 
kidneys, but no difference btw KL of 
normal fetuses and IUGR fetuses 













16 – 38 
wks 
Once TA, 2D, No readers NR 
Reviewed US images 
to find max KL image 
then measured area 
of kidney 
Normal ranges of total fetal renal 
parenchymal area. 
Combined fetal nomogram with their 
previously devised birth to 























Summary of Reported 
Findings 
Shin et al. 
200713 




216 LNMP or 
CRL 
16 – 41 
wks 
Once TA, 2D, 1 reader 
Reviewed US images 
to find max KL image 
& TS image then 
measured length, TS 
& area of kidney in 
long & TS 
Normal ranges of total fetal renal 
parenchymal area in long and TS and 
normal ranges of KL.  








128 LNMP & 
CRL 
20 – 40 
wks 
Once TA, 2D, 2 operators 
Anterior & posterior 
parenchymal 
thickness measured 
in long & TS planes  
Normal ranges of ant & post 
parenchymal thickness in long & TS. 
Gradual linear growth of 
parenchyma throughout pregnancy. 
Findings indicate parenchymal 
thickness measured on long section 
are more reliable & reproducible 









































21 – 37 
wks 




obtained images NR 
Length, cortical 
thickness (CT) & 
medullary thickness 
(MT) both in long, 
assessed cortical 
echogenicity 
KL increased with GA. 
Cortical echogenicity (CE) evolved 
with GA. After 32 weeks GA, the CE 
should not be higher than the liver 
or spleen. 
Normal ranges of CT and MT 
according to GA. CT/MT ratio 
calculated and decreased with 
increasing GA. 
 
AGA, appropriate-for-gestational age; BPD, biparietal diameter; Btw, between; CRL, crown rump length; CS, cross-sectional; CT, cortical thickness; GA, gestational age; 
IUGR, intrauterine growth restriction; KL, kidney length; LNMP, last normal menstrual period; Long, longitudinal; MT. medullary thickness; NR, not recorded; P, prospective; 
R, retrospective; TA, transabdominal; TS, transverse. 
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Overall ultrasound features of the studies and measurement methods were well described. Most 
studies focused on the mid-second trimester to third trimester9, 13, 14, 16, 18-31, 33-35, 37-39, as imaging the 
fetal kidneys well under 20 weeks can be difficult.33, 40 The three studies that reported data below 
14 weeks GA used transvaginal scanning.15, 17, 36 The GA range assessed was very variable between 
studies. Two studies showed only a snap shot in time with a GA range of 15 days (around 34 
weeks)34 and 4 weeks (28 to 32 weeks).9 One study measured the fetal kidneys at 23 weeks and 
again at 32 weeks.18 Studies covering the longest GA ranges were Chitty and Altman20 16 to 42 
weeks, van Vuuren et al.32 16 to 42 weeks and Hsieh et al.25 15 to 40 weeks.  The GA range was 
unclear in one study.23 
2.4.1 Differences between right and left kidneys and gender 
Overall, the evidence strongly supported no significant difference between right and left fetal 
kidney size (17 of the 18 studies) for all ultrasound measurements regardless of the technique 
used.13, 15-17, 19, 23-26, 28-33, 35, 38 Six of the seven studies that examined gender differences found no 
significant difference between fetal kidney measurements.17-19, 23, 29, 30 Only one study demonstrated 
a difference in size between right and left kidneys and males and females.9 This was a large study; 
however, it had a small four-week gestational window (28.4 to 32.6 weeks) when each fetus was 
measured once. The study revealed right kidneys had a larger transverse and antero-posterior 
dimension when compared to left kidneys, resulting in larger calculated renal volumes. No 
difference, however, was found between kidney lengths. All kidney measurements were smaller in 
females than males.9 
2.4.2 Standard two-dimensional (2D) measurements 
Nineteen studies reported on a standard two-dimensional (2D) ultrasound  
measurement.9, 13, 15-23, 29, 31, 32, 34, 36-39 Standard 2D measurements of the fetal kidneys were the earliest 
and simplest method utilised to assess kidney size at different gestational ages. 41, 42 Most reviewed 
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studies involved a low risk, uncomplicated pregnancy to obtain normal fetal kidney  
nomograms.16-20, 23, 32, 36, 38  
A longitudinal design was used by four studies that reported on 2D  
measurements19, 22, 32, 37, with the best quality longitudinal study being Van Vuuren et al.32 This study 
of 96 participants measured all three dimensions of the kidney and clearly defined how GA was 
determined. Good longitudinal data was obtained every two weeks. Participants were divided into 
two groups. Each group came every four weeks, however, one group started at 16 weeks and the 
other at 18 weeks.  Reference charts were constructed for kidney length, antero-posterior diameter, 
transverse diameter and volume.32 In the other longitudinal studies, one did not report how GA 
was determined37, another only measured kidney length19 and the third study had a small sample 
size of ten normal pregnancies.22 
Overall, evidence from the selected studies using standard 2D ultrasound measurements suggest 
fetal kidney growth correlates positively with GA. The velocity of kidney growth is highest between 
26 and 34 weeks in appropriately grown fetuses. This was termed the “critical period” for fetal 
kidney growth37 and was supported by other studies. 9, 34 Kidney size was linked positively with 
fetal weight and size.9, 18, 38  
Few studies used standard 2D methods to investigate fetal kidney growth in abnormal fetal growth. 
Compared to appropriately grown fetuses, kidneys of IUGR fetuses demonstrated significant 
reductions in transverse and antero-posterior dimensions.31 This is particularly marked during the 
critical kidney growth period (26 to 34 weeks). No significant difference was demonstrated 
between the renal lengths of IUGR fetuses compared to appropriately grown fetuses.  
2.4.3 Renal volumes – Calculated from two dimensional (2D) measurements 
Kidney volume calculations should technically be a better estimate of overall kidney size and shape 
than single linear measurements.43, 44 Traditionally fetal renal volumes were calculated using 2D 
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ultrasound measures. Three orthogonal kidney diameters are applied to the volume formula of an 
ellipsoid shape to obtain a volume estimate (length x transverse x antero-posterior x 0.523).45 The 
ellipsoid formula was used to calculate renal volumes in nine studies.9, 18, 20-22, 32-34, 38 Findings from 
the studies of appropriately grown fetuses in normal pregnancies demonstrated fetal kidney 
volume increases exponentially until birth32 or with some slowing of growth velocity after 36 
weeks.20  
Studies assessing fetal renal 2D volumes during abnormal fetal growth were scarce. One such study 
was a large study, however was cross-sectional in design and examined a very narrow GA window 
of 28.4 weeks to 32.6 weeks (median age 30.4 weeks).9 Their findings suggested that IUGR, 
placental insufficiency and fetal redistribution of blood flow result in decreased fetal kidney 
volumes, around the critical kidney growth period of 26 to 34 weeks.  Smaller kidney volumes 
were also associated with reduced amniotic fluid suggesting an association with fetal kidney 
function.9 Another cross-sectional study of IUGR fetuses reported considerable reductions in the 
kidney volumes of IUGR fetuses.21 When corrected for fetal weight, there was a 15% reduction of 
kidney volume for IUGR fetuses compared to appropriately grown fetuses.21  
No studies were found evaluating fetal kidney growth in large for gestational age (LGA) fetuses. 
Fetal kidney growth in hyperglycaemic pregnancies was investigated by one study.33 This 
longitudinal study compared 2D kidney volumes of normoglycaemic pregnancies with 
hyperglycaemic pregnancies. Often fetuses of hyperglycaemic mothers are LGA due to 
organomegaly and increased fat deposition from the increased glycogen to the fetus33, however, 
the relationship between fetal size and kidney size was not reported. This study demonstrated 
maternal hyperglycaemia was associated with alterations in fetal kidney volume. The median fetal 
kidney volumes of hyperglycaemic pregnancies were significantly larger than the 75th percentile for 
normoglycaemic pregnancies.33 This finding warrants further examination. 
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2.4.4 Renal volumes – Three dimensional (3D) 
Three dimensional (3D) techniques were used to calculate fetal kidney volumes in six studies. One 
of two methods were used to obtain 3D volumes: the multiple parallel plane method (multiplanar) 
or the rotational Virtual Organ Computer-aided AnaLysis (VOCAL) method. The older 
multiplanar technique is utilised in the four earlier studies, between 2000 and 200824-27 and involves 
manually tracing multiple adjacent sequential planes of the organ. VOCAL is the newer, more 
automated volumetric tool employed by the two later 3D studies (2009 and 2013).28-35 
Most of the included 3D studies focused on constructing reference curves for 3D fetal kidney 
volumes correlating to GA. Only one of these studies was longitudinal in design and able to truly 
assess growth, unfortunately this study had the narrowest gestational range of between 24 to 34 
weeks.26 All studies reporting on 3D kidney volumes demonstrated substantial differences of 
reported “normal” values. For example, two similarly designed studies published the same year, 
from the same country, using the same equipment reported at 35 weeks a kidney volume of 7.9mL 
as the 50th centile in one study24 and below the 5th centile for the other.25 Even when reviewing two 
studies using the newer VOCAL method, one study reported the 50th centile of the right kidney at 
34 weeks as 21.8cm3 35  and the other reported 11.7cm3 as their 50th centile at 34 weeks.28 These 
considerable variations are highly unlikely to be due to different population characteristics. In 
clinical practice, it would be impossible to know which reference curves to use and these results 
should therefore be used with caution. 
3D ultrasound assessment of abnormal fetal kidney growth was evaluated in only one study. This 
study compared 3D fetal renal volumes between IUGR fetuses and appropriately grown fetuses.27 
Volumes in IUGR fetuses were significantly smaller when compared to appropriately grown 
fetuses.27 This evidence is not strong as this one cross-sectional study measured volumes only once 
in 28 IUGR fetuses and the considerable variation in normal 3D fetal kidney volumes is likely to 
also be an issue in measurements of abnormally grown fetuses. 
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2.4.5 Other ultrasound techniques 
Five studies investigated other ultrasound techniques to assess fetal renal growth or size, with a 
focus on the kidney parenchyma.13, 14, 29, 30, 39 The kidney parenchyma has more recently become an 
emphasis of investigation as it contains the nephrons. In a hydronephrotic kidney, the length, 
transverse and antero-posterior dimensions and kidney volume may be normal or above normal. 
However, the parenchyma may be thinner than normal and the kidney may have impaired 
function.46  
The study by Devriendt et al.39 measured cortical thickness (from the outer renal capsule to the 
external limit of the pyramids) and medullary thickness (the pyramid from the papilla to its base) 
of the parenchyma separately and demonstrated that these measures increased with GA. There 
was poor reproducibility with an inter-observer variability of 16.5% for cortical thickness and 
28.6% for medullary thickness39. This was likely due to the various and changing shape of the renal 
pyramids, making accurate and reproducible placement of the calipers difficult. 
In contrast, Hadar et al.30 conducted a study measuring the entire kidney parenchyma from the 
renal capsule to the sinus-pyramidal interface and indicated there was a gradual linear growth of 
the parenchyma with increasing GA.30 Both the anterior and posterior parenchyma thicknesses 
were measured in transverse and longitudinal planes. Their findings demonstrated that measuring 
parenchymal thickness on longitudinal sections was more reliable and reproducible than transverse 
measurements and had significantly better intra and inter-observer variability than Devriendt et 
al.39 at 0.6% and 8.8% for anterior parenchyma and 3.5% and 2.4% for posterior parenchyma 
respectively.30 Supporting the consistency of this study30 is that measurements were completed 
while performing the ultrasound rather than measured offline, by a reader, from archived images, 
as was done in the study by Devriendt et al.39 
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The echogenicity of the parenchyma was subjectively evaluated and compared to kidney size by 
one study.29 This study reported a significantly higher biparietal diameter/kidney length ratio in 
those fetuses with hyperechogenicity of the kidney parenchyma and proposed this parenchymal 
hyperechogenicity is an indicator of depression of fetal renal perfusion.  These results should be 
interpreted with caution as their standard deviation for fetal kidney length was large at 5.4mm and 
the study had other technical issues, including a non-validated technique to assess fetal hypoxia.29  
Kidney parenchymal area was measured in two other studies.13, 14 Unfortunately, they were 
retrospective in design and the entire area of the kidney in transverse and longitudinal was 
measured. These two studies in fact did not measure renal parenchyma and actually measured 
kidney area. Both used their data to develop nomograms of kidney area. 
2.5 Discussion 
After reviewing 28 studies using ultrasound to assess fetal kidney development, this systematic 
review revealed several ultrasound techniques to evaluate fetal kidney growth. These techniques 
had a wide variety of sensitivity and reproducibility. Identification of abnormal kidney morphology 
or growth is aided by availability of normal fetal kidney biometry charts. Unfortunately, this review 
identified most studies had some methodological limitations.  
There is limited data on actual kidney growth. Some studies reported kidney growth as an outcome, 
however, they were cross-sectional in design.13, 14, 24, 25, 30, 38 It is common for size and growth to be 
confused and used interchangeably. A limitation of cross-sectional studies is they are not 
appropriate to evaluate growth and can only be used to produce kidney size reference curves.47 
Only one cross-sectional study recognised this limitation.20 Longitudinal studies can overcome this 
limitation as the same fetal kidneys are measured at multiple time periods during the pregnancy. A 
large, longitudinal study of kidney size and volume would provide reference curves for kidney size 
and growth.47  
51 
In IUGR fetuses, AP and TS dimensions were significantly decreased, but kidney length remained 
similar to appropriately grown fetuses. The kidney shape changes to long and skinny or “sausage-
shaped” as described by Konje et al.31 and suggests the thinning of the kidney could be due to 
fewer layers of nephrons. Lampl et al.22 investigated effects of maternal smoking during pregnancy 
on fetal kidney growth, proposing maternal smoking affected growth patterns, resulting in long 
thin “sausage-shaped” kidneys late in the third trimester. Unfortunately, the number of participants 
with recorded birth outcomes was small (6 smokers and 21 non-smokers) and thus the results 
deemed insufficient to suggest any meaningful outcomes.22 
Kidney length is the most popular single fetal kidney 2D measurement used in current clinical 
practice and in the selected studies. It was not, however, seen to be a good indicator of growth. 
This may make kidney length more useful for estimating GA, where dates are uncertain16, 19, 23 and 
highlights its lack of sensitivity in assessing alterations in fetal kidney growth. 
Kidney volume calculations estimate overall kidney size and shape. 2D volumes are simpler and 
quicker than 3D volume calculations and can be done with any basic ultrasound equipment. 3D 
volume calculations require higher-level ultrasound equipment with additional 3D-specific 
transducers and proprietary software. The disadvantage of calculating fetal kidney volumes from 
2D measurements is it erroneously assumes that the kidney is an ellipsoid shape. Compared to the 
gold standard of fluid displacement, an in vitro study demonstrated using the ellipsoid formula 
underestimated actual renal volumes by 24%.48 
3D ultrasound volume calculations are not dependent on an assumed geometric shape and 
therefore are thought to more precisely estimate volumes of irregular shaped organs.49 Large 
variations between reported results for these 3D studies is likely due to methodological 
inconsistencies. It is apparent from the selected studies that there is substantial variation in data 
collection, analysis and presentation of 3D volumes. This is mostly due to ultrasound machines 
having proprietary file formats that prevent viewing and analysis of data sets outside the specific 
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machine brand. Universal standardisation of 3D file formats and software, regardless of equipment 
used, is overdue.  
All studies describe the technique utilised to acquire 3D data sets and subsequent 3D volume 
calculations; however, the studies lack explicit image landmarks for volume acquisition and calliper 
placement for volume measurement. This is necessary for any ultrasound measurement to provide 
accurate and reproducible results. This is even more crucial when calculating 3D volumes as several 
planes need to be consistently demarcated and any error in calliper placement is multiplied over 
the volume.50  
By far the biggest issue compromising the evidence from all the reviewed 3D volume studies is 
the lack of acceptable reproducibility data. Two studies did not report any intra or inter-observer 
variability.24, 25 The other four reported either only intra-observer variability, when there was one 
operator26, 27, or both intra and inter-observability, if there was more than one operator.28, 35 
Surprisingly all four studies only assessed reproducibility on the analysis and measurement of the 
already obtained 3D data set. Errors introduced during acquisition of the 3D data set can be a 
considerable source of error.  Factors such as the depth of the kidney, the number and orientation 
of the slices and movement of the patient, the fetus or the probe all affect spatial accuracy and can 
significantly influence the 3D kidney volume obtained.26 It is important to assess the variability of 
the post-processed images; however, it is illogical for all studies to ignore the variability associated 
with 3D data acquisition.  
Additionally, it was not clear in most studies how many operators had obtained the 3D data sets 
and no information on their qualifications and skill level.  It was also unclear if the same person 
acquiring the data was analysing the data. These omissions may considerably influence the quality 
of the results. In most clinical settings ultrasound scans are performed by multiple operators and 
variability is unavoidable. This needs to be accounted for, or at least, it needs to be reported along 
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with what quality assurance steps were taken to try and maintain some consistency and 
standardisation of measurements.  
3D ultrasound equipment and software are expensive and not as readily available as 2D ultrasound 
equipment. 3D imaging has a higher workload than 2D measurements: longer acquisition times, 
followed by time for post processing the volume of interest. The quality of the acquired image 
significantly affects the 3D outcome. All studies report that performing the 3D acquisition requires 
a “quiet” fetus which can take substantial time to achieve.24 In summary, the reviewed 3D 
ultrasound studies had no acceptable evidence of true intra or inter-observer variability and 
therefore good reliability and reproducibility of 3D volumes has not yet been demonstrated.  
Hyperechogenicity of the fetal kidneys may be associated with disruption of kidney growth and 
changes in kidney function. Suranyi et al.29 investigated the echogenicity of the parenchyma and 
fetal kidney size to establish a correlation with fetal hypoxia. Their findings, however, are 
questionable for several reasons. Hyperechogenicity of the kidney medullae was subjectively 
established by comparing the echogenicity of the kidney to the liver or spleen. The authors stated 
that kidney hyperechogenicity was a sensitive sign of fetal hypoxia and they appear to use this to 
determine severity of fetal hypoxia.29 Renal parenchymal echogenicity and corticomedullary 
differentiation are reported in the literature, however, are yet to be validated.39 In 2003, as it is 
today, fetal medullary hyperechogenicity is not a validated or clinically used method to establish 
the presence or absence of fetal hypoxia.  
During fetal hypoxia, blood flow is redistributed away from the kidneys to more essential organs.51 
Suranyi et al.29 propose that this reduced kidney perfusion possibly delays fetal kidney development 
resulting in hypoplasia of the kidney and a hyperechogenic appearance.  The role of the kidney 
parenchyma and blood flow in assessing fetal kidney growth and future renal function has not yet 
been well evaluated. Preliminary data from term neonates52 and children53 indicates parenchymal 
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thickness may be a more reliable investigative method to define normal and abnormal kidney 
development. More research is needed to validate these propositions.  
Magnetic resonance imaging (MRI) is being increasingly utilised to image the fetal kidneys and 
provides excellent delineation of anatomy.54 Fetal kidney measurements and volumes have been 
described with MRI.55, 56 There are still some safety concerns around MRI for the fetus, such as 
biological effects and acoustic noise.54 MRI is more expensive than ultrasound, is limited by fetal 
movement, has several contraindications and has similar problems to ultrasound with regards to 
maternal obesity. Ultrasound imaging provides real-time images, is non-invasive and relatively 
inexpensive and is still the modality of choice for routine evaluation of fetal kidney growth.54, 57  
2.5.1 Limitations 
The search was restricted to English language and studies published from the last 20 years (from 
1996) as it was felt that the significant advances in ultrasound imaging made these older studies 
less relevant. The major limitation of this systematic review is most of the included studies were 
of a cross-sectional design rather than longitudinal. Widely variable gestational age ranges were 
analysed. Most studies involved low-risk, uncomplicated pregnancies as most studies were 
establishing normal ranges. 
2.6 Conclusions 
Following a review of 28 studies investigating fetal kidney growth using ultrasound, we can 
conclude that the collective results provide some normal ranges of 2D and 3D fetal kidney size 
and volume. However, there are few large, good quality, longitudinal studies. There is also a paucity 
of research into the effects of abnormal fetal growth, particularly overgrowth, on fetal kidney 
development. Kidney length is the most popular single fetal kidney measurement; however, it does 
not seem to be a good indicator of growth. In IUGR fetuses, kidney length remained similar to 
appropriately grown fetuses whereas antero-posterior and transverse dimensions were significantly 
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decreased. Currently there is no easily reproducible, sensitive method for measuring changes in 
fetal kidney growth. New ultrasound techniques concentrating on the parenchyma of the kidney 
and the perfusion to the kidney may provide improved information on fetal kidney development.  
2.7 Update: Recent Progress in The Evaluation of Fetal Kidney Growth Using 
Ultrasound (Jan 2017 – June 2020)    
2.7.1 Introduction 
This section summarises recent progress in the literature that was published after January 2017 as 
this was the period the above published systematic review included up until. During this time, the 
studies for this thesis were being conducted.  
2.7.2 Method 
A systematic review of observational studies was conducted using the same protocol designed for 
the above paper “Evaluation of fetal kidney growth using ultrasound: a systematic review” which 
was published in the European Journal of Radiology. The protocol follows the PRISMA 
guidelines. The same databases and search strategy were used other than the search time was 
between January 2017 to June 2020. Only studies reporting on an ultrasound technique assessing 
fetal kidney growth were included. 
2.7.3 Results 
A total of 177 articles were identified. After review of the title and abstract and removal of 
duplicates, the full text of seven of these were assessed for eligibility for inclusion. All seven were 
eligible for inclusion and a summary of the main characteristics of these studies are presented in 
Table 2.1.  All studies were prospective with four cross-sectional in design58-61 and three 
longitudinal.62-64 Two studies were both from the ongoing Gomeroi Gaaynggal study, which is a 
prospective longitudinal cohort study involving mothers and their Indigenous Australian fetus into 
childhood.59, 63 These two studies used a sample from the same cohort of participants, however, 
56 
they reported on different renal measurements and analysed them with different variables. For 
example, one study used only one time point from the 3rd trimester59 and the other used 
measurements from each of the three trimesters.63 Consequently, both studies were kept in the 
review. 
Participant selection methods, the number of participants eligible, included, excluded, and lost to 
follow-up was poorly reported, as was the number of operators performing the ultrasound 
examinations and missing data points. No study clearly outlined all of these items as recommended 
in the STROBE guidelines.65 GA was most commonly estimated using LNMP or first trimester 
ultrasound or both. Only one study did not state how GA was estimated.64 
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Table 2.4  























Brazil P/Long Normal AGA 
singleton 
preg 




14 – 40 
wks 
Approximately 
every 4 weeks 
from 14 
weeks 
TA, 2D, 3 
operators 
KL, TS, AP & 
2D volume 
References ranges of KL, TS, AP & 2D 
volume 14 to 39wks with 10th, 50th & 90th 
centiles. 
No significant difference between males 
and females and right and left kidneys. 
Osho et 
al. 2019 58 
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Once TA, 2D, 1 
operator 
KL, TS, AP & 
2D volume 
Kidney length most accurate single 
biometric measurement for GA comparing 
it to FL, BPD, HC and AC. No significant 
difference between right and left kidneys. 
Lee et al. 
2019 59 















Once TA, 2D, No 
operators 
NR 
KL, TS, AP, 
2D volume, 
EFW 
In late preg, fetal kidney volume relative to 
EFW is negatively associated with 
maternal adiposity. No association 
between infant kidney function and 






















Summary of Reported 
Findings 
Diehm et 
al. 2018 63 















(1st, 2nd, 3rd) 
might have 
more but no 
clear  
TA, 2D, No 
operators 
NR 
KL, TS, AP, 
2D volume 
Strong relationship between EFW and 
combined kidney volume. Kidney volume 
of fetuses from mothers who smoke are 
small than mothers that don’t however 
were in proportion to birth weight and 












20 – 41 
wks 




Kidney length most accurate single 
biometric measurement for GA comparing 
it to FL, BPD, HC and AC. Left kidney was 
significantly longer than the right. 
Nagar et 
al. 2018 60 
Israel P/CS Normal AGA 
singleton 











14 – 40 
wks 
Once TA, 2D, No 
operators 
NR 




at level of 
renal pelvis 
 
Renal AP to abdominal AP ratio was 
constant throughout pregnancy. Very good 

























Belgium P/Long Normal AGA 
singleton 





AGA = 58 
SFK = 74 
NR 20/24 – 
36 wks 
AGA – every 4 
wks. SFK – 
every 4wks or 
more 
TA, 2D, 3D, 
2 operators 
KL, TS, AP, 
2D volume, 
3D VOCAL 
2D & 3D volumes significantly higher in 
SFK group. 3D volumes greater than 2 D 
volumes. No correlation between prenatal 
or postnatal SFK volume and GFR at 2 
years of age. 
 
Note: AC, abdominal circumference; AGA, appropriate-for-gestational age; AP, anterio-posterior; BPD, biparietal diameter; CS, cross-sectional; EFW, estimated fetal 
weight; FL, femur length; GA, gestational age; HC, head circumference; KL, kidney length; LNMP, last normal menstrual period; Long, longitudinal; NR, not recorded; P, 
prospective; Preg, pregnancy; SFK, single functioning kidney; TA, transabdominal; TS, transverse; US, ultrasound.
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Generally, the ultrasound measurements and methodology were well described. All seven 
studies investigated 2D ultrasound measurements of the kidney, with only one of these 
studies also obtaining a 3D volume of the kidneys using the VOCAL technique.64 Most of 
the studies (5/7) measured all three linear dimensions of the kidney (length, AP, TS) and 
then used the ellipsoid formula to calculate a 2D volume.58, 59, 62-64 Fetal kidney length was 
found by two studies, to be the most accurate single biometric measurement for estimating 
GA in the 2nd and 3rd trimester when comparing it to femur length, bi-parietal diameter 
(BPD), head circumference and abdominal circumference.58, 61 
One longitudinal study involving a low-risk pregnancy cohort created reference charts for 
kidney length, AP and TS dimensions and kidney volume. The authors provide little 
information on the statistical analysis used to generate the charts other than stating they were 
built by quantile regression analysis for each measurement related to GA.62 No table 
reporting the mean and SD of each measurement and number of participants at each 
gestational week, and no scatter diagram of raw data is provided.62  
A novel ratio of the AP dimension of the kidney to the AP dimension of the abdomen in the 
transverse plane at the level of the renal pelvis was found to be constant throughout 
pregnancy. This ratio was then evaluated for its use in identification of alterations in normal 
kidney size.60 The reliability of the ratio was also assessed and the intraobserver reliability was 
found to be excellent (ICC = 0.95) and the interobserver reliability as moderate (ICC = 
0.72).60 The authors suggest this ratio can be used as a marker for screening renal 
abnormalities, however so far, they have only used the marker to assess nine cases of renal 
abnormality that did not demonstrate any hydronephrosis. 
The two reports from the Gomeroi Gaaynggal study were concerned with factors that may 
affect fetal kidney development. Maternal smoking was associated with significantly smaller 
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2D fetal kidney volumes than when compared with those from mothers who did not smoke. 
However, this effect  disappeared when gender was taken into consideration.63 This is likely 
due to fetal kidney volumes of males being higher than females and male kidney volume to 
body weight ratio also higher than in females.63 Generally, fetal kidney measurements in the 
third trimester were not associated with maternal body fat or pre-pregnancy BMI other than 
the right AP diameter being positively associated with maternal body fat, however not 
strongly (p = 0.03, r2 = 0.2).59 The left fetal 2D kidney volume to EFW ratio and the 
combined fetal kidney volume to EFW ratio were negatively associated with maternal body 
fat in the third trimester, but again the effect was small (p = 0.04, r2 = 0.02 / p = 0.03, r2 = 
0.03, respectively).59 
2.7.4 Discussion 
This update on the earlier systematic review revealed seven studies which have evaluated 
fetal kidney growth between January 2017 and June 2020. Remarkably, there were not any 
significantly new techniques or advances reported on since the systematic review was 
published in 2017.66 Furthermore, it was disappointing to see that there continues to be vague 
reporting of some aspects of studies even when increasingly journals are insisting on 
following guidelines such as STROBE for reporting observational studies.65  
Several studies investigated normal fetal kidney lengths and its accuracy to determine GA.58, 
61, 62 Reference ranges of fetal kidney measurements and the use of kidney length as an 
estimate for GA has now been well established in multiple different populations.9, 15-17, 19, 20, 23, 
32, 38 These new studies of normal kidney length ranges and their accuracy to estimate GA 
provide little additional information.58, 61, 62 They do, however, continue to support the 
principle that fetal kidney length is not a sensitive method to assess alterations in kidney 
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growth, for example in cases of fetal growth restriction, as the kidney length appears to be 
maintained.22, 31, 34, 37 
The reference charts for kidney length, AP, TS and volume by Barbosa et al.62 were developed 
using a non-parametric method which is not commonly used to derive fetal charts.47, 67 The 
selection of an appropriate statistical methodology for fetal charts is important for accuracy, 
particularly if clinical decisions are to be based on these charts. It is known that there is 
increasing variation in fetal measurements with increasing GA.47, 68 Additionally, the between-
subject variability also tends to increase with GA.67 These charts do not appear to account 
for how variability (SD) is changing with increasing GA and this can have significant impact 
on the accuracy of the charts.  The paper does not provide a summary table reporting the 
sample size, mean and SD of each measurement for each gestational week. There is also no 
verification that the centiles are a good fit to the data, for example, no scatter diagram of the 
raw data with the centiles superimposed. Currently, mixed effects (multilevel) modelling with 
fractional polynomials is suggested as the best method to model growth data.47, 67, 69 
It was predicted that there would be more studies investigating the use of 3D volumes of 
kidneys since the earlier review, however this was not the case with only one study including 
3D kidney volumes.64 The difficulties previously highlighted, such as no universal 
standardisation 3D file formats and software, no standardised image landmarks, no 
established calliper placement for volume acquisition and measurement, and poor 
reproducibility, have not yet been overcome.66 Obtaining a 2D kidney volume from linear 
measurements was more prevalent.58, 59, 62-64 It is relatively easy to obtain a 2D volume from 
three orthogonal linear measurements of the kidney and it does not require additional 
equipment to the standard ultrasound machine. 
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The studies in this review utilised similar 2D measurements as was reported in our earlier 
review, however, there were some novel applications of these measurements, particularly to 
account for kidney size relative to body size. A ratio of the AP diameter of the kidney to AP 
diameter of the fetal abdomen was found to be constant throughout pregnancy in a low risk 
pregnancy group and was then tested on a group of nine pregnancies with suspected renal 
anomaly but no hydronephrosis.60 This ratio may be sensitive to changes in kidney size, 
however, is not specific for diagnosis and has not been validated in cases of fetal growth 
restriction or large for gestational age fetuses. Furthermore, upper urinary tract dilatation 
(hydronephrosis) is one of the most diagnosed fetal abnormalities by ultrasound.70-72 
Therefore, if this ratio is unable to be used in cases of hydronephrosis its usability is limited. 
At this time, it is not possible to use it as a diagnostic criterion for renal abnormalities and 
will need to be further validated in larger cohorts of abnormal fetal growth.  
Aside from congenital renal abnormalities, factors that might affect the development of the 
fetal kidneys in a high-risk population for kidney disease and hypertension were assessed by 
analysing 2D kidney volumes in fetuses.59, 63 Both maternal body fat and maternal smoking 
were linked to alterations in fetal kidney development, particularly when the fetal kidney 
volume to overall fetal size was considered. The study by Lee et al., appears to be the only 
study so far to investigate any association between maternal adiposity measures and fetal 
kidney development.59 Evidence from these studies has not yet demonstrated a strong 
association between maternal smoking or maternal obesity with altered kidney growth. The 
Gomeroi gaaynggal study is still ongoing and therefore, a larger sample collected over a 
longer time may present more definitive data. Obesity during pregnancy, as well as smoking 
and poor maternal health are all thought to have a negative effect on renal development and 
further research is required in this area.73-76 
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2.7.5 Future research 
Overall, the disadvantage of 2D measurements and 3D volumes are that they include the 
entire kidney containing the parenchyma and the collecting system. As proposed in the earlier 
review, measuring only the renal parenchyma concentrates the analysis on the important 
functional part of the kidney containing the developing nephrons. Therefore, methods such 
as measuring renal parenchymal thickness, renal volume to parenchymal thickness ratio and 
renal perfusion may give us more meaningful information on nephron endowment and 
future renal function. Larger, longitudinal, rather than cross-sectional, studies are needed to 
assess fetal kidney growth in compromised intrauterine environments. These are encouraging 
parameters that should be investigated to see if they can provide improved diagnostic criteria 
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Chapter. 3 Study Design and Methods 
 
At the beginning of this thesis the research protocol for the overall study was published. The 
reference for this paper is below and the paper is attached in Appendix D. 
Brennan S, Schneider M, Watson D, Kandasamy Y, Rudd D. The renal parenchyma - 
evaluation of a novel ultrasound measurement to assess fetal renal development: protocol 
for an observational longitudinal study. BMJ Open. 2017; 7(12). 
As the thesis evolved, portions of the research protocol changed. Therefore, the original 
published paper referenced above has been updated for this chapter so that the chapter 
accurately reflects how the study was performed. The formatting of section sub-headings 
and references, and numbering of figures and tables have been modified from the original 
publication to match the thesis format. The wording has also been changed to past tense. 
This chapter describes the study design and methods of the overall study. As the results 
Ch 1: Introduction and background 
Ch 2: Systematic review 
Ch 3: Study design and methods 
Ch 4: Normal ranges of fetal renal parenchyma 
Ch 5: Normal ranges of fetal renal arteries 
Ch 6: Fetal renal parenchymal growth and fetal growth restriction 
Ch 7: Fetal renal parenchymal growth and fetal overgrowth 
Ch 8: Fetal renal parenchymal growth and diabetes in pregnancy 








chapters are publications, included in chapters 4 to 8 is additional relevant methodology 
specific to the study for that chapter. 
3.1 Introduction 
Chronic kidney disease is an increasing contributor to the global burden of disease, with 
hypertension now the leading risk factor.1 Recognition of the risk factors and implementation 
of preventive strategies is crucial to reducing hypertension and kidney disease. Abnormalities 
in fetal growth, such as fetal growth restriction (FGR), have a profound effect on the kidney 
development.2, 3 The association between an adverse intrauterine environment and chronic 
kidney disease later in life is now compelling.4-6 
During early fetal life, there is transient development and regression of the primary 
(pronephros) and secondary (mesonephros) fetal kidneys between day 23 and day 112 of 
embryonic life.7 The permanent functional tertiary fetal kidney is the metanephros which 
begins developing on day 30.7 Nephrogenesis involves the formation of the functional units 
of the kidney called nephrons and continues up to 36 weeks gestational age.8, 9  It is essential 
that appropriate nephrogenesis is achieved in-utero as the number and quality of nephrons 
directly influences lifetime kidney function.10 
FGR can result in a significant reduction in nephron number, however, being large for 
gestational age (LGA), particularly related to maternal hyperglycaemia, is also associated with 
abnormal fetal kidney development and an increased risk of hypertension and chronic kidney 
disease.11 A better understanding of the relationship between abnormal fetal growth and 
nephrogenesis is needed. Presently, the only accurate method of calculating human nephron 
number is during an autopsy.12 A non-invasive measure of nephron endowment is needed.  
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Ultrasound is the primary imaging modality for evaluating fetal kidneys.  We conducted a 
systematic review into the evaluation of fetal kidney growth using ultrasound which revealed 
there are few good quality, longitudinal studies.13  The most commonly reported ultrasound 
measurement was renal length; however, renal length alone was not found to be very sensitive 
to evaluate disruptions in fetal kidney growth in the presence of FGR.13  Few studies analysed 
the effects of FGR on fetal kidney growth and no studies have, to date, analysed if LGA has 
an effect on fetal kidney growth. Results from 2D and 3D renal volume calculations were 
disappointing.  Volumes calculated from 2D measurements underestimate renal volumes by 
as much as 24%.14 Substantial variations were reported for “normal” 3D kidney volumes and 
good reliability and reproducibility has not yet been demonstrated.  Currently there is no 
easily repeatable, sensitive method of measuring changes in fetal kidney growth.13  
Measuring the renal parenchyma with ultrasound is a novel method to assess fetal kidney 
development and predict future renal function. Measuring just the renal parenchyma will 
measure only the important functional part of the kidney which contains the nephrons (Fig. 
3.1). One small cross-sectional study measured fetal renal parenchyma in normally grown 
fetuses15 however, no studies have evaluated the fetal renal parenchyma in abnormally grown 
fetuses. Preliminary data from term neonates16 and children17 indicates that the parenchymal 
thickness may be a more reliable investigative method to define normal and abnormal kidney 
development. Methods such as measuring the parenchymal thickness, renal volume to 
parenchymal thickness ratio, renal artery Dopplers are potential non-invasive methods to 
evaluate nephron endowment and future renal function.  
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Figure 3.1 Measurement of kidney length [1] and the anterior [2] and posterior [3] 
fetal renal parenchymal thickness from the inner aspect of the renal capsule to the 
sinus-pyramidal apex interface. Source: Townsville University Hospital. 
 
The aim of this study was to use ultrasound to assess the fetal renal parenchymal growth in 
a pregnant population demonstrating either normal or abnormal growth, or diabetes in 
pregnancy, and determine if these abnormal fetal conditions influence fetal renal 
parenchymal growth. Non-invasive ultrasound techniques were used. The results could help 
identify factors that adversely affect kidney development so that they could be modified by 
public health interventions and education programs. This may promote improved fetal 
nephron number and quality at birth and reduce susceptibility to chronic disease in later life. 
3.2 Methods and Analysis 
3.2.1 Study design and setting 
This was a prospective, longitudinal, observational study conducted between May 2017 and 
February 2019, in the Ultrasound Department of the Townsville University Hospital, 
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Australia. Townsville Hospital and Health Service (THHS) provides tertiary perinatal 
services to North Queensland, which has a catchment area of around 700,000 with 10,000 
births per year.18 
3.2.2 Participants 
Pregnant women of 18 years or older, with an accurately dated singleton pregnancy of 16 
weeks gestation or more were included. Gestational age was based on the last normal 
menstrual period (LNMP) and first trimester ultrasound, that agreed within seven days, or 
on first trimester ultrasound if LNMP was uncertain. Pregnant women with uncertain dates, 
multiple pregnancy or any known major congenital fetal abnormality or chromosomal fetal 
abnormality were excluded. Explicitly, any fetal kidney abnormality, including dilatation of 
the renal pelvis of ≥ 4mm up to 28 weeks gestation or ≥ 7mm after 28 weeks gestation, was 
excluded from the study.  
3.2.3 Recruitment and consent of participants  
Between May 2017 and October 2018, pregnant patients who present to the Medical Imaging 
Department at the Townsville University Hospital for an obstetric ultrasound were invited 
to participate. In addition, mixed risk patients were also informed about the study by their 
treating obstetrician, midwife or sonographer.  Detailed written information was given to the 
patient and written consent obtained. The participant information sheet and consent form 
are attached in Appendix B. 
3.2.4 Study process 
Figure 3.2 outlines the flow schedule of the participants. On commencement of the study, 
participants completed a questionnaire which included demographic, medical and obstetric 
data. The participant questionnaire form is attached in Appendix B. The first ultrasound scan 
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was typically performed between 16- to 26-weeks and then follow-up ultrasounds were 
performed at least every four weeks from the first ultrasound examination. Some women, 
particularly with high risk pregnancies, required more than one clinically indicated 
ultrasound. For example, some women with a growth restricted fetus needed to be 
monitored by ultrasound more frequently than monthly. Conversely, the control group of 
low-risk pregnant women may have only required one to two clinically indicated scans 
between 16 to 40 weeks gestation. Therefore, to obtain good longitudinal data, the women 
were asked to attend for additional research scans every 4 weeks until delivery.  
3.2.5 Ultrasound examinations 
Three Australian Accredited Medical Sonographers, with at least two years post ultrasound 
qualification experience, performed all ultrasound examinations. Prior to commencement of 
the study, sonographers were trained to use a standardised protocol for renal measurements 
by authors DW and SB. A follow-up audit, to ensure measurement consistency between 
sonographers, was conducted three months after commencement of the study. The 
sonographers were not blinded to all clinical and biometric information as most studies 
included a diagnostic ultrasound scan. A Voluson E8 (GE Healthcare Ultrasound, 
Milwaukee, WI, USA) or an Epiq 7 (Philips Ultrasound, Bothell, WA, USA) were used for 
the ultrasound examinations and the highest frequency transducer possible (1-5MHz), which 
matched the mother’s body habitus was selected. When a woman attended for a clinically 
indicated scan, this was the priority and then the additional fetal renal measurements required 





Figure 3.2 Study participants flow chart. 
 
Where possible the fetal kidneys were measured with the fetal spine up (anterior) or as close 
as possible to this position. All measurements were performed on both kidneys. The image 
was magnified so that the kidney occupied most of the image. The renal parenchymal 
thickness measurement was obtained from a midsagittal plane of the kidney by measuring 
from the inner aspect of the renal capsule to the sinus-pyramidal apex in both the anterior 
and posterior aspects (Fig 3.1). The maximum kidney length (L) was also measured in this 
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midsagittal plane. In a transverse section of the fetal kidney, at the level of the renal pelvis, 
the maximum anteroposterior diameter (H) and transverse diameter (W) were measured. 
Every measurement was performed twice, with the mean measurement recorded.  
Bilateral fetal renal artery Dopplers were obtained in a coronal view of the kidneys. Colour 
flow was utilised to identify the renal artery arising from the aorta and entering the kidney. 
A low wall filter of between 30 to 60 Hertz was used and a sample gate of size 2mm to 3mm 
was placed in the mid trunk of the renal artery. Using an angle as close to 0 degrees as 
possible, a pulse wave signal was obtained. The mean of at least three consistent, consecutive 
waveforms was used to calculate the resistivity index (RI) and pulsatility index (PI).  
The following routinely performed obstetric measurements were also recorded for the study: 
• Single deepest vertical pocket of amniotic fluid 
• Umbilical artery (UA) Doppler  
• Middle cerebral artery (MCA) Doppler (where clinically indicated or 30 weeks 
gestation and over) 
• Ductus venosus (where clinically indicated) 
• Biometry – head circumference (HC), biparietal diameter (BPD), abdominal 
circumference (AC), femur length (FL). 
3.2.6 Birth data 
3.2.6.1 Outcome measures  






After baby’s birth, perinatal data was collected from the mother and baby’s electronic medical record 
 Birth Data to be collected  
Demographic, medical and 
obstetric history from 
participant questionnaire 
Gestational age at birth Antenatal steroids 
Birth weight Other antenatal medications 
Gender Maternal medical history: e.g.  
Apgar scores at 1 & 5mins • Diabetes 
Onset of labour Umbilical artery cord PH • Hypertension 
Mode of delivery Base Excess (BE) • Renal disease 
Admission to NICU or SCN Lactate  
 
Note: NICU, neonatal intensive care unit; SCN, special care nursery. 
3.2.6.1.1 Primary outcome measure 
1. Renal parenchymal thickness – anterior and posterior thickness in the longitudinal 
plane. 
3.2.6.1.2 Secondary outcome measures: 
1. Renal volume (RV) - calculated using the formula RV = Length x Width x Height x 
0.523 
2. Fetal growth biometry – HC, BPD, AC and FL 
3. Amniotic fluid – single deepest vertical pocket 
4. UA Doppler flow – RI and PI calculated from the average of at least three 
consecutive waveforms 
5. MCA Doppler flow – RI and PI calculated from the average of at least three 
consecutive waveforms 
6. Cerebroplacental ratio (CPR) – calculated using the formula CPR = MCA PI/UA 
PI, with the last CPR recorded before birth used to assist in group classification 
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7. Renal artery Doppler flow – RI and PI calculated from the average of at least three 
consecutive waveforms. 
3.2.7 Sample size 
Optimal sample size was calculated based on a statistical power of 80% and a significance 
level of 0.05 (two-tailed). Data from our previously published study16 has demonstrated that 
the renal parenchymal thickness was 9.4mm (± 1.1mm) for normal birth weight neonates 
and 8.3mm (± 1.0) mm for low birth weight neonates at term. Therefore, it was estimated 
that a sample size of 45 will be needed (15 FGR fetuses, 15 LGA fetuses and 15 appropriate-
for-gestational-age). Allowing for the possibility of loss to follow-up, at least 20 participants 
would be recruited for each group resulting in a total of 60 participants, each having an 
ultrasound scan at least every four weeks.  
3.2.8 Data analysis 
After the ultrasound examination was completed, and the baby was born, all data was 
collated, and participants were assigned to different groups:  
• Low-risk pregnant women 
• Women with an infant born appropriate-for-gestational age (AGA) 
• Women with a FGR infant 
• Women with an infant born LGA 
• Women with diabetes in pregnancy.  
The different groups were decided a priori and were used for different analyses. Therefore, 
participants could be in more than one group e.g. a woman could be in the AGA group and 
the diabetes in pregnancy group. Criteria for the groups and the different analyses performed 
for each study is explained in detail in the relevant chapter for that study. For the different 
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analyses, the participant’s data were independently analysed and assigned to groups by two 
authors (SB and DW). Any discrepancies between the authors were discussed and resolved. 
A third author was available (YK) if a consensus was not able to be reached, however, they 
were not required. Intraobserver and interobserver reliability were also assessed. Statistical 
analyses were performed using IBM SPSS Statistics 24 (Armonk, NY, USA), R statistical 
Language in R studio (v1.2.1335, Vienna, Austria) and Stata/MP (v14.2, Stata Corp LP, 
College Station, Texas, USA). The full details of the statistical analyses for the different 
studies is explained in the relevant chapters.   
3.2.9 Data management 
Data collection commenced in May 2017 and finished in June 2019. Participant data was de-
identify and assigned a number code to ensure confidentiality for each woman and baby. 
Electronic data was stored and saved on a password protected computer. Hard (paper) copies 
of the consent form, questionnaire and data sheets from the ultrasound examinations are 
stored in a locked filing cabinet in the principal researcher’s office. This office is a secure 
room within the Townsville University Hospital. Only the principal researcher and members 
of the research team had access to the data. 
3.3 Ethics 
This study was approved by the Townsville Health District Human Research Ethics 
Committee (HREC/16/QTHS/216) (Appendix A). 
3.4 Summary 
This was the first study to use a novel ultrasound measurement of the fetal renal parenchyma 
and measurements of fetal renal blood flow to assess fetal kidney growth. The goal of the 
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study was to evaluate the measurement of the fetal renal parenchymal thickness and to 
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This study presents a novel evaluation of the fetal renal parenchyma to better assess kidney 
growth and estimate nephron number. The fetal renal parenchymal thickness chart may be 
useful to aid diagnosis of prenatal kidney disease and predict future kidney function. 
4.1 Abstract 
Objective 
The objective of this study was to develop new standard charts for fetal renal parenchymal 
thickness, length and volume to define normal ranges for use in clinical practice and to assess 
the reliability of these measurements.  
Methods 
This was a prospective, longitudinal study of 72 low-risk singleton pregnancies undergoing 
serial ultrasound examinations at least every four weeks.  Multiple renal measurements were 
performed on both kidneys at each scan. The renal parenchymal thickness was measured in 
the mid-sagittal plane. Standard charts were developed and the intra and interobserver 
reliability for the renal measurements was analysed.  
Results 
Standard charts were developed for fetal renal parenchymal thickness, length and volume.  
Conclusion 
We present novel charts which demonstrate the growth of the fetal renal parenchyma during 
pregnancy. They will be useful in clinical practice to identify any alterations from these 
normal ranges, which may be an important criterion for assisting prenatal diagnosis of renal 




Normal development of the kidneys during pregnancy is vital for future kidney health. It is 
well established that abnormal early kidney development is associated with increased risks of 
hypertension, kidney disease and cardiovascular disease in post-natal life.1-4 Found within the 
parenchyma, nephrons are the functional units of the kidneys. Abnormal fetal growth and/or 
prematurity is thought to impact nephron number and development.5-7 Ultrasound is the 
primary imaging modality to visualise fetal kidneys as it is non-invasive, safe and able to 
accurately measure the size of the kidneys8. Obstructive fetal renal pathologies are commonly 
diagnosed with antenatal ultrasound; however, renal parenchymal pathologies are 
underdiagnosed due to the lack of objective criteria of the renal parenchyma.9, 10 
Ultrasound charts of normative fetal kidney growth mostly include kidney length and 
volume.11, 12 Kidney length has not proven to be a sensitive method of assessing kidney 
growth.13, 14 Kidney volume measurements may appear to be a more accurate measure, 
however, tends to underestimate actual kidney volumes by around 20% due to inherent 
variance present in the three orthogonal measurements applied to the formula.15-17 
Furthermore, kidney volume measurements include the entire kidney and therefore, parts of 
the kidney not directly involved in filtration, such as the collecting system and the capsule 
are included. There is an unmet need for a more reliable method of detecting alterations in 
kidney growth.  
Ultrasound measurement of the renal parenchymal thickness is a non-invasive, easily 
performed measurement that focusses analysis on the functional tissue of the kidney.15, 18, 19 
Measurement of the fetal renal parenchymal thickness may aid in the prenatal diagnosis of 
parenchymal pathologies and be an indirect measure of nephron number and future kidney 
function. 
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The aim of this study was to use serial ultrasound scans to develop standard charts for fetal 
renal parenchyma, as well as kidney length and volume from 16- to 38-weeks’ gestation. 
4.3 Methods 
A prospective, longitudinal, observational study was conducted among a cohort of low-risk 
pregnancies between May 2017 and February 2019 in the Maternal Fetal Medicine Unit and 
Ultrasound Department of the Townsville University Hospital, Australia. This study was 
approved by the Townsville Hospital and Health Service Human Research Ethics Committee 
(HREC/16/QTHS/216). 
4.3.1 Study population 
Townsville Hospital and Health Service (THHS) provides tertiary perinatal services to North 
Queensland, which has a catchment population of around 700,000 with 10,000 births per 
year.20  Between May 2017 and October 2018, pregnant patients aged 18 years or older, who 
presented to the Medical Imaging Department at the Townsville University Hospital for a 
second trimester obstetric ultrasound scan were invited to participate.  Alternatively, patients 
were informed about the study by their treating obstetrician, midwife or sonographer.  
Inclusion criteria were singleton pregnancy up to 28-weeks’ gestation, accurate dating based 
on last normal menstrual period (LNMP) and 1st trimester ultrasound, that agreed within 
seven days, or on 1st trimester ultrasound if LNMP was uncertain. Exclusion criteria were 
uncertain dates, multiple pregnancy, congenital or chromosomal fetal abnormality, maternal 
disease that was likely to affect the growth of the fetus (diabetes mellitus, heart disease, 
hypertension requiring treatment, kidney disease, pre-eclampsia) and subsequent preterm 
birth less than 32-weeks.  
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4.3.2 Study process 
Prior to the first ultrasound scan, the participant completed a questionnaire which included 
demographic, medical and obstetric data. The first ultrasound was planned to be performed 
between 16- to 24-weeks, however, 11 women had their first ultrasound between 26- and 29-
weeks. Women were then asked to attend for ultrasound scans every four weeks from their 
first scan until delivery. Some women had additional clinically indicated ultrasounds, for 
example, for decreased fetal movements, and if this ultrasound was performed two or more 
weeks from the previous ultrasound, renal measurements were performed again for the 
study. After baby’s birth, data relating to the delivery and condition of baby at birth was 
collected.  The gestational ages (GA) of 16- to 38-weeks were used for creation of the 
standard charts.  
4.3.3 Ultrasound measurements 
Three Australian Accredited Medical Sonographers with at least two years post ultrasound 
qualification experience performed the examinations.  A protocol clearly outlined the 
additional renal measurements and how they were to be performed. Training of the 
sonographers was conducted by the authors (DW and SB) prior to commencement of the 
study and an audit and follow-up was conducted with the sonographers three months after 
commencement of the study to confirm adherence to the study protocol. An Epiq 7 (Philips 
Ultrasound, Bothell, WA, USA) or Voluson E8 (GE Healthcare Ultrasound, Milwaukee, WI, 
USA) were used for the examinations. To obtain the highest image resolution, the highest 
frequency transducer possible, matching the mother’s body habitus, was selected (1-5MHz).  
Where possible the fetal kidneys were measured with the fetal spine anteriorly, or as close as 
possible to this fetal position. The image was magnified so that the kidney occupied most of 
the image and the right and left kidney were identified. A midsagittal scan of both kidneys 
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along their longest length was recorded and the longest length (L) of both kidneys was 
measured. The anterior and posterior renal parenchymal thickness was also measured in this 
midsagittal plane. It was measured from the inner aspect of the renal capsule to the sinus-
pyramidal interface (Fig 4.1). A transverse section of the fetal kidneys at the level of each 
renal pelvis was obtained. The maximum anteroposterior diameter (H) and transverse 
diameter (W) was measured for both kidneys (Fig 4.1). Each measurement was performed 
twice and the mean of the two measurements recorded. Kidney volume was calculated using 
the ellipsoid formula: KV = 0.523  L  W  AP (π/6 x L x W x AP).21 
  
 
Figure 4.1 Fetal kidney measurements (a) Measurement of kidney length (1) the 
anterior (2) and posterior (3) fetal renal parenchymal thickness from the inner 
aspect of the renal capsule to the sinus-pyramidal apex interface at 24 weeks 
gestational age. (b) Measurement of kidney transverse (1) and antero-posterior (2) 
dimensions at 20 weeks gestational age. Source: Townsville University Hospital. 
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4.3.4 Measurement reliability 
A sample of 15 pregnancies, some who were a part of the study and some additional 
pregnancies, were measured for analysis of intra and interobserver reliability. The gestational 
age range of the pregnancies was 19 to 36 weeks. The three sonographers involved in the 
study obtained real time measurements of each renal measurement twice. They were blinded 
to their own and each other’s measurements by concealing the measurements on the 
monitor. The mean of each observer’s two measurements was analysed.  
4.3.5 Analysis  
Maternal and birth characteristics and intra and interobserver variability were analysed using 
IBM SPSS version 25. Normality of the maternal and birth data was tested using 
Kolmogorov-Smirnov test and visually inspecting histograms. Normally distributed variables 
were reported as mean and standard deviation (SD) and non-normally distributed variables 
as a median and interquartile range. To assess intra and interobserver reliability an ANOVA 
model was used and SD, Cronbach’s alpha (α) and the intraclass correction coefficient (ICC) 
with 95% confidence intervals were calculated. 
All other statistical analyses were performed using Stata/MP v14.2 for windows (Stata Corp 
LP, College Station, TX, USA) and the graphics were created with ggplot222 in R Studio 
(version 1.2.1335).23 Statistical significance was accepted as p < 0.05. Methods of the 
INTERGROWTH 21st Project for fetal growth were applied.24 The Stata function fp was 
used to ascertain the best fitting model for the mean of each renal measurement as a function 
of a fractional polynomial in GA (rounded down to whole week). For kidney volume a cubed 
root transformation was required as models for kidney volume fit poorly (in terms of 
functional form, non-constant variance, skewness of data at later time points and predicted 
values less than zero). A two level, mixed effect regression model was then built for each 
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measurement, including fixed effects for the polynomial function of GA, and accounting for 
repeated measures on participants using random intercept and slope with unstructured 
covariance (i.e. allowing each individual to have different growth trajectories and starting 
values, which allows partitioning of the variation within and between participants).  
Normality of the residuals was assessed using quantile plots and histograms. The Huber-
White sandwich (robust) estimator was used for standard error estimation due to non-
constant variance. Scaled (multiplied by √(π/2)) absolute residuals from this model were then 
regressed on GA to determine the optimal factional polynomial terms for the standard 
deviation function in a fixed effects model. Percentiles of the distribution of the renal 
measures by GA were assumed normal and calculated using the formula: 
Mean + Z x SD 
Where Z is – 1.88, - 1.645, - 1.28, 0, 1.28, 1.645, 1.88 for the 3rd, 5th, 10th, 50th, 90th, 95th and 
97th centiles respectively.  
Differences between the renal measurements were investigated according to gender, side 
(right/left) or in the case of parenchymal thickness, if the anterior or posterior parenchyma 
was measured. This did reduce the sample size of the group, for these analyses, and therefore 
the models are likely to be underpowered and there is a risk of overfitting. Due to there being 
less data at some gestational weeks, two weekly classification of GA (rounded down to the 
nearest even number) was used. For each of the variables (gender, side (right/left) and with 
parenchymal thickness, anterior/posterior parenchyma) a two-level saturated mixed effects 
model was fitted with fixed effects for GA and the variable, and a term for the interaction of 
GA and exposure. A random intercept accounted for repeated measurements on participants 
and all models, except for the anterior/posterior interaction model used Huber-white 




The study recruited 155 pregnant women. Eighty-three participants were excluded (Fig 4.2). 
For the remaining 72 low-risk pregnancies, the mothers’ and babies’ characteristics are 
summarised in Table 4.1. The median GA at delivery was 38.8 weeks with a range of 34.1 – 
41.7 as this included 8 neonates that were born preterm (before 37 weeks but after 32 weeks). 
Induction of labour was often for a combination of reasons; however, the primary reasons 
were for reduced fetal movements 6 (25%), pre-labour rupture of members 5 (21%), concern 
around slowing of growth 5 (21%), post-dates 2 (1%) and 6 (25%) for other reasons. No 
labour, resulting in caesarean section, was due to repeat caesarean section 10 (63%), breech 
presentation 3 (19%) and 3 (19%) for other reasons.  Measurements were obtained from 
both fetal kidneys with a total of 393 separate ultrasound examinations carried out between 
16 to 39 weeks GA. The median number of ultrasound scans per pregnancy was five (range 








Table 4.1  
Characteristics of study population of 72 women and their newborns 
Participant Characteristics N = 72 
MATERNAL  
Maternal age (years) 29.3 ± 5.2 
Maternal height (cm) 164 ± 6.0 
Maternal weight (kg) 66.0 (58.0–79.5) 
Maternal BMI (kg/cm2) 24.9 (21.6 – 28.5) 
Maternal race origin N=56† 
• Aboriginal/Torres Strait Islander 4 (5.6%) 
• Asian 1 (1.4%) 
• Caucasian 49 (68.0%) 
• Other 3 (4.2%) 
Parity  
• Nulliparous 39 (54.2%) 
• Parous 33 (45.8%) 
Conception N=60‡ 
• Spontaneous 51 (70.8%) 
• Assisted 9 (12.5%) 
Onset of labour  
• Spontaneous labour 32 (44.5%) 
• Induction of labour 24 (33.3%) 
• No labour 16 (22.2%) 
NEONATAL  
GA at birth (weeks) 38.8 (37.9–39.7) 
Preterm - <37 weeks > 32 (weeks)§ 8 (11.1%) 
Birth weight (grams) 3143 (2850-3568) 
Male  41 (56.9%) 
Female 31 (43.1%) 
Note: Data are given as means ± SD, median (interquartile range) or n (%). †16 (22.2%) participants 
declined to answer. ‡12 (16.7%) participants declined to answer. §Pregnancies resulting in a preterm 
birth before 32 weeks were excluded. GA, gestational age. 
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For renal parenchymal thickness, there were 1576 observations, as there were four 
measurements on each participant at each ultrasound examination measuring the anterior 
and posterior parenchyma for the right and left kidney.  For the other measurements, there 
were two measurements (right and left) at each ultrasound examination. Some patients, 
however, only had one measurement at some visits, therefore there were 786 observations 
for kidney length and 785 for kidney volume in total. Table 4.2 shows the number of 
participants for each GA. In one participant’s scan at 28-weeks the transverse and antero-
posterior measurements of the left kidney were not performed, and the left kidney volume 
could not be calculated at this GA. In another participant at 36-weeks, the length of both 
kidneys was missed and therefore the kidney volume could also not be calculated at that 
particular GA. For all renal measurements there was a lack of evidence of any significant 
difference between right and left kidneys, gender or in the case of parenchymal thickness, 




Table 4.2  
Number of participants according to each gestational age (rounded down to whole week) 



























4.4.1 Growth models for renal parenchymal thickness 
The centiles for all renal measurements were calculated using the equation: mean +Z x SD, 
where Z is the Z score for the respective centile. Table 4.3 presents the calculated centiles 
for each completed gestational week and the fitted standard deviation. A standard chart of 
the 3rd, 10th, 50th, 90th and 97th smoothed centiles of the fetal renal parenchymal thickness 
measurements between 16- and 38-weeks GA with the raw data superimposed is presented 
in Figure 4.3.  
 
Figure 4.3 Standard chart of fetal renal parenchymal thickness showing all raw 
measures (dots) and the 3rd, 10th, 50th, 90th and 97th smoothed centiles calculated 
from the derived equations for the mean and SD according to gestational age. 
 
The resulting equation for the mean renal parenchymal thickness was: 




The resulting equation for the standard deviation (SD) was: 
SD = -0.0223467 + 0.0003774 x GA3 – 0.0000974 x GA3 x ln(GA). 
Table 4.3  
Fitted 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles calculated from the derived equations for the 





Mean SD c3 c5 c10 c50 c90 c95 c97 
16 64 3.03 0.42 2.30 2.30 2.50 3.00 3.60 3.70 3.80 
17 12 3.37 0.48 2.50 2.60 2.80 3.40 4.00 4.10 4.30 
18 4 3.71 0.54 2.70 2.80 3.00 3.70 4.40 4.60 4.70 
19 16 4.07 0.60 2.90 3.10 3.30 4.10 4.80 5.10 5.20 
20 124 4.44 0.66 3.20 3.40 3.60 4.40 5.30 5.50 5.70 
21 32 4.81 0.73 3.50 3.60 3.90 4.80 5.70 6.00 6.20 
22 32 5.19 0.79 3.70 3.90 4.20 5.20 6.20 6.50 6.70 
23 28 5.57 0.85 4.00 4.20 4.50 5.60 6.70 7.00 7.20 
24 168 5.95 0.91 4.20 4.40 4.80 6.00 7.10 7.50 7.70 
25 24 6.32 0.97 4.50 4.70 5.10 6.30 7.60 7.90 8.20 
26 56 6.69 1.03 4.70 5.00 5.40 6.70 8.00 8.40 8.60 
27 48 7.04 1.09 5.00 5.30 5.70 7.00 8.40 8.80 9.10 
28 164 7.38 1.14 5.20 5.50 5.90 7.40 8.80 9.20 9.50 
29 44 7.69 1.18 5.50 5.80 6.20 7.70 9.20 9.60 9.90 
30 84 7.99 1.22 5.70 6.00 6.40 8.00 9.60 10.00 10.30 
31 64 8.26 1.25 5.90 6.20 6.70 8.30 9.90 10.30 10.60 
32 136 8.50 1.28 6.10 6.40 6.90 8.50 10.10 10.60 10.90 
33 80 8.70 1.30 6.30 6.60 7.00 8.70 10.40 10.80 11.10 
34 72 8.86 1.31 6.40 6.70 7.20 8.90 10.50 11.00 11.30 
35 60 8.98 1.31 6.50 6.80 7.30 9.00 10.70 11.10 11.40 
36 164 9.06 1.30 6.60 6.90 7.40 9.10 10.70 11.20 11.50 
37 44 9.08 1.27 6.70 7.00 7.40 9.10 10.70 11.20 11.50 
38 44 9.04 1.24 6.70 7.00 7.50 9.00 10.60 11.10 11.40 
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Only one small study was identified that had measured the fetal renal parenchymal thickness 
(between 20- and 40-weeks) and had published raw centile data.19 It was difficult to directly 
compare our results with their results due to technical differences in the studies. Their mean 
number of participants for a whole gestational week was 5.7 (min = 1, max = 14). Their 
exclusions included any maternal disease or pregnancy complication (however did not state 
what these might be), small for gestational age or fetal growth restriction (defined as fetal 
weight below the 10th centile), oligohydramnios or any kidneys that were smaller or larger 
than expected for GA. Excluding any smaller or larger than expected kidneys introduces bias 
into the chart. 
4.4.2 Growth models for fetal kidney lengths and volumes  
Centiles for the fetal kidney lengths and kidney volumes were calculated using the equation: 
mean +Z x SD, where Z is the Z score for the respective centile. The standard charts of the 
3rd, 10th, 50th, 90th and 97th smoothed centiles of the measurements between 16- and 38-weeks 
GA for fetal kidney length and kidney volume, are presented in Figure 4.4. Tables 4.4 and 
4.5 present the calculated centiles for each and below are the resulting equations of the mean 
and SD: 
Mean kidney length = 4.122128 + (0.0087023 X GA3) - (0.0022069 X GA3 X ln(GA)). 
SD kidney length = 4.738434 - (53.57991 X GA-1) + (0.0000218 X GA3). 
 
Mean kidney volume = 2.422287 + (0.0045001 X GA3) - (0.0011408 X GA3 X ln(GA)). 






Figure 4.4 Standard fetal charts of (a) kidney length and (b) kidney volume showing 
all raw measures (dots) and the 3rd, 10th, 50th, 90th, and 97th smoothed centiles 
calculated from the derived equations for the mean and SD according to gestational 
age. 
 
These new kidney length and volume charts were compared with charts previously published 
by Chitty and Altman (2003) as these charts had very similar inclusion and exclusion criteria 
to this study and published the 3rd 10th, 50th, 90th and 97th centiles for each  
measurement 12. A comparison was made with our study by plotting equivalent centiles on 
their charts (Fig 4.5 & 4.6).  
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Table 4.4 
Fitted 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles calculated from the derived equations for the 




vations Mean SD c3 c5 c10 c50 c90 c95 c97 
16 32 14.7 1.5 11.9 12.3 12.8 14.7 16.6 17.1 17.5 
17 6 16.2 1.7 13.0 13.4 14.0 16.2 18.3 18.9 19.3 
18 2 17.7 1.9 14.1 14.6 15.3 17.7 20.1 20.8 21.2 
19 8 19.2 2.1 15.4 15.8 16.6 19.2 21.9 22.6 23.1 
20 62 20.9 2.2 16.7 17.2 18.0 20.9 23.7 24.5 25.0 
21 16 22.5 2.4 18.0 18.6 19.4 22.5 25.5 26.4 27.0 
22 16 24.1 2.5 19.4 20.0 20.9 24.1 27.4 28.3 28.9 
23 14 25.8 2.7 20.8 21.4 22.4 25.8 29.2 30.2 30.8 
24 84 27.5 2.8 22.2 22.8 23.9 27.5 31.1 32.1 32.7 
25 12 29.1 2.9 23.6 24.3 25.3 29.1 32.9 33.9 34.6 
26 28 30.7 3.1 24.9 25.7 26.8 30.7 34.6 35.7 36.5 
27 24 32.2 3.2 26.3 27.0 28.2 32.2 36.3 37.5 38.2 
28 82 33.7 3.3 27.5 28.3 29.5 33.7 38.0 39.2 39.9 
29 22 35.1 3.4 28.7 29.5 30.7 35.1 39.5 40.7 41.6 
30 42 36.4 3.5 29.8 30.6 31.9 36.4 41.0 42.2 43.1 
31 32 37.6 3.7 30.7 31.6 32.9 37.6 42.3 43.6 44.5 
32 68 38.7 3.8 31.5 32.4 33.8 38.7 43.5 44.9 45.8 
33 40 39.6 3.9 32.2 33.1 34.6 39.6 44.5 46.0 46.9 
34 36 40.3 4.0 32.7 33.7 35.1 40.3 45.4 46.9 47.8 
35 30 40.8 4.1 33.0 34.0 35.5 40.8 46.1 47.6 48.6 
36 82 41.2 4.3 33.1 34.1 35.7 41.2 46.6 48.2 49.2 
37 22 41.3 4.4 33.0 34.0 35.6 41.3 46.9 48.5 49.5 






Fitted 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles calculated from the derived equations for the 





mean sd c3 c5 c10 c50 c90 c95 c97 
16 32 7.9 0.7 6.5 6.7 6.9 7.9 8.9 9.1 9.3 
17 6 8.7 0.8 7.1 7.3 7.6 8.7 9.7 10.0 10.2 
18 2 9.4 0.9 7.7 7.9 8.2 9.4 10.6 11.0 11.2 
19 8 10.2 1.0 8.3 8.6 8.9 10.2 11.6 11.9 12.2 
20 62 11.1 1.1 9.0 9.3 9.7 11.1 12.5 12.9 13.2 
21 16 11.9 1.2 9.7 10.0 10.4 11.9 13.5 13.9 14.2 
22 16 12.8 1.3 10.4 10.7 11.1 12.8 14.4 14.9 15.2 
23 14 13.7 1.4 11.1 11.4 11.9 13.7 15.4 15.9 16.2 
24 84 14.5 1.5 11.8 12.1 12.6 14.5 16.4 16.9 17.3 
25 12 15.4 1.5 12.5 12.8 13.4 15.4 17.3 17.9 18.3 
26 28 16.2 1.6 13.1 13.5 14.1 16.2 18.3 18.9 19.2 
27 24 17.0 1.7 13.8 14.2 14.8 17.0 19.2 19.8 20.2 
28 81 17.8 1.8 14.4 14.9 15.5 17.8 20.0 20.7 21.1 
29 22 18.5 1.8 15.0 15.5 16.1 18.5 20.8 21.5 21.9 
30 42 19.2 1.9 15.6 16.1 16.7 19.2 21.6 22.3 22.7 
31 32 19.8 1.9 16.1 16.6 17.3 19.8 22.3 23.0 23.4 
32 68 20.3 2.0 16.6 17.1 17.8 20.3 22.9 23.6 24.1 
33 40 20.8 2.0 17.0 17.5 18.2 20.8 23.4 24.1 24.6 
34 36 21.2 2.1 17.3 17.8 18.5 21.2 23.8 24.6 25.0 
35 30 21.5 2.1 17.6 18.0 18.8 21.5 24.1 24.9 25.4 
36 82 21.6 2.1 17.7 18.2 19.0 21.6 24.3 25.1 25.6 
37 22 21.7 2.1 17.8 18.3 19.0 21.7 24.4 25.2 25.6 





4.4.3 Measurement reliability 
A summary of the analysis of the interobserver and intraobserver variation for all renal 
measurements are shown in Tables 7 and 8. The interobserver and intraobserver ICC was 
excellent for renal parenchymal thickness, length, transverse and antero-posterior 
dimensions being over 0.95. 
 
 
Figure 4.5 Comparison of 3rd, 10th, 50th, 90th and 97th centiles for fetal kidney 
length measurements according to gestational age obtained from this study (solid 







Figure 4.6 Comparison of 3rd, 10th, 50th, 90th and 97th centiles for fetal kidney 
volume according to gestational age obtained from this study (solid black lines) 





Interobserver reliability for fetal renal measurements 
Variable (N = 15) 
 Mean +/- SD (mm)  
Cronbach's α ICC (95% CI) 
Observer 1 Observer 2 Observer 3 
Anterior parenchymal 
thickness 7.60 +/- 1.85 7.53 +/- 1.97 7.19 +/- 1.79 0.98 0.98 (0.94-0.99) 
Posterior parenchymal 
thickness 7.97 +/- 1.95 7.57 +/- 1.92 7.12 +/- 1.85 0.97 0.96 (0.86-0.99) 
Kidney length 35.50 +/- 7.58 36.37 +/- 7.78 35.44 +/-7.62 0.99 0.99 (0.97-0.99) 
Kidney transverse diameter 17.26 +/- 3.33 17.74 +/- 3.67 17.19 +/- 3.88 0.97 0.97 (0.92-0.99) 
Kidney antero-posterior 






Intraobserver reliability for fetal renal measurements 
Variable Mean +/- SD Cronbach's α ICC (95% CI) 
Anterior parenchymal thickness 7.58 +/- 1.89 0.98 0.98 (0.92-0.99) 
Posterior parenchymal thickness 7.95 +/- 1.97 0.97 0.97 (0.90-0.99) 
Kidney length 35.65 +/- 7.76 0.98 0.98 (0.95-0.99) 
Kidney transverse diameter 17.23 +/- 3.39 0.96 0.96 (0.89-0.99 
Kidney antero-posterior diameter 19.00 +/- 4.25 0.97 0.97 (0.92-0.99) 
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4.5 Discussion 
This study developed a standard chart of fetal renal parenchymal thickness, length and 
volume from 16- to 38-weeks’ gestation. These charts can be utilised for both growth and 
size comparison as they are derived from longitudinal data using mixed effects modelling. 
Mixed effects modelling is a sophisticated and powerful method utilising every data point 
and can better account for the heterogeneity of the timing of the scans and missing data.25 
This chart of renal parenchymal thickness represents an innovative method that will provide 
more detailed information on fetal kidney growth and potentially function. 
Antenatal ultrasound is a reliable technique for diagnosing fetal obstructive pathologies, such 
as hydronephrosis and lower urinary tract obstruction; however, it is less reliable at assessing 
parenchymal pathologies and determining renal reserve.9 The parenchyma of the kidney 
comprises the cortex and medulla. Nephrons develop within the parenchyma and are the 
important filtration part of the kidney containing the glomeruli.26 Nephrogenesis continues 
up until 34 to 36 weeks GA in a normal pregnancy with around 60% of nephrons formed in 
the third trimester.27 The role of measuring the fetal renal parenchyma to assess kidney 
growth and estimate nephron number has not yet been well established.13 We previously 
investigated the renal parenchymal thickness of neonates and demonstrated that it was a 
single measure which had less variance than kidney volume and could be used to assess 
neonatal kidney growth.15  
Renal parenchymal thickness measurements offer a superior evaluation of fetal kidney 
growth and future kidney function as changes in the parenchymal thickness through the 
pregnancy should indirectly reflect nephron number. A dramatic improvement in ultrasound 
imaging over the last decade provides high-quality ultrasound images and allows non-
invasive, accurate identification of the fetal renal parenchyma and presents a potentially 
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reliable technique to assess kidney development and indirectly estimate nephron number.  
This is not only important for prenatal diagnosis of renal parenchymal pathologies but also 
as a marker of future kidney function. Diminished nephron numbers at birth likely renders 
the kidney more vulnerable to damage which could substantially impact kidney function 
throughout later life.28 
Our renal parenchymal thickness chart demonstrates that the parenchyma increases in 
thickness with increasing GA up until around 34-weeks. It then plateaus between 34- and 
36-weeks which correlates with completion of nephrogenesis. This is consistent with an 
ultrasound study by Konje et al. (1996) which demonstrated that the period between 26- and 
34-weeks’ gestation underwent the most rapid fetal kidney growth.29  
This standard chart of renal parenchymal thickness could be used in clinical practice to assist 
in the antenatal diagnosis of renal parenchymal pathologies and as an indirect estimate of 
nephron number. Deviation in the thickness of the renal parenchyma from these normal 
standards may indicate an alteration in normal kidney growth and could be employed as 
criteria for identifying infants with parenchymal pathologies or those who might be at future 
risk of kidney disease. Providing multiple centiles enables the chart to be used as a screening 
tool (using the 10th and 90th as lower and upper limits respectively) or more as a diagnostic 
tool (using the 3rd and 97th as lower and upper limits respectively).30  
Our standard fetal kidney length and volume charts add to the knowledge of previously 
created charts. The most widely used kidney size charts are those by Chitty and Altman 
(2002) and we compared our charts to these.12 Kidney lengths in our cohort were very similar, 
other than in earlier GA where our kidney measurements are longer. We had more 
participants at these early gestations and better imaging resolution due to the advancement 
of ultrasound equipment. The kidney length in our chart plateaus from around 34-weeks, 
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while their chart shows continued increases. However, the Chitty and Altman charts are 
based on cross-sectional data and we speculate that our longitudinal data may be more 
accurate with regards to kidney growth and the slowing of this growth towards the end of 
pregnancy as nephrogenesis is complete. There is some difference between our kidney 
volume charts and those published by Chitty and Altman.12 Our chart appears to have 
narrower ranges. This is likely due to kidney volumes being based on a composite calculation 
and having more variance than a single linear measurement, as well as the longitudinal 
characteristics of our data measured using more modern equipment.  
4.5.1 Limitations of the study 
Due to the small sample size at GA prior to 20-weeks and after 36-weeks, estimates from 
the models may only be reliable in the GA range from 20 to 36 weeks. There may have been 
some potential measurement bias due to the lack of blinding of the sonographers. As most 
of the ultrasound examinations included a diagnostic scan, it was difficult to blind the 
sonographer to all clinical and biometric information. Sonographers are generally trained not 
to look at measurement as they are performing them and having multiple sonographers, 
rather than only one, perform the examinations reduces some of the possible bias.  
4.6 Conclusion 
This study highlights the need for an accurate method to assess fetal kidney growth and 
indirectly estimate nephron number as a surrogate for kidney function. The standard chart 
for renal parenchymal thickness developed by our group will be useful in clinical practice to 
identify alterations in kidney development. Deviations in the thickness of the renal 
parenchyma from these established normal standards presents a new criterion in the 
diagnosis of kidney anomalies, particularly in the diagnosis of fetuses with parenchymal 
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pathologies or reduced nephron numbers, which leaves them susceptible to future kidney 
disease. We demonstrated excellent intra and interobserver reliability for measurement of the 
parenchymal thickness. The charts of fetal kidney length and volume strengthens our 
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The purpose of this chapter was to establish the normal ranges of fetal renal artery resistivity 
index (RI) and pulsatility index (PI) during pregnancy. The relationship between fetal renal 
blood flow and amniotic fluid levels was also investigated. 
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The objective of this study was to develop new standard charts for fetal renal artery blood 
flow to define normal ranges and to assess the reliability of these measurements. The 
correlation between amniotic fluid levels and fetal renal artery blood flow were also analysed. 
Methods 
This was a prospective, longitudinal study of 72 low-risk singleton pregnancies undergoing 
serial ultrasound examinations at least every four weeks.  Pulse wave Doppler was used to 
obtain the resistivity and pulsatility indices of the fetal renal arteries.  Standard charts of the 
fetal renal arteries were developed and the intra and interobserver reliability for the renal 
blood flow measurements were analysed. 
Results 
Standard charts of the normal ranges of the renal artery resistive index (RI) and pulsatility 
index (PI) of the fetal renal arteries were created. The 3rd, 5th, 10th, 50th, 90th, 95th and 97th 
centiles were calculated. No correlation was observed between the amniotic fluid levels and 
RI or PI. The intraclass correlation coefficient was acceptable for intraobserver reliability (RI 
= 0.66, PI = 0.88) and poor for interobserver reliability (RI = 0.11, PI = -0.56).  
Conclusion 
We present novel charts which demonstrate the change of the fetal renal artery blood flow 
during pregnancy. These may be useful in clinical practice to identify any variations from 
these normal ranges and for use in future studies in the prediction of kidney function.  
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5.2 Introduction  
Appropriate vascularisation and blood flow to fetal organs is crucial for normal fetal 
development and organ growth.1 To enable glomerular filtration and tubular reabsorption 
and secretion, the mature kidneys require a complex arterial and venous system.2 It is 
therefore essential to understand what blood flow is expected for the normal development 
of the fetal kidneys.  
Increasing advancements in antenatal ultrasound have allowed the investigation of many fetal 
vessels including the renal arteries.3 Pulsed wave Doppler is the best non-invasive method to 
study the haemodynamic changes in fetal vessels. Quantification of the normal evolution of 
the fetal renal blood flow during pregnancy will enable identification of  aberrations in blood 
flow, such as may be seen during fetal hypoxia when blood flow is preferentially shunted 
away from the kidneys to more vital organs.4 Analysis of the resistivity index (RI) and 
pulsatility index (PI) of the fetal renal arteries may potentially provide a more sensitive 
method to assess renal haemodynamics and may be used to assist in the differential diagnosis 
of renal pathologies.  
Antenatal assessment of renal function is challenging, and a non-invasive method has not yet 
been uncovered.2, 5 Innovative methods need to be explored to try and find a solution. After 
20 weeks gestation, the fetal kidneys provide over 90% of the amniotic fluid through 
urination.6 We postulated that there may be a correlation between fetal renal blood flow and 
amniotic fluid levels which may contribute to a surrogate, non-invasive evaluation of fetal 
renal function.    
The aim of this study was to use serial ultrasound examinations to develop standard charts 
of the normal ranges of RI and PI of the fetal renal arteries from 16- to 38-weeks’ gestation 
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for use in clinical practice. This study also aimed to evaluate the reliability of RI and PI 
measurements and assess for any correlation between renal artery blood flow indices and 
amniotic fluid levels.  
5.3 Materials and Methods  
In this prospective, observational study, serial ultrasound examinations on a cohort of low-
risk pregnancies were performed between May 2017 and February 2019. The study was 
conducted in the Maternal Fetal Medicine Unit and Ultrasound Department of the 
Townsville University Hospital, Australia. This study was approved by the Townsville 
Hospital and Health Service Human Research Ethics Committee (HREC/16/QTHS/216). 
5.3.1 Study population 
Townsville Hospital and Health Service (THHS) provides tertiary perinatal services to North 
Queensland and has a catchment population of around 700,000.7 Pregnant women aged 18 
years or older, who presented to the Medical Imaging Department at the Townsville 
University Hospital for a second trimester obstetric ultrasound scan between May 2017 and 
October 2018 were invited to participate.  Patients were also informed about the study by 
their obstetrician, midwife or sonographer.  
Accurately dated singleton pregnancies, based on last normal menstrual period (LNMP) and 
1st trimester ultrasound, that agreed within seven days, or on 1st trimester ultrasound if LNMP 
was uncertain, up to 28-weeks’ gestation were included in the study. Women with uncertain 
dates, multiple pregnancy, congenital or chromosomal fetal abnormality, maternal disease 
that was likely to affect the growth of the fetus (diabetes mellitus, heart disease, hypertension 
requiring treatment, kidney disease, pre-eclampsia) and subsequent preterm birth less than 
32-weeks were excluded.  
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5.3.2 Study process 
On commencement of the study, the participant completed a questionnaire which included 
demographic, medical and obstetric data. The first ultrasound was typically performed 
between 16- to 26-weeks, however, six women had their first ultrasound between 28- and 
29-weeks. Women were asked to attend for ultrasound examinations every four weeks from 
their first scan until delivery. If participants had additional clinically indicated ultrasounds, 
such as for decreased fetal movements, fetal renal Dopplers were performed if this additional 
ultrasound was two or more weeks from the previous ultrasound.  After birth, data were 
collected on mode of delivery, gestational age (GA) at birth, birth weight, gender and 
condition of infant at birth from the electronic medical record. 
5.3.3 Ultrasound measurements 
All examinations were performed by three Australian Accredited Medical Sonographers with 
at least two years post ultrasound qualification experience using a clearly defined protocol. 
Training of the sonographers was conducted by the authors (DLW and SB) and a follow-up 
audit was conducted with the sonographers three months after commencement of the study 
to verify adherence to the study protocol. An Epiq 7 (Philips Ultrasound, Bothell, WA, USA) 
or Voluson E8 (GE Healthcare Ultrasound, Milwaukee, WI, USA) were used for the 
examinations. A curved linear transducer of the highest frequency possible, which matched 
the mother’s body habitus, was selected (1-5MHz) so that the maximum image resolution 
could be achieved.  
A coronal view of the fetal kidneys was obtained, and colour flow Doppler was utilised to 
identify the renal artery arising from the aorta and entering the kidney. A sample gate of size 
2 - 3mm was placed in the mid trunk of the main renal artery and the wall filter was set low 
at between 30 to 60 Hertz. A pulse wave signal was obtained from both fetal renal arteries 
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using an angle as close to 0 degrees as possible (Fig 5.1). The mean of at least three consistent, 
consecutive waveforms was used to calculate the RI and PI.  
The amniotic fluid level at each ultrasound examination was assessed by using the standard 
measurement of single deepest vertical pocket (SDP).8, 9 While the participant was lying 
supine, a single vertical measurement of the deepest pocket of amniotic fluid, that was at 
least 1cm wide and did not contain any fetal parts or umbilical cord, was measured.8,9   
 
 
Figure 5.1 Colour and pulse wave Doppler from the mid-trunk of the left main renal 
artery at 28 weeks gestational age. Source: Townsville University Hospital. 
5.3.4 Measurement reliability 
For analysis of intra and interobserver reliability, a sample of 15 pregnant women across a 
range of gestational ages, some who were a part of the study and some additional pregnant 
women who were happy to have repeated measurements underwent these assessments.  The 
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gestational age range of these pregnancies was 19 to 36 weeks. All three sonographers 
engaged in the study obtained real-time measurements of each renal artery Doppler twice. 
They were blinded to their own and each other’s measurements by concealing the 
measurements on the monitor. The mean of each sonographer’s two measurements was 
analysed.  
5.3.5 Statistical analysis  
The maternal and neonatal characteristics, and intra and interobserver reliability were 
analysed using IBM SPSS (Version 25, Armonk, NY, USA). Normality of the maternal and 
infant data was tested by visually inspecting histograms and a Kolmogorov-Smirnov test. 
Variables that were normally distributed were reported as mean and standard deviation (SD) 
and variables that were non-normally distributed as a median and interquartile range. An 
ANOVA model was used to analyse intra and interobserver reliability. The SD, Cronbach’s 
alpha (α) and the intraclass correlation coefficient (ICC) with 95% confidence intervals were 
calculated. 
All other statistical analyses were performed using Stata/MP v14.2 for windows (Stata Corp 
LP, College Station, TX, USA). The program ggplot210 in R Studio (version 1.2.1335)11 was 
used to create the graphs. Statistical significance was taken as p < 0.05. Methods of the 
INTERGROWTH 21st Project for fetal growth were applied.12 The Stata function fp was 
used to ascertain the best fitting model for the mean RI and PI of the renal artery as a 
function of a fractional polynomial in GA (rounded down to whole week). A two level, mixed 
effects regression model for RI and PI was then built, including fixed effects for the 
polynomial function of GA, and accounting for repeated measures on participants using 
random intercept and slope with unstructured covariance (i.e. allowing each individual to 
have different growth trajectories and starting values, which allows partitioning of the 
122 
variation within and between participants). The standard charts were developed for 16- to 
38 weeks GA. 
Quantile plots and histograms were used to evaluate normality of the residuals. The Huber-
White sandwich (robust) estimator was applied for standard error estimation due to non-
constant variance. To determine the ideal factional polynomial terms for the standard 
deviation function in the fixed effects model, scaled (multiplied by √(π/2)) absolute residuals 
from this model were regressed on GA. Percentiles of the distribution of RI and PI by GA 
were assumed normal and calculated using the formula: 
Mean + Z x SD 
Where Z is – 1.88, - 1.645, - 1.28, 0, 1.28, 1.645, 1.88 for the 3rd, 5th, 10th, 50th, 90th, 95th and 
97th centiles respectively. 
Differences between the RI and PI of the renal arteries were investigated according to gender 
and kidney side (right/left). Dividing the cohort for this analysis did reduce the sample size 
of the groups and the models are likely to be underpowered, resulting in a risk of overfitting. 
Due to there being less data at some gestational weeks, for these analyses, two weekly 
classification of GA (rounded down to the nearest even number) was used. For each of the 
variables (gender and side) a two-level saturated mixed effects model was fitted with fixed 
effects for GA and the variable, and a term for the interaction of GA and exposure. A 
random intercept accounted for repeated measurements on participants and Huber-white 
(robust) estimator was used for standard errors estimated for non-constant variance. 
Pearson’s correlation was used to compare the amniotic fluid level to the RI and PI of the 




In total, 155 pregnant women were recruited into this study. Eighty-three participants were 
ultimately excluded, due to maternal disease likely to affect fetal growth, (73) fetal 
abnormality, (6) premature birth before 32 weeks GA (3) or failure to attend, (1) resulting in 
72 low-risk pregnancies being included in the study (Fig 5.2).   The characteristics of the 
mothers and infants are summarised in Table 5.1. Three hundred and ninety-three separate 
ultrasound examinations were performed between 16 to 39 weeks GA, with the median 
number of ultrasound scans per pregnancy being five (range of three to nine scans). There 
were 761 RI and PI measurements each. The renal artery Doppler was unable to be obtained 
for one kidney in twelve scans and for both renal arteries in four scans.  This was due to the 
renal artery Doppler being technically difficult to obtain due to fetal position, movement and 
breathing. There was no significant difference between right and left kidneys or gender for 












Characteristics of study population of women and their infants 
Participant Characteristics N = 72 
MATERNAL   
Maternal age (years) 29.3 ± 5.2 
Maternal height (cm) 164 ± 6.0 
Maternal weight (kg) 66.0 (58.0–79.5) 
Maternal BMI (kg/cm2) 24.9 (21.6 – 28.5) 
Maternal race origin N=56a 
• Aboriginal/Torres Strait Islander 4 (5.6%) 
• Asian 1 (1.4%) 
• Caucasian 49 (68.0%) 
• Other 3 (4.2%) 
Parity  
• Nulliparous 39 (54.2%) 
• Parous 33 (45.8%) 
Conception N=60b 
• Spontaneous 51 (70.8%) 
• Assisted 9 (12.5%) 
NEONATAL  
GA at birth (weeks) 38.8 (37.9–39.7) 
Preterm – (<37 weeks > 32 weeks)c 8 (11.1%) 
Birth weight (grams) 3143 (2850-3568) 
Male  41 (56.9%) 
Female 31 (43.1%) 
 
Note: Data are given as means ± SD, median (interquartile range) or n (%).  a16 
(22.2%) participants declined to answer. b12 (16.7%) participants declined to 
answer. cPregnancies resulting in a preterm birth before 32 weeks were excluded. 
GA, gestational age. 
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5.4.1 Fetal renal artery RI and PI charts 
Centiles for the RI and PI of the renal arteries were calculated using the equation: 
mean +Z x SD, where Z is the Z score for the respective centile. 
The standard charts of the 3rd, 10th, 50th, 90th and 97th smoothed centiles of the measurements 
between 16- and 39-weeks GA for fetal renal artery RI and PI are presented in Figure 5.3 
and 4. Tables 5.2 and 5.3 present all the calculated centiles for RI and PI. The equations for 
RI and PI are: 
• Mean RI = -0.2556362 – (0.043501 X GA) + (0.449057 X GA0.5); 
• SD RI = 0.0781253 – (0.0003515 X GA2) + (0.0000903 X GA2 X ln(GA)); 
• Mean PI = -0.7966501 – 176.19 X GA-1 + 79.45.009 X GA-1 X ln(GA); and 
• SD PI = 0.3675488 – 0.0000423 X GA3 + 0.0000119 X GA3 X ln(GA). 
 
 
Figure 5.3 Standard fetal chart of fetal renal artery resistivity index (RI) showing all 
raw measures (dots) and the 3rd, 10th, 50th, 90th, and 97th smoothed centiles 





Figure 5.4 Standard fetal chart of fetal renal artery pulsatility index (PI) showing all 
raw measures (dots) and the 3rd, 10th, 50th, 90th, and 97th smoothed centiles 




Table 5.2  
Fitted 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles calculated from the derived equations for the 




vations Mean SD c3 c5 c10 c50 c90 c95 c97 
16 27 0.84 0.05 0.75 0.76 0.78 0.84 0.91 0.93 0.94 
17 5 0.86 0.05 0.76 0.77 0.79 0.86 0.92 0.94 0.95 
18 2 0.87 0.05 0.77 0.79 0.80 0.87 0.93 0.95 0.96 
19 8 0.88 0.05 0.79 0.80 0.81 0.88 0.94 0.95 0.96 
20 61 0.88 0.05 0.80 0.81 0.82 0.88 0.94 0.96 0.97 
21 13 0.89 0.04 0.81 0.82 0.83 0.89 0.95 0.96 0.97 
22 16 0.89 0.04 0.81 0.82 0.84 0.89 0.95 0.96 0.97 
23 13 0.90 0.04 0.82 0.83 0.84 0.90 0.95 0.97 0.98 
24 82 0.90 0.04 0.82 0.83 0.85 0.90 0.95 0.97 0.98 
25 11 0.90 0.04 0.83 0.84 0.85 0.90 0.95 0.97 0.98 
26 27 0.90 0.04 0.83 0.84 0.85 0.90 0.95 0.97 0.98 
27 24 0.90 0.04 0.83 0.84 0.85 0.90 0.95 0.97 0.98 
28 81 0.90 0.04 0.83 0.84 0.85 0.90 0.95 0.97 0.98 
29 22 0.90 0.04 0.83 0.84 0.85 0.90 0.95 0.96 0.97 
30 42 0.90 0.04 0.83 0.84 0.85 0.90 0.95 0.96 0.97 
31 32 0.90 0.04 0.82 0.83 0.85 0.90 0.95 0.96 0.97 
32 68 0.89 0.04 0.82 0.83 0.84 0.89 0.94 0.96 0.97 
33 38 0.89 0.04 0.81 0.82 0.84 0.89 0.94 0.95 0.96 
34 36 0.88 0.04 0.81 0.82 0.83 0.88 0.94 0.95 0.96 
35 30 0.88 0.04 0.80 0.81 0.83 0.88 0.93 0.95 0.96 
36 77 0.87 0.04 0.79 0.80 0.82 0.87 0.93 0.94 0.95 
37 20 0.87 0.04 0.78 0.79 0.81 0.87 0.92 0.94 0.95 




Fitted 3rd, 5th, 10th, 50th, 90th, 95th and 97th centiles calculated from the derived equations for the 




vations Mean SD c3 c5 c10 c50 c90 c95 c97 
16 27 2.0 0.3 1.3 1.4 1.5 2.0 2.4 2.5 2.6 
17 5 2.1 0.3 1.5 1.5 1.7 2.1 2.5 2.6 2.7 
18 2 2.2 0.3 1.6 1.6 1.8 2.2 2.6 2.7 2.8 
19 8 2.2 0.3 1.6 1.7 1.8 2.2 2.6 2.8 2.8 
20 61 2.3 0.3 1.7 1.8 1.9 2.3 2.7 2.8 2.9 
21 13 2.3 0.3 1.7 1.8 1.9 2.3 2.7 2.8 2.9 
22 16 2.4 0.3 1.8 1.9 2.0 2.4 2.8 2.9 2.9 
23 13 2.4 0.3 1.8 1.9 2.0 2.4 2.8 2.9 3.0 
24 82 2.4 0.3 1.8 1.9 2.0 2.4 2.8 2.9 3.0 
25 11 2.4 0.3 1.8 1.9 2.0 2.4 2.8 2.9 3.0 
26 27 2.4 0.3 1.8 1.9 2.0 2.4 2.8 2.9 3.0 
27 24 2.4 0.3 1.8 1.9 2.0 2.4 2.8 2.9 3.0 
28 81 2.4 0.3 1.8 1.9 2.0 2.4 2.8 2.9 2.9 
29 22 2.4 0.3 1.8 1.8 2.0 2.4 2.8 2.9 2.9 
30 42 2.3 0.3 1.7 1.8 1.9 2.3 2.7 2.9 2.9 
31 32 2.3 0.3 1.7 1.8 1.9 2.3 2.7 2.9 2.9 
32 68 2.3 0.3 1.7 1.8 1.9 2.3 2.7 2.8 2.9 
33 38 2.3 0.3 1.6 1.7 1.8 2.3 2.7 2.8 2.9 
34 36 2.3 0.4 1.6 1.7 1.8 2.3 2.7 2.8 2.9 
35 30 2.2 0.4 1.6 1.6 1.8 2.2 2.7 2.8 2.9 
36 77 2.2 0.4 1.5 1.6 1.7 2.2 2.7 2.8 2.9 
37 20 2.2 0.4 1.4 1.5 1.7 2.2 2.7 2.9 2.9 
38 20 2.2 0.4 1.4 1.5 1.6 2.2 2.7 2.9 3.0 
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5.4.2 Measurement reliability 
A summary of the analysis of the intraobserver and interobserver reliability for renal artery 
RI and PI are shown in Tables 5.4 and 5.5. The intraobserver ICC for measuring the renal 
artery was moderate at 0.66 for the RI and good for the PI at 0.88. However, the 
interobserver ICC for measuring the renal artery was poor at 0.11 for RI and -0.56 PI. Poor 
reliability was assessed as an ICC less than 0.50, moderate as between 0.50 and 0.75, good as 
between 0.75 and 0.90 and excellent as more than 0.90.13   
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Table 5.4  
Intraobserver reliability for fetal renal artery Dopplers 
Variable Mean +/- SD Cronbach's α ICC (95% CI) 
Renal artery RI 0.90 +/- 0.03 0.66 0.66 (-0.01-0.89) 




Interobserver reliability for fetal renal artery Dopplers 
Variable (N = 15) 
 Mean +/- SD (mm)  
Cronbach's 
α 
ICC (95% CI) 
Observer 1 Observer 2 Observer 3 
Renal artery RI 0.90 +/-0.02 0.89 +/-0.04 0.87 +/-0.04 0.12 0.11 (-0.77-0.64) 
Renal artery PI 2.41 +/- 0.27 2.38 +/- 0.38 2.12 +/-0.27 -0.71 -0.56 (-2.11-0.37) 
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5.4.3 Correlation between amniotic fluid level and renal artery RI and PI 
There was no correlation between the single deepest pocket of amniotic fluid and the RI (cor = 
0.035, p=0.179) or PI (cor = 0.027, p=0.296) of the renal arteries.  
5.5 Discussion 
This study developed standard charts of fetal renal artery RI and PI from 16- to 38-weeks’ gestation 
to provide more detailed information on normal ranges of fetal renal artery blood flow during 
pregnancy. We showed that the RI and PI of the fetal renal arteries demonstrated little alteration 
during the pregnancy.  These charts may be utilised to provide additional information in cases of 
high-risk pregnancy and possible fetal renal abnormalities. The strengths of this study are the wide 
range of gestational ages assessed and that these charts are derived from longitudinal data using 
mixed effects modelling which considers every data point and allows for variation between and 
within participants. This provides true change of renal haemodynamics over the duration of the 
pregnancy.   
There are a limited number of studies investigating normal fetal renal artery blood flow, and most 
have small sample sizes, are cross sectional in design and have heterogeneous inclusion and 
exclusion criteria making direct comparison difficult.14-19 Some earlier studies showed that the PI 
decreased with increasing GA.14, 15 The study most similar to our study, in that it was a longitudinal 
design and used mixed effects modelling, also demonstrated that the RI and PI remained relatively 
unchanged throughout the pregnancy.18 Other recent studies demonstrated similar findings; 
however, these were not longitudinal studies.16, 17 A study in 2015 reported longitudinal reference 
intervals for fetal renal arteries however was not truly longitudinal as although the design was 
longitudinal, the data were not analysed as longitudinal data.17 The mean of the renal Doppler 
measurements was calculated for each gestational age group disregarding the repeated measures 
and non-independence of the data.17 Minimal change in renal haemodynamics during pregnancy is 
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likely due to the fetal kidneys having limited true function in-utero as the placenta performs most 
of the prenatal renal excretory functions and the proportion of cardiac output to the fetal kidneys 
is low at only 3 to 5%.1, 20 
Our study had adequate intraobserver reliability for RI and PI, however, the interobserver 
reliability was poor for both indices. Few studies have assessed intra and interobserver reliability 
of the RI and PI of the fetal renal artery. One recent study assessed the reliability of the fetal renal 
artery PI and, similar to our study, found adequate intraobserver reliability (ICC = 0.528) but poor 
interobserver reliability (ICC = 0.114).17 Obstetric care is becoming increasingly dependent on fetal 
Dopplers; however, most studies do not investigate or report on intra and interobserver 
reliability.21 Currents studies on maternal and fetal blood flow that have reported on reliability of 
these Dopplers have revealed poor-to-moderately-poor results.22, 23 It can be argued that there is 
known physiological variations in spectral Doppler traces of fetal blood flow due to fetal 
movements, breathing and heart rate changes that should be factored into reliability of these 
Doppler indices.24 We need to acknowledge that the variability of fetal Doppler traces will always 
be more than a fixed two-dimensional measurement of a fetal structure and that innovative 
techniques will likely not initially have a high enough reliability for clinical decision making. They 
may require further development and refinement. These are important concerns that should not 
be underrated. Care should be employed in having too much confidence in a diagnostic test with 
unclear or questionable reliability.  
These normative ranges of renal artery RI and PI, which include multiple different centiles, could 
be useful for future studies to investigate the redistribution of blood flow away from the kidneys 
that is thought to occur in most growth restricted fetuses.4, 25 If changes in the renal artery blood 
flow profile could be quantified, these alterations in renal haemodynamics might become a useful 
diagnostic tool for fetal growth restriction. Renal blood flow indices may also have the potential 
to predict the severity of fetal growth restriction or be a novel marker for postnatal renal function, 
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particularly in instances of renal abnormalities. At this stage, however, the findings for RI and PI 
of fetal renal artery Dopplers are variable and need to be validated. They should be utilised with 
care as the usefulness of fetal renal artery blood flow measurements in clinical practice is still 
unclear. It should also be noted that RI and PI are not measures of perfusion but rather a reflection 
of vascularity and flow intensity. Further larger studies utilising newer enhanced Doppler 
techniques with standardised methods may identify and refine their future value.  
Recently, novel 3D volume Doppler flow techniques have been investigated to obtain vascular 
indices of flow index (FI), vascular index (VI) and vascularisation flow index (VFI) of the fetal 
renal arteries.26, 27 They are showing promise to assess the renal haemodynamic characteristics and 
their relationship to variations in flow associated with fetal growth restriction. Currently, they 
suffer from poor reproducibility due to technical matters such as multiple non-standardised 
machine settings to select prior to acquisition of data, depth of insonation, patient habitus and 
fetal movements which result in measurements with high variability.26, 28, 29 
A relationship between amniotic fluid levels and changes in fetal renal perfusion seems plausible 
as a simple indicator for fetal renal function. However, fetal urine production is determined by 
both renal perfusion and tubular reabsorption, and regulation of amniotic fluid volumes is a 
complex interaction of many different fetal systems not just the urinary tract.30, 31 Methods of 
assessing amniotic fluids levels are only estimates and there is currently no particularly accurate 
non-invasive method.30, 32 Our study found, as others have, no good correlation between amniotic 
fluid levels and renal artery blood flow.17, 33 
A limitation of the study was the small sample size at gestational ages prior to 20-weeks and after 




Pulse wave Doppler of the fetal renal arteries allows detailed analysis of the haemodynamic 
characteristics of the blood supply to the developing kidneys. Our standard charts provide the 
normal ranges of the RI and PI of the fetal renal arteries during pregnancy so that potential 
physiological or pathological alterations in renal blood flow can be investigated in high-risk 
pregnancy. Considering the problems with reliability, these charts do need to be used with caution. 
No correlation was found between amniotic fluid levels and fetal renal artery RI or PI. Further 
studies of fetal renal artery blood flow are needed to evaluate improved techniques and assess the 
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The purpose of this chapter was to provide in-vivo evidence of the effect of fetal growth 
restriction on the developing renal parenchyma and evaluate the use of measuring the fetal renal 
parenchyma as an indirect estimate of nephron number. 
6.1 Abstract  
Chronic kidney disease continues to be under recognised and is associated with a significant global 
health burden and costs. An adverse intrauterine environment may result in a depleted nephron 
number and an increased risk of chronic kidney disease. Antenatal ultrasound was used to measure 
the fetal renal parenchymal thickness, as a novel method to estimate nephron number. Fetal renal 
artery blood flow was also assessed. This prospective, longitudinal study evaluated the fetal kidneys 
of 102 appropriately grown and 30 fetal growth restricted fetuses between 20 weeks and 37 weeks 
gestational age to provide vital knowledge on the influences fetal growth restriction has on the 
developing kidneys. The fetal renal parenchymal thickness and renal artery blood flow was 
measured at least every four weeks using ultrasound. The renal parenchymal thickness was found 
to be significantly thinner in growth restricted fetuses compared to appropriately grown fetuses 
(likelihood ratio (LR) = 21.06, p = <0.0001) and the difference increases with gestational age. In 
fetuses with the same head circumference, a growth restricted fetus was more likely to have a 
thinner parenchyma than an appropriately grown fetus (LR=8.9, p=0.0028), supporting the 
principle that growth restricted fetuses preferentially shunt blood towards the brain. No significant 
difference was seen in the renal arteries between appropriately grown and growth restricted fetuses. 
Measurement of the renal parenchymal thickness appears to be a more sensitive measure than 
current methods. It has the potential to identify infants with a possible reduced nephron 
endowment allowing for monitoring and interventions to be focused on individuals at a higher 




Globally, it is estimated that between 5 to 10 million people die annually due to kidney disease.1 
Chronic kidney disease is a significant and often neglected chronic disease which continues to be 
under recognised, despite being identified as a huge economic burden.1 Its link with other major 
diseases such as cardiovascular disease, hypertension, and diabetes is often underestimated.1, 2 
Effective screening, prevention and early treatment can slow or reduce the incidence of chronic 
kidney disease.3 Understanding the influences for the healthy development of the kidneys and 
subsequent kidney function is a priority.  
It is well established that developmental programming of the fetal kidney can affect kidney 
evolution in-utero and in early life, which can in turn impact kidney growth patterns and function.4,5 
The association between an adverse intrauterine environment and the development of chronic 
kidney disease and hypertension later in life is compelling.6-8 Low birth weight (defined as birth 
weight < 2500g) is associated with a 70% increased risk of developing chronic kidney disease.9  
Low birth weight, or small for gestational age (SGA) (defined as birth weight < 10th centile), is 
often used as a proxy for fetal growth restriction, previously known as intrauterine growth 
restriction (IUGR). The two terms, however, are different, as not all SGA infants are growth 
restricted and not all growth restricted infants are SGA. True fetal growth restriction (FGR) is a 
major cause of morbidity and mortality and is believed to predispose to a range of diseases later in 
life.10-12 Serial antenatal ultrasound growth measurements and uteroplacental and fetal Dopplers 
are employed to diagnose FGR.10, 13 
A reduced nephron endowment is associated with an increased susceptibility to hypertension and 
renal disease.4, 6, 14 Nephrogenesis in-utero is the main determinant of life-long nephron number and 
so it is vital to consider the impact of fetal life programming, such as fetal growth restriction, on 
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the risks of developing kidney disease.8, 15 The challenge remains to find a method to quantify 
nephron numbers in-utero and develop useful early prognostic factors for future renal function.7,16,17 
Measurement of the fetal renal parenchymal thickness with antenatal ultrasound is a novel, non-
invasive method to assess changes in kidney growth. The parenchymal tissue of the kidney 
comprises the renal cortex and medulla, which contain the functional units of the kidney – the 
nephrons and glomeruli. The renal parenchyma measurement is a single, easily performed 
measurement focusing on the nephron rich area. Additionally, quantifying fetal renal artery blood 
flow may be valuable to investigate alterations in perfusion, as it is well established that during fetal 
hypoxia, such as seen in fetal growth restriction, blood flow is preferentially shunted away from 
the kidneys to more essential organs such as the heart, brain and adrenals.18 There is very little 
information on the usefulness of assessing the fetal renal parenchyma as a prognostic tool for renal 
function. 
The aim of this study was to determine the effect of fetal growth restriction on the development 
of the fetal kidneys by evaluating the renal parenchymal thickness during consecutive ultrasound 
examinations between 20- and 36-weeks gestational age. The primary outcome measure was the 
difference in renal parenchymal thickness between appropriately grown and growth restricted 
fetuses and the secondary outcome measure was the blood flow to the fetal kidneys between these 
two groups. We hypothesised that fetal growth restriction impairs renal parenchymal thickness 
growth.  
6.3 Method 
This prospective, longitudinal, observational study was conducted between May 2017 and 




6.3.1 Study population 
The Townsville Hospital and Health Service provides tertiary, perinatal services and receives public 
and private referrals for obstetric care from all over North Queensland, with a catchment 
population of around 700,000 and 10,000 births per year.19 Pregnant patients aged 18 years or 
older, who presented to the Townsville Hospital for a second trimester obstetric ultrasound scan 
between May 2017 and October 2018 were invited to participate, or they were informed about the 
study by their treating obstetrician, midwife or sonographer.  
Women were included if they had a singleton pregnancy up to 30 weeks gestation with an 
accurately dated pregnancy based on last normal menstrual period (LNMP) and 1st trimester 
ultrasound, that correlated with each other within seven days, or on 1st trimester ultrasound if 
LNMP was uncertain. Women were excluded if they had a multiple pregnancy, uncertain dates or 
any major congenital fetal abnormality or chromosomal abnormality. Detailed written information 
was given to the patient and written consent was obtained.  
6.3.2 Study process 
Participants completed a questionnaire, which included demographic, medical and obstetric data. 
The first ultrasound was most commonly performed between 16 weeks to 26 weeks gestational 
age (GA); however, nine women had their first ultrasound between 28- and 30-weeks GA and one 
at 30 weeks. To obtain robust longitudinal data, women were asked to attend ultrasound scans 
every four weeks from their first ultrasound until delivery. Some women, particularly those with 
high risk pregnancies, had additional clinically indicated ultrasounds. If an ultrasound was 
performed at two or more weeks from the previous ultrasound recorded for the study, renal 
measurements were performed again for the study.  
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6.3.3 Ultrasound examination 
Three Australian Accredited Medical Sonographers, with at least two years post ultrasound 
qualification experience, performed all examinations. A documented protocol outlined the 
required renal measurements and how they were to be performed for the study. Training of the 
sonographers was conducted prior to commencement of the study. An audit and follow-up were 
conducted with all participating sonographers three months after commencement of the study to 
confirm adherence to the study protocol. A Voluson E8 (GE Healthcare Ultrasound, Milwaukee, 
WI, USA) or an Epiq 7 (Philips Ultrasound, Bothell, WA, USA) were used for the ultrasound 
examinations and the highest frequency transducer possible, matching the mother’s body habitus 
(1–5MHz), was selected to obtain the highest image resolution for each participant.  
Where possible the fetal kidneys were measured with the fetal spine positioned anteriorly, or as 
close as possible to this position. The image was magnified so that the kidney occupied most of 
the image and one focus was placed at the level of the kidney. The renal parenchymal thickness 
was measured in the midsagittal plane of the kidney. It was measured from the inner aspect of the 
renal capsule to the sinus-pyramidal apex interface in two directions - from the posterior aspect of 
the kidney to the sinus-pyramidal apex (posterior parenchyma) and from the anterior border of 
the kidney to the sinus-pyramidal apex (anterior parenchyma) (Fig 6.1). Each measurement was 
performed twice and the mean of the two measurements were recorded. Both kidneys were 
measured. 
Bilateral fetal renal artery Dopplers were performed in a coronal view of the kidneys. Colour flow 
was employed to identify the renal artery arising from the aorta and entering the kidney. A low 
wall filter of between 30 to 60 Hertz was used and a sample gate of size 2mm to 3mm was placed 
in the mid-trunk of the main renal artery. A pulse wave signal was obtained using an angle as close 
to 0 degrees as possible and when there was no fetal movement or breathing (Fig 6.2). The average 
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of at least three consistent consecutive waveforms was used to calculate the resistivity index (RI) 




Figure 6.1 Measurement of the renal parenchymal thickness posteriorly (1) and anteriorly 
(2) from the inner aspect of the renal capsule to the sinus-pyramidal apex interface at 20 





Figure 6.2 Colour and pulse wave Doppler from the mid-trunk of the left main renal 
artery at 33 weeks gestational age. Source: Townsville University Hospital. 
6.3.4 Sample size 
The sample size was calculated based on a statistical power of 80% and a significance level of 0.05 
(two-tailed). Data from our previously published study demonstrated that the mean renal 
parenchymal thickness was 9.4mm (± 1.1mm) for normal birth weight neonates and 8.3mm (± 
1.0) mm for low birth weight neonates at term.20 Therefore, it was estimated that a sample size of 
30 would be needed (15 growth restricted fetuses and 15 appropriate-for-gestational-age). 
Allowing for the possibility of loss to follow-up, at least 20 participants would be recruited for 
each group resulting in a total of 40 participants, each having ultrasound scans at least every four 
weeks.  
6.3.5 Analysis 
After birth, the infants were assigned to one of two groups – appropriate-for-gestational age 
(AGA) or fetal growth restriction (FGR). These groups were defined a priori.13  Birth weight was 
plotted on Hadlock et al. fetal weight charts21, as it has been demonstrated that neonatal charts do 
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not represent a random sample of the population at a given GA.10 Infants born preterm are over-
represented with cases of FGR and therefore fetal growth should be assessed against 
measurements of on-going pregnancies at that gestational age as opposed to a birth weight of 
infants born at a given gestational age.10, 22  Those infants with a birth weight above the 90th centile 
were considered large for gestational age (LGA) and were excluded from this analysis. The criteria 
for classification of FGR is shown in Table 6.1 and was based on a consensus definition of FGR 
obtained by Delphi survey of 45 international experts in the field.13 Infants who were neither LGA 
nor FGR were considered AGA.  
Table 6.1 
Classification of Fetal Growth Restriction (FGR)  
Early FGR: Gestational Age < 32 weeks Late FGR: Gestational Age ≥ 32 weeks 
• AC or EFW < 3rd centile or UA - AEDF • AC or EFW < 3rd centile 
Or Or at least two of the following 
• AC or EFW < 10th centile combined with  • AC or EFW < 10
th centile 
• Uterine artery - PI > 95th centile and/or • AC or EFW crossing centiles > 2 quartiles 
• UA-PI > 95th centile • CPR < 5
th centile or UA-PI > 95th centile 
 
Note: AC, abdominal circumference; AEDF, absent end diastolic flow; CPR, cerebroplacental ratio; EFW, 
estimated fetal weight; FGR, fetal growth restriction; PI, pulsatility index; UA, umbilical artery (based on 
Gordijn et al).13 
 
Analysis of maternal and birth characteristics was performed using IBM SPSS version 25, Armonk, 
NY, USA. Normality of the demographic data was tested using a Kolmogorov-Smirnov test and 
visually inspecting the histograms. Normally distributed variables were reported as a mean and 
standard deviation (SD) and non-normally distributed variables as a median and interquartile range. 
All other analyses were conducted using R Statistical Language in R Studio (version 1.2.1335, 
Vienna, Austria).23,24 Visual inspection of residual plots did not reveal any obvious deviations from 
homoscedasticity or normality. No outliers were removed.  The nlme package (version 3.1-139)25 
was used to fit a random slopes linear mixed effects model to describe the effects of explanatory 
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variables on renal parenchymal thickness. The graphics were created with ggplot2.26 Two models 
were fitted: 
The first model focused on the relationship between the renal parenchymal thickness and 
gestational age. For this analysis, the response variable was renal parenchymal thickness and fixed 
effects in the model were gestational age (GA), growth (either AGA or FGR), kidney side (right 
or left), and the interaction between GA and growth. The relationship between parenchymal 
thickness and GA showed significant curvature, so a quadratic term was also included in the model. 
Other fixed effects were also tested (anterior or posterior parenchyma and gender), however they 
did not improve the fit.  Random effects were participants, with random intercepts as well as 
random slopes for the effect of GA. Alternative models of different complexity were compared 
using likelihood ratio (LR) tests and Akaike’s Information Criteria (AIC).  
The second model assessed the effects of growth (AGA vs FGA) on the relationship between the 
thickness of the fetal renal parenchyma and the head circumference.  We assumed a power 
function of the form: 
y = axb 
was appropriate to describe this relationship, where y = parenchymal thickness and x = head 
circumference.  Since y and x are both linear measurements, the value of b should equal 1 if both 
grow at the same rate. In order to fit the model, the renal parenchyma and head circumference 
measurements were log transformed to convert the power function to a linear equation of the 
form: 
log(y) = log(a) + b (log(x)) 
The fixed effects in the model were head circumference (log10), growth (either AGA or FGR) and 
kidney side (right or left).  In this case the interaction term did not improve the model fit and is 
omitted from the final model, as are other fixed effects tested (anterior or posterior parenchyma 
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and gender). Random effects were participants with random intercepts as well as random slopes 
for head circumference (log10). 
Analysis of the fetal renal arteries (for both resistivity and pulsatility index) used fixed effects of 
GA (as a quadratic fit), growth (AGA or FGR), with interaction, and kidney side (right or left).  
Other fixed effects tested which did not improve the model included - anterior or posterior 
parenchyma and gender. Random effects were participants with random intercepts as well as 
random slopes for the effect of GA. As in previous models, likelihood ratio tests and Akaike’s 
Information Criteria (AIC) were used to compare alternative models.  
6.4 Results 
One hundred and fifty-five pregnant women were recruited for the study, with 23 excluded (Fig 
6.3). Among the remaining 132 pregnancies, 102 were AGA and 30 were FGR. The characteristics 
of the mother and baby are summarised in Table 6.2. FGR was associated with a significantly lower 
birth weight, an earlier GA at birth and a lower rate of diabetes.  
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Characteristics of 102 appropriate-for-gestational age (AGA) and 30 fetal growth restricted (FGR) pregnancies 
and their infants 
 
Participant Characteristics AGA (N=102) FGR (N=30) p value 
MATERNAL     
Maternal age (years) (means ± SD) 29.6 ± 5.2 32.0 ± 6.4 0.099a 
Maternal height (cm) (means ± SD) 1.65 ± 0.06 1.62 ± 0.07 0.411a 
Maternal weight (kg) (M, IQR) 72.0 (60.0–86.5) 70.8 (55.0 - 87.7) 0.615b 
Maternal BMI (kg/cm2) (M, IQR) 25.8 (22.7 – 31.6) 25.6 (23.2 – 33.9) 0.996b 
Maternal race origin, n (%) N=82#  N=25# 0.354c 
• Aboriginal/Torres Strait 
Islander 
7 (6.9%) 5 (16.7%)  
• Asian 3 (2.9%) 0 (0%)  
• Caucasian 69 (67.6%) 19 (63.3%)  
• Indian 1 (1.0%) 0 (0%)  
• Other 2 (2.0%) 1 (3.3%)  
Parity, n (%)   0.584d 
• Nulliparous 50 (49.0%) 13 (43.3%)  
• Parous 52 (51.0%) 17 (56.7%)  
Maternal Medical Disorders, n (%)    
Pregestational Diabetes 3 (3.0%) 1 (3.3%) 1.000e 
Gestational diabetes 35(34.3%) 4 (13.3%) 0.039e* 
Thyroid disease 14 (13.7%) 2 (6.7%) 0.524e 
Hypertension (needing treatment) 6 (5.9%) 4 (13.3%) 0.234e 
Other maternal medical disorders 15 (14.7%) 7 (23.3%) 0.274e 
NEONATAL    
GA at birth (weeks) (M, IQR) 38.7 (38.0 – 39.3) 37.4 (35.2- 38.2) <0.0001b* 
Birth weight (grams) (M, IQR) 3390 (2978 - 3603) 2345 (1811 - 2820) <0.0001b* 
Male 52 (51%) 15 (50%) 0.925d 
Note: AGA, appropriate for gestational age; FGR, fetal growth restriction; GA, gestational age; IQR, 
interquartile range; M, median; SD, standard deviation. 
#20 (19.6%) AGA and 5 (16.7%) FGR participants declined to answer maternal race.  
* = p<0.05. a Independent t-test; b Mann-Whitney U; c Likelihood Ratio; d Pearson Chi-Squared; e 
Fisher’s exact test. 
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Due to the small numbers of examinations below 20 weeks and over 38 weeks GA, data was only 
included from between 20 weeks 0 days and 37 weeks 6 days GA. Measurements were obtained 
from both fetal kidneys and renal arteries with a total of 638 separate ultrasound examinations 
performed between 20 to 37 weeks GA. The median number of scans per pregnancy was five 
(range was one to eight). The full set of planned examinations were not completed in some cases 
as the participant delivered prior to the end of the study. 
6.4.1 Renal parenchymal thickness 
In total, 2556 renal parenchymal thickness measurements were made - four measurements on each 
fetus at each GA, corresponding to one each by side (right or left) and anterior and posterior. 
During modelling, no significant effect was found according to gender (p=0.177) or whether the 
anterior and posterior parenchyma was measured (p=0.163) and therefore these were not included 
in the model. There was a significant difference in the renal parenchymal thickness between the 
right and left kidneys with the left parenchyma measuring significantly thinner (p = 0.001) and 
therefore kidney side was included in the model. 
The findings have demonstrated that the renal parenchymal thickness is significantly thinner in 
growth restricted fetuses when compared to appropriately grown fetuses and the effect is strong 
(LR = 21.06, p = <0.0001). P-values are obtained by likelihood ratio (LR) tests of the full model 
with the growth of the fetus (whether they are appropriately grown or not) in the model against a 
model without the fetal growth included. With increasing gestational age, the difference between 
the thickness of the parenchyma of appropriately grown and growth restricted fetuses increases. 
The overall regression line (assuming independence) is illustrated in Fig 6.4. Table 6.3 displays the 
fixed effects estimates and Table 6.4 displays the random effects. The equations for renal 




• Right AGA RPT = 4.37 + 0.448GA – 0.00885(GA2); 
• Right FGR RPT = 4.37 + (0.448 – 0.0383)GA – 0.00885(GA2); 
• Left AGA RPT = (4.37 – 0.108) + 0.448GA – 0.00885(GA2); and 
• Left FGR RPT = (4.37 – 0.108) + (0.448 – 0.0383)GA – 0.00885(GA2). 
 
Figure 6.4 Renal parenchymal thickness by gestational age for appropriately grown and 
fetal growth restricted fetuses (a) overall regression lines with all data points (b) overall 
regression lines. Shades denote 95% confidence interval. 
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Table 6.3 
Fixed effects estimates for renal parenchymal thickness by gestational age modelling 
 Estimate Confidence Interval SE p-value 
Intercept 4.372 4.222 – 4.520 0.0754 <0.0001 
Gestational age 0.448 0.419 – 4.476 0.0146 <0.0001 
Growth (AGA to FGR) -0.364 -0.646 - - 0.082 0.1412 0.0110 
Gestational age (quadratic) -0.009 -0.010 - - 0.007 0.0007 <0.0001 
Side (right to left) -0.108 -0.173 - -0.043 0.0331 0.0011 
Gestational age: Growth 
interaction 
-0.038 -0.070 - -0.006 0.0161 0.0181 
 
Note: 95% confidence intervals. AGA, appropriate-for-gestational-age; FGR, Fetal growth 
restriction; SE, standard error. 
 
Table 6.4 
Random effects estimates for participants 
Participant Level Estimate Confidence Interval 
SD Intercept 0.484 0.380 – 0.617 
SD Gestational Age 0.062 0.051 – 0.075 
Cor (intercept, Gestational Age) -0.132 -0.412 – 0.171 
 
Note: 95% confidence intervals. SD, standard deviation. 
 
6.4.2 Renal parenchymal thickness compared to head circumference 
Growth of the renal parenchymal thickness was compared to head circumference (HC) (Fig 6.5) 
and this showed a significant difference between AGA and FGR fetuses (LR=8.9, p=0.0028) with 
the renal parenchymal thickness growing at a slower rate compared to HC in FGR than in AGA 
fetuses. There was, however, no difference in the slope of the growth. Fixed and random effect 






Figure 6.5 Relationship between log(10) transformed renal parenchymal thickness and 
head circumference for appropriately grown and fetal growth restricted fetuses. Shades 
denote 95% confidence interval. 
Table 6.5 
Fixed effects estimates for Renal parenchymal thickness(log10) to Head Circumference(log10) 
 Estimate Confidence 
Interval 
SE p-value 
Intercept -4.515 -4.760 - -4.269 0.1252 <0.0001 
Head Circumference (log10) 0.195 1.122 – 1.211 0.0225 <0.0001 
Growth (AGA to FGR) -0.0.57 -0.095 - -0.019 0.0191 0.0032 
Side (right to left) -0.015 -0.023 - -0.005 0.0046 0.0014 
 








Random effects estimates for participants for Renal parenchymal thickness(log10) to Head Circumference(log10) 
Participant Level Estimate Confidence Interval 
SD Intercept 1.080 0.888 – 1.314 
SD Head Circumference (log10) 0.195 0.161 – 0.237 
Cor (intercept, head circumference(log10)) -0.997 -0.998 - -0.995 
 
Note: 95% confidence intervals. SD, standard deviation. 
 
6.4.3 Renal artery Dopplers 
In total 1235 renal artery Dopplers were carried out. Doppler of the renal artery was not able to 
be obtained for one kidney in 25 scans and for both kidneys in 12 scans due to fetal position 
and/or persistent movement. No significant difference was seen between AGA and FGR fetuses 
in the resistivity index (RI) (p = 0.182) or pulsatility index (PI) (p = 0.554) of the renal arteries. 
Table 6.7 to 6.10 show the fixed and random effects estimates respectively. 
Table 6.7 
Fixed effects estimates for Renal artery resistivity index (RI) 
 Estimate Confidence 
Interval 
SE p-value 
Intercept 0.874 0.865 – 0.884 0.0047 <0.0001 
Gestational age 0.006 0.004 – 0.007 0.0009 <0.0001 
Growth (AGA to FGR) 0.004 -0.014 – 0.021 0.0090 0.6856 
Side (right to left) 0.005 0.001 – 0.009 0.0022 0.0224 
Gestational age (quadratic) -0.000 <-0.001 - <-0.001 <0.0001 <0.0001 
Gestational age: Growth -0.001 -0.003 – <0.001 0.0008 0.2031 
 






Random effects estimates for Renal artery resistivity index (RI) 
Participant Level Estimate Confidence Interval 
SD Intercept 0.029 0.033 – 0.046 
SD Gestational age 0.003 0.003 – 0.004 
Cor (intercept, gestational age) -0.804 -0.891 - -0.662 
 
Note: 95% confidence intervals. SD, standard deviation. 
 
Table 6.9 
Fixed effects estimates for Renal artery pulsatility index (PI) 
 Estimate Confidence 
Interval 
SE p-value 
Intercept 2.245 2.177 – 2.311 0.0341 <0.0001 
Gestational age 0.025 0.011 – 0.038 0.0068 0.0003 
Growth (AGA to FGR) 0.056 -0.068 – 0.179 0.0626 0.3762 
Side (right to left) 0.023 -0.010 – 0.056 0.0168 0.1632 
Gestational age (quadratic) -0.002 -0.002 - -0.001 0.0003 <0.0001 
Gestational age: Growth -0.007 -0.019 – 0.005 0.0061 0.2787 
 




Random effects estimates for Renal artery pulsatility index (PI) 
Participant Level Estimate Confidence Interval 
SD Intercept 0.180 0.132 – 0.246 
SD Gestational age 0.019 0.015 – 0.025 
Cor (intercept, gestational age) -0.697 -0.839 - -0.466 
 
Note: 95% confidence intervals. SD, standard deviation. 
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6.5 Discussion 
6.5.1 Renal parenchymal thickness and fetal growth restriction 
Our study demonstrates that the renal parenchymal thickness is significantly thinner in growth 
restricted fetuses when compared to appropriately grown fetuses. A point of difference with this 
study is that fetal size and Doppler criteria were used to classify true fetal growth restriction.13 
Almost all previous fetal and kidney studies use small for gestational age (SGA) as a surrogate for 
FGR.6, 27-29 Recent advances in medical imaging technology and publication of an international 
consensus on FGR classification13 enables clinicians and researchers to improve the diagnose of 
FGR and understand FGR is a failure to achieve optimal growth and not just smallness.  
SGA is based only on a weight cut off after birth, such as a birth weight less than 2500g, and 
therefore includes genetically small fetuses, but healthy, and excludes infants within the normal 
weight range but who are truly growth restricted. FGR is defined as a pathologically small fetus 
who does not meet its optimal growth and will usually be associated with abnormal uteroplacental 
or fetal blood flow.10, 13 It is largely independent of absolute growth and is principally based on 
growth trajectory.30  If fetal growth drops from the 80th centile to the 20th centile over time the 
fetus is considered growth restricted even though the fetal weight is within the normal range.  
As this was a longitudinal study, we can truly assess the growth of the parenchyma in real-time. In 
the literature, only limited data is available on actual fetal kidney growth, as although some studies 
report kidney growth the studies are cross-sectional in design and therefore unsuitable to assess 
growth.16 A strength of our study was having longitudinal data analysed by mixed effects modelling. 
Mixed effects modelling is much more flexible and powerful than traditional analyses that perform 
overall averaging.31 Every data point is considered using fixed and random effects in a single model 
to account for all sources of variation. Mixed effects models can deal with missing data and 
naturally handles unevenly spaced repeated measures which commonly occurs in human studies.  
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Our study demonstrated a significant difference in thickness and growth trajectory of the renal 
parenchyma between AGA and FGR fetuses. With increasing gestational age, the difference 
between thickness of the parenchyma in the two groups increased. Placental insufficiency is the 
most common cause of FGR.10, 11 It is therefore plausible that this deceleration in growth of the 
parenchyma of FGR fetuses may be at least partly due to increasing placental insufficiency and 
redistribution of fetal blood supply away from the fetal kidneys. This is particularly important for 
kidney development as nephrogenesis continues up until 36 weeks GA, with 60% of nephrons 
formed in the third trimester.32 Ultrasound studies also indicate maximum kidney growth occurs 
in the third trimester.33 ,34 This coincides with the timing of incidence of the majority of FGR.35 
Our analysis has shown that the right fetal renal parenchyma was thicker than the left by 0.11mm. 
This is not thought to be clinically important. In a recent systematic review completed by our 
group on the evaluation of fetal kidney growth using ultrasound we discovered almost all studies 
found no significant difference between right and left fetal kidney size.16 One large study (n=1215) 
did find that the right kidney was significantly wider and deeper than the left kidney, however, not 
longer.33 This is consistent with our study demonstrating a thicker parenchyma in right kidneys. 
Our ability to detect this difference may be due to the higher sensitivity provided by the mixed 
effects modelling in our study.  
Fetal and neonatal kidney volumes have been used as a surrogate measure of nephron number and 
kidney function.36-39 There are some limitations, however, with using kidney volume as an estimate 
of nephron number. Obtaining a kidney volume involves acquiring three orthogonal 
measurements and then applying an ellipsoid formula. There is error associated with each 
measurement and the formula. A study we conducted in neonates demonstrated that kidney 
volume measurements had a significantly higher variance than renal parenchymal thickness 
measurements.20 Ultrasound kidney volumes calculated using the ellipsoid formula have also been 
found to underestimate actual kidney volume compared to in vivo and ex vivo models by more than 
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20%.40, 41The advantage of measuring the renal parenchymal thickness is that instead of measuring 
the entire kidney, a single measurement is performed of the functional, nephron containing region 
and the collecting system is not included. For example, in cases of hydronephrosis measurements 
of kidney volume could significantly overestimate nephron number due to the enlargement of the 
collecting system when in fact the renal parenchyma could be thinner than normal, and the kidney 
may have impaired function. 
Kadioglu (2010) appears to be the first author to report normative ultrasound values for renal 
parenchymal thickness for children to assess for alterations in normal growth42. Our studies since 
on the renal parenchymal thickness of neonates and other studies in children highlight the potential 
of the parenchymal thickness measurement as a possible marker for renal function and to monitor 
renal parenchymal changes20, 43-45. One study has reported some normal ranges for fetal renal 
parenchymal thickness46, however, to our knowledge no study has investigated the growth of the 
renal parenchyma with gestational age in growth restricted fetuses. This new parenchymal 
thickness measurement is a more specific, indirect evaluation of nephron endowment. 
Measurement of fetal renal parenchymal thickness could be used to monitor the effects of FGR 
on fetal kidney growth and the effects of any possible interventions for FGR treatment. FGR can 
arise from fetal, placental and/or maternal disorders and often may be due to a combination of 
more than one cause.11, 35 When placental abnormalities or maternal disease is the cause, nutrients 
and oxygen flow to the fetus may be impaired. The fetus compensates for this by preferentially 
shunting blood away from organs such as the kidneys, towards the more essential organs of the 
brain (known as “brain sparing”), heart and adrenals.18 
Considering that there may be brain sparing in the FGR fetuses, the growth of the renal 
parenchymal thickness was compared to the growth of the head circumference between the AGA 
and FGR groups and a significant difference was seen in our study. In fetuses with the same head 
circumference, a growth restricted fetus was more likely to have a thinner parenchyma than an 
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appropriately grown fetus. This suggests that in small growth restricted fetuses the renal 
parenchyma is thinner than could be expected purely based on fetal size compared to an 
appropriately grown fetus. A possible mechanism for this differential renal parenchyma growth is 
preferential shunting of fetal blood away from the kidneys to the brain due to fetal hypoxia which 
impacts on appropriate nephrogenesis. The fact that the slopes are the same for both groups may 
imply that the “brain-sparing” effect happens earlier than 20 weeks gestation and that the kidneys 
never catch up once they have been compromised.   
6.5.2 Fetal renal arteries 
The renal arteries were analysed for any changes in blood flow to the kidneys. No significant 
difference in the resistivity or pulsatility index of the fetal renal arteries between AGA and FGR 
fetuses was seen. This is consistent with the findings from other studies.27, 47 This observation may 
be due to several reasons. 1. Fetal blood flow to the kidneys is very low with only 5% of cardiac 
output going to the kidneys compared to 9% after birth.48 Therefore, any change in fetal blood 
flow may be too subtle for us to detect using ultrasound. It is also possible that our study was not 
powered to specifically detect a difference in the renal blood flow. 2. A much larger study of FGR 
fetuses with identifiable abnormal uteroplacental or fetal blood flow is needed to detect a 
difference.  
6.5.3 Limitations of the study 
There were some limitations to our study. The lack of blinding of the sonographers could have 
potentially introduced measurement bias. It was difficult to blind the sonographer to all clinical 
and biometric information as most of the studies included a diagnostic scan. Sonographers are 
generally specifically trained not to look at the measurements at the time that they are being 
performed. Additionally, the infants were not assigned to AGA and FGR groups until after birth 
and it was based on birth weight and not the estimated fetal birth weight calculated from the 
measurements done by the sonographer. Having multiple sonographers performing the 
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examinations rather than only one reduces some of the bias. Another limitation was the number 
of the FGR group compared to the AGA group. The fetuses in the FGR group were more likely 
to be delivered earlier before all planned ultrasound examinations could be performed. 
6.5.4 Future direction 
Although it is widely accepted that fetal growth restriction has an effect on nephron number and 
future kidney function, there is a lack of in vivo proof of the mechanisms occurring in utero.6 This 
study provides evidence of an effect on the development of the renal parenchyma which likely 
represents a reduced nephron number, in circumstances of true fetal growth restriction. 
Life-long monitoring of growth restricted, low birth weight and preterm infants along with those 
exposed to pre-eclampsia or gestational diabetes is advocated.49 Such an implementation would 
involve a significant number of the population and be a significant health cost burden. 
Measurement of the renal parenchymal thickness, in contrast, has the potential to more 
appropriately and accurately identify infants with a reduced nephron endowment so that 
monitoring and interventions can be focused on those individuals at a higher risk of developing 
neonatal acute kidney injury and future hypertension and chronic kidney disease.  
6.6 Conclusion 
Kidney disease is associated with a significant global burden and health costs and this study 
improves our understanding and assists in identifying adverse effects on the kidney during 
gestation. Utilising ultrasound to measure the fetal renal parenchymal thickness provides a simple, 
non-invasive estimate of nephron number. Our data suggests that fetal growth restriction has a 
negative influence on nephron numbers as it is associated with a significantly thinner parenchyma 
and slower growth trajectory. It should be remembered that having a reduced nephron number 
alone does not mean hypertension or chronic kidney disease is inevitable, but that the kidney may 
be less able to endure future kidney injury in later life. Using the approach outlined in our study, 
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Chapter. 7 Is Bigger Better?  The Large for Gestational Age 
Fetus and Kidney Development 
Brennan S, Watson D, Schneider M, Rudd D, Kandasamy Y. Is bigger better?  The large for 
gestational age fetus and kidney development. In Preparation. 
 
There is growing evidence of the long-term health effects of infants born large for gestational age 
and recently emerging links between a high birth weight and chronic kidney disease. To our 
knowledge no study had yet investigated the possible effects of fetal overgrowth on fetal kidney 
development. The aim of this chapter was to address the lack of research in this area. This paper 
is currently being prepared for submission to a journal. 
  
Ch 1: Introduction and background 
Ch 2: Systematic review 
Ch 3: Study design and methods 
Ch 4: Normal ranges of fetal renal parenchyma  
Ch 5: Normal ranges of fetal renal arteries 
Ch 6: Fetal renal parenchymal growth and fetal growth restriction 
Ch 8: Fetal renal parenchymal growth and diabetes in pregnancy 










Objective:   
A non-invasive ultrasound measurement of the fetal renal parenchymal thickness was employed 
to investigate possible adverse effects of fetal overgrowth on fetal kidney development and renal 
perfusion. The aim of this study was to measure the fetal renal parenchymal thickness and evaluate 
whether fetal overgrowth affects the growth of the fetal renal parenchyma. The fetal renal artery 
blood flow was also assessed. 
Methods 
This prospective, observational study used serial ultrasound measurements to assess the growth of 
the fetal renal parenchyma. Mixed effects modelling was used to compare 16 large-for- gestational 
age (LGA) fetuses with 102 appropriate-for-gestational (AGA) age fetuses.  
Results 
The fetal renal parenchyma measurement of LGA fetuses was significantly thicker than the AGA 
fetuses (LR Chisq=6.1, df=1, p=0.013), however, this thickness was proportional to the increased 
size of the LGA fetuses. No significant difference was seen between the fetal renal artery resistivity 
index and pulsatility index of LGA and AGA fetuses.  
Conclusion 
This is the first study, to our knowledge, to investigate any possible effects of fetal overgrowth on 
the developing kidneys. The increased thickness in the renal parenchyma of LGA fetuses was 
proportional to the increased size of these fetuses and therefore no significant adverse effect on 
the growth of the fetal renal parenchyma were demonstrated. Most LGA infants were born to 
mothers with diabetes and therefore it would be of value to evaluate the influence of diabetes on 
the developing fetal renal parenchyma. 
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7.2 Introduction 
Fetal overgrowth is associated with increased risks to the mother and infant, such as emergency 
caesarean section, instrumental delivery, shoulder dystocia and trauma to the birth canal.1, 2 The 
large for gestational age (LGA) fetus is defined as having a weight greater than the 90th centile for 
a given gestational age (GA).1, 3 The term LGA is preferred to macrosomia as macrosomia is based 
on a birth weight cut off and does not consider GA. Fetal growth is influenced by nutritional, 
hormonal, genetic and environmental factors, many of which are modifiable.3  
The long-term risks for infants born LGA includes diabetes mellitus, obesity and metabolic 
syndrome.4, 5 These are also strong risk factors for chronic kidney disease (CKD) and hypertension, 
with diabetes being the leading cause of CKD.6, 7 Current research supports renal programming 
in-utero, with a high birth weight now becoming apparent as a developmental risk for future kidney 
disease and hypertension.8-10 
Nephrons are the functional units of the kidneys and their number and function are determined 
in-utero.11, 12 Abnormal fetal growth can influence kidney growth and may yield a lower compliment 
of nephrons, thus exposing the kidneys to impaired renal function and an increased risk of future 
kidney disease.13, 14 It is well established that fetal growth restriction is associated with fewer 
nephron numbers,15-17 however, there are currently no known studies assessing the impact of fetal 
overgrowth on the growing kidneys.18 Additionally, evidence of any alterations in renal perfusion 
in-utero and its role in any possible reduction in future renal function is gaining interest.19, 20 To our 
knowledge, there are no previous studies investigating the possible association between LGA and 
fetal renal blood flow.  
It is important to understand what, if any, adverse effects of fetal overgrowth (including fetal renal 
perfusion) have on kidney development, throughout pregnancy. An ultrasound measurement of 
the fetal renal parenchyma is a non-invasive method to evaluate renal growth and can provide a 
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surrogate estimate of nephron number.21 The main aim of this study was to measure the fetal renal 
parenchymal thickness of LGA fetuses and compare this to appropriate for gestational age (AGA) 
fetuses. These measurements allow evaluation of the possible effects of fetal overgrowth on the 
growth of the fetal kidneys. Evaluation of the fetal renal artery blood flow was also assessed. We 
hypothesised that the thickness of the fetal renal parenchyma of LGA fetuses would differ from 
AGA fetuses. 
7.3 Methodology 
The overall research methodology and the methodology for the ultrasound measurements 
performed for this study have been outlined in Chapter 3. Methods specific to this analysis are 
described below. 
7.3.1 Study design 
After birth, infants were assigned to one of two groups – LGA or AGA. These groups were 
defined a priori.  LGA was defined as infants with a birth weight above the 90th centile.1, 3 Infants 
who were classified as having fetal growth restriction (FGR), as described in Chapter 6, were 
excluded from this analysis. Infants who were neither LGA nor FGR were considered AGA. Birth 
weight was plotted on Hadlock et al.22 fetal weight charts, rather than neonatal charts, as it has 
been demonstrated that neonatal charts do not represent a random sample of the population at a 
given GA.23 Infants born preterm are over-represented with cases of FGR and therefore fetal 
growth should be assessed against measurements of on-going pregnancies at that GA as opposed 
to a birth weight of infants born at a given GA.23, 24  
7.3.2 Statistical analyses 
All statistical analyses were performed using R Statistical Language in R Studio (version 
1.2.1335)25,26 and the ggplot2 package was used to create the graphics.27  Normality of the maternal 
and neonatal demographic data was assessed by visually inspecting the histograms, normal Q-Q 
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plots and box plots. Normally distributed variables were reported as a mean and standard deviation 
(SD) and non-normally distributed variables as a median and interquartile range.  
The nlme package (version 3.1-139)28 was used to fit a random slopes linear mixed effects model 
to describe the effects of explanatory variables on fetal renal parenchymal thickness and renal 
artery blood flow. Visual inspection of residual plots did not reveal any obvious deviations from 
homoscedasticity or normality. No outliers were removed.   
Fixed effects of gender and anterior vs posterior (in the case of parenchymal thickness) were tested 
in all models but did not improve the fit. Determining whether or not to include different effects 
in the final model was done by comparing alternative models using likelihood ratio (LR) test and 
Akaike’s Information Criteria (AIC). The GA variable was modified to 16 weeks = 0, to ensure 
the intercept term in the summary output would represent the parenchymal thickness or renal 
artery value for the AGA group at 16 weeks. Three different models were fitted: 
7.3.2.1 Model 1. Renal parenchymal thickness growth  
The relationship between the renal parenchymal thickness and GA of LGA and AGA fetuses was 
compared.  The response variable was renal parenchymal thickness and fixed effects in the model 
were GA, growth (either LGA or AGA), kidney side (right or left), and the interaction between 
GA and growth. The relationship between parenchymal thickness and GA showed significant 
curvature, so GA was included as a quadratic orthogonal polynomial term. Random effects were 
a random intercept for each participant and the random slopes element used the orthogonal 
polynomial term for the effect of GA. Appendix C2 provides the details of the models fitted with 
their outputs.   
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7.3.2.2 Model 2. Renal parenchymal thickness growth compared to abdominal circumference 
(AC) growth 
The relationship between the thickness of the fetal renal parenchyma and the abdominal 
circumference (AC) was analysed by assuming a power function to describe the relationship of the 
form: 
y = axb 
where y = parenchymal thickness and x = AC.  Y and x are both linear measurements and 
therefore, the value of b should equal 1 if both grow at the same rate. To enable the model to be 
fitted, the renal parenchymal thickness and AC measurements were log transformed to translate 
the power function to the following linear equation: 
log(y) = log(a) + b (log(x)). 
For these models, the response variable was the renal parenchyma (log10) and the fixed effects were 
AC (log10), growth (either LGA or AGA) and kidney side (right or left).  An interaction between 
AC (log10) and growth was included so that the slopes of the regression lines for the LGA or AGA 
groups could be compared. A random intercept was included for each participant and a random 
slope for the effect of AC (log10). 
7.3.2.3 Model 3. Renal artery blood flow 
These models evaluated the resistivity index (RI) and pulsatility index (PI) of the fetal renal arteries 
with the RI and PI being the response variable in each of their respective models. The fixed effects 
were GA, growth (LGA or AGA) and kidney side (right or left), and an interaction between GA 
and growth. GA was again included as a quadratic orthogonal polynomial to allow for curvature 
in the relationship between GA and RI or PI. Each participant had a random intercept and the 
random slopes component used the orthogonal polynomial for the effect of GA. 
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7.4 Results 
A flowchart of the recruitment data is shown in Figure 7.1. A total of 155 pregnant women were 
recruited. Thirty-seven were excluded, mostly due to fetal growth restriction, resulting in 16 LGA 
infants and 102 AGA infants. There were 633 ultrasound examinations performed between 16- to 
39 weeks GA. The mean (SD) number of scans per pregnancy was 5.4 ± 1.4. The first ultrasound 
was usually completed between 16- and 26-weeks, however, six women had their first ultrasound 
at 28 weeks.  
 
Figure 7.1 Flowchart of participant inclusion and exclusion process. 
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The characteristics of the mothers and infants are summarised in Table 7.1. Mothers of LGA 
infants had a significantly higher pre-pregnancy weight and BMI (median weight 93kg; BMI 32.3) 
when compared to mothers of AGA infants (median weight 72kg; BMI 25.8; p = <0.05). In 75% 
of the LGA infants the mother had pregestational or gestational diabetes mellitus during 
pregnancy. Despite their lower gestational age at birth, the LGA infants had a significantly higher 
birth weight and birth weight centile than the AGA infants. A comparison of maternal BMI 





Characteristics of appropriate-for-gestational age (AGA) and large-for-gestational age (LGA) pregnancies and 
their infants 
Participant Characteristics AGA (N=102) LGA (N=16) p value 
MATERNAL     
Maternal age (years) 29.6 ± 5.2 30.0 ± 5.0 0.758a 
Maternal height (cm) 165 ± 6 165 ± 6 0.789a 
Maternal weight (kg) (M, IQR) 72.0 (60.0 – 86.5) 93.0 (75.3 – 106.8) 0.015b* 
Maternal BMI (kg/cm2) (M, IQR) 25.8 (22.7 – 31.6) 32.3 (38.0 – 39.8) 0.010b* 
Maternal race origin N = 82# N = 14#  
• Aboriginal/Torres Strait 
Islander 
7 (8.5) 2 (14.3) 0.798c 
• Asian 3 (3.7) 1 (7.1)  
• Caucasian 69 (84.1) 11 (78.6)  
• Indian 1 (1.2) 0  
• Other 2 (2.4) 0  
Multiparous 52 (51.0) 13 (81.2) 0.024d*  
Diabetes   0.0001c* 
• No diabetes 64 (62.7) 4 (25.0)  
• Pregestational Diabetes 3 (3.0) 6 (37.5)  
• Gestational diabetes 35 (34.3) 6 (37.5)  
NEONATAL    
GA at birth (weeks) (M, IQR) 38.7 (38.0 – 39.3) 38.3 (36.3 – 38.8) 0.035b* 
Preterm (<37 weeks GA) 8 (7.8) 5 (31.3) 0.037c* 
Birth weight (grams) (M, IQR) 3390 (2978 – 3603) 3905 (3684 – 4123) <0.0001b* 
Birth centile 44.5 (24.0 – 67.5) 94.5 (91.5 – 97.5) <0.0001b* 
Male 52 (51.0) 11 (68.8) 0.185d 
 
Note: #20 (19.6%) AGA and 2(12.5%) LGA participants declined to answer maternal race. Means ± SD. M, 
median; IQR, interquartile range or n (%). GA, gestational age. * = p<0.05 





Figure 7.2 Comparison of appropriate for gestational age (AGA; N=102) and large for 
gestational age (LGA; N=16) fetuses according to the mother’s BMI (p = 0.010, Mann-
Whitney). 
7.4.1 Renal parenchymal thickness growth 
A total of 2536 renal parenchymal thickness measurements were obtained. At each ultrasound 
examination four measurements were performed, corresponding to the anterior and posterior 
thickness of both the right and left kidneys. Statistical modelling found no significant difference 
in the renal parenchymal thickness for fetal gender or whether the anterior or posterior 
parenchyma was measured and therefore these were not included in the final model. Kidney side 
(right or left) was included as a fixed effect in all models, as the renal parenchymal measurement 
of the right kidney was significantly thicker than the left (p=<0.05). The complete output of the 
models is provided in Appendix C2. 
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The fetal renal parenchyma measurement of LGA fetuses was significantly thicker than the AGA 
fetuses (LR Chisq=6.1, df=1, p=0.013) (Fig 7.3). No significant interaction was seen between GA 
and whether the fetus was LGA or AGA, indicating that the parenchymal growth rate of both 
groups over time was not significantly different (Appendix C2 part 2). 
 
Figure 7.3 Overall regression lines of fetal renal parenchymal thickness for AGA and 
LGA groups (p= 0.013). Shaded areas denote 95% confidence interval. 
7.4.2 Renal parenchymal thickness growth compared to AC growth 
Renal parenchyma growth was compared to growth of the AC throughout the pregnancy for the 
LGA or AGA fetuses. There was no significant difference demonstrated between the LGA or 
AGA groups (LR Chisq=1.1, df=1, p=0.290). Renal parenchymal thickness grew proportional 






Figure 7.4 Overall regression lines of the relationship between fetal renal parenchymal 
thickness (log10) and abdominal circumference (log10) for AGA and LGA groups. 
Shades denote 95% confidence interval. 
7.4.3 Renal artery Dopplers 
Fetal renal artery Dopplers were also measured during the ultrasound examination. In total 1203 
renal artery Dopplers were carried out. Due to fetal position and/or persistent fetal movements, 
the renal artery Doppler could not be performed for both kidneys in 28 scans and for one kidney 
in 35 scans. No significant difference was seen between LGA or AGA fetuses in the RI (LR 







Figure 7.5 Overall regression lines of AGA and LGA groups for fetal renal artery (a) 
resistivity index (RI) and (b) pulsatility index (PI). Shades denote 95% confidence 
interval. 
7.5 Discussion 
The aim of this study was to investigate the effect of fetal overgrowth on the developing fetal 
kidneys through the use of a novel ultrasound measurement of renal parenchymal thickness and 
renal artery Doppler in AGA and LGA pregnancies. LGA is a significant problem, associated with 
many fetal and maternal complications, and should be taken as seriously as other obstetric 
conditions.2 The role of fetal overgrowth in fetal renal programming is also under-researched and 
not well understood.9,29 Some links with increased risks of kidney disease and hypertension have 
been demonstrated, however, to our knowledge, no study has previously analysed the growth of 
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the kidneys in LGA fetuses.18 It is important to try and understand the effect of fetal overgrowth 
on the developing kidneys. 
7.5.1 Fetal renal parenchymal thickness growth 
The results from this study demonstrated that the renal parenchyma of fetuses born LGA was 
significantly thicker than AGA fetuses.  The birth weight and birth centiles are significantly higher 
in the LGA group compared to the AGA group and, therefore the kidneys of the LGA fetuses 
appeared to be proportionately larger, in-line with the larger infants. To test this, the renal 
parenchymal growth was compared to abdominal circumference growth for LGA and AGA 
groups. This demonstrated no difference in the growth profile between the two groups indicating 
that the larger fetus had a proportionately thicker renal parenchyma.  
7.5.2 Influences of diabetes in pregnancy on fetal renal parenchymal thickness growth 
LGA infants are a heterogeneous population which include individuals from diabetic pregnancies, 
obese mothers and normal genetically large infants and a combination of these. Often in studies 
the aetiology of fetal overgrowth is not reported.8 The results from this study did indicate an 
association between LGA and maternal pre-pregnancy weight and BMI. The mothers of LGA 
infants were significantly heavier and had a higher BMI. The mothers of LGA infants were also 
more likely to have pregnancies complicated by diabetes, with 75% having some type of diabetes. 
Diabetes in pregnancy is a leading cause for having a LGA infant.1, 30 
There is a difference in the body composition and distribution of muscle and fat of infants who 
are born to a mother with diabetes.30 LGA infants of diabetic mothers have a higher fat to muscle 
ratio and tend to have asymmetric growth of the abdominal circumference and thorax, whereas 
LGA infants of mothers without diabetes tend to be symmetrically large and have a similar fat to 
muscle ratio as appropriately grown infants.1, 30  
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7.5.3 Fetal renal artery Doppler analysis 
This study investigated the fetal renal artery Doppler measurements for LGA and AGA 
pregnancies. The fetal renal artery blood flow did not demonstrate any significant difference in the 
RI or PI between LGA or AGA fetuses. Blood flow in the fetal renal arteries of LGA fetuses, to 
our knowledge, has not been previously reported and no significant changes in fetal blood flow 
have been associated with fetal overgrowth. There is significant overlap of confidence intervals for 
both RI and PI between the LGA or AGA groups which is likely due to the relatively poor 
interobserver reliability of these measurements that we have previously reported (Chapter 5). 
Additionally, the fetal kidneys receive only 3 - 5% of overall cardiac output and therefore any 
changes in this blood flow would likely be very subtle.31, 32 A much larger study of LGA fetuses 
would be required to detect any significant difference from AGA pregnancies.    
There is evidence of a link between maternal obesity, diabetes, LGA infants and future kidney 
disease. However, the precise effect of each and the combined implications on fetal programming 
remains unclear.8, 29 Our study did not find any adverse effect of fetal overgrowth on the growth 
of the parenchyma during the pregnancy which is quite different to the adverse effect on the fetal 
renal parenchyma growth seen in growth restricted fetuses.15 LGA is associated with childhood 
obesity and metabolic syndromes, which are strong risk factors for hypertension and CKD later 
in life.5, 7, 9, 33 This is a small study and therefore at this stage we cannot say there is no effect on the 
developing kidneys until further larger studies are conducted. Also, in these infants, it may be in 
early childhood that the bulk of programming of the kidneys occurs.34, 35 
7.5.4 Limitations 
There was only a small number of LGA infants in our cohort which limited our analyses. Larger 




No adverse effect on the growth of the renal parenchyma was demonstrated in fetuses who were 
LGA. The majority of LGA infants were born to mothers with diabetes in pregnancy. It would 
therefore be of value to further investigate the influence of diabetes on the developing fetal renal 
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Chapter. 8 The Effect of Diabetes During Pregnancy on Fetal 
Renal Parenchymal Growth 
Brennan S, Kandasamy Y, Rudd DM, Schneider ME, Jones RE, Watson DL. J. The effect of 
diabetes during pregnancy on fetal renal parenchymal growth. J Nephrol. In press. 
 
This chapter is a copy of the journal paper, referenced above, except for minor textural 
modifications. The formatting of section sub-headings and references, and numbering of figures 
and tables have been modified from the original publication to match the thesis format. This paper 
has been accepted for publication and is currently in press. 
Diabetes in pregnancy is thought to adversely affect the developing fetal kidneys however it is 
unclear how hyperglycaemia impacts the development of the kidneys. Our study uses a novel 
ultrasound measurement to provide unique data on how diabetes in pregnancy influences fetal 
kidney growth. 
Ch 1: Introduction and background 
Ch 2: Systematic review 
Ch 3: Study design and methods 
Ch 4: Normal ranges of fetal renal parenchyma 
Ch 5: Normal ranges of fetal renal arteries 
Ch 6: Fetal renal parenchymal growth and fetal growth restriction 
Ch 7: Fetal renal parenchymal growth and fetal overgrowth 










Diabetes in pregnancy is thought to adversely affect the developing kidneys. The rate of gestational 
diabetes is increasing globally with major consequences for future renal function. Very little is 
known about the impact of hyperglycaemia on the fetal renal parenchyma which contains the 
developing nephrons. The aim of this study was to measure the fetal renal parenchymal thickness 
and evaluate whether diabetes during pregnancy affects the growth of the fetal kidneys. 
Methods 
This prospective, observational study used serial ultrasound measurements to evaluate the fetal 
renal parenchymal growth of 55 pregnancies with diabetes compared to 72 control pregnancies. 
Mixed effects modelling was used to analyse the data. 
Results 
The renal parenchyma of fetuses from mothers with gestational diabetes was significantly thicker 
than those from the control group (LR Chisq=4.8, df=1, p=0.029), however, the difference was 
proportional to the larger size of these fetuses. Fetuses of pregestational diabetics demonstrated 
no significant difference in renal parenchymal thickness compared to the control group even 
though they were also larger fetuses. Parenchymal growth slowed with increasing abdominal 
circumference in the pregestational diabetic group, suggesting an adverse effect on nephrogenesis, 
however this did not reach statistical significance.  
Conclusions 
Our study provides unique data on how diabetes during pregnancy influences fetal kidney growth. 
Appropriate management of diabetic pregnancies may mitigate some of the adverse effects on the 
fetal kidneys. Increasing degrees of hyperglycaemia, as seen sometimes in pregestational diabetes, 




Hyperglycaemia in pregnancy is an increasingly common condition compounded by an increase in 
obesity and maternal age.1, 2 Pregestational diabetes refers to type 1 and type 2 diabetes mellitus 
that exists prior to pregnancy, while gestational diabetes mellitus refers to diabetes identified during 
pregnancy.2, 3 The prevalence of type 2 diabetes in pregnancy and gestational diabetes mellitus is 
increasing.1, 4 The global incidence of gestational diabetes has been reported to be around 20%; 
however, variations in screening protocols, criteria for diagnosis and risk factors means that the 
incidence varies between different pregnant populations.4 Glucose is an essential nutrient for the 
fetus. To facilitate glucose transfer to the fetus, maternal insulin sensitivity decreases during 
pregnancy by 50-60%.1 Elevated maternal glucose levels, however, are known to be teratogenic 
and are associated with an increased risk of adverse perinatal and maternal outcomes such as 
abnormal fetal growth, preterm birth, birth trauma and operative delivery.2, 5  
Hyperglycaemia in pregnancy is also associated with adverse effects on the developing kidneys. 
One study demonstrated a three-fold increase in renal dysgenesis and agenesis.6 Studies using 
animal models have confirmed this association, with offspring of hyperglycaemic mothers 
demonstrating reduced nephron numbers, increased blood pressure, microalbuminuria and a 
reduced glomerular filtration rate.7, 8. Human studies have demonstrated that adults born to 
mothers with diabetes in pregnancy have an increased risk of hypertension, chronic kidney disease 
and diabetes mellitus.9, 10. Current evidence suggests an adverse programming effect on the fetus 
due to exposure to hyperglycaemia during pregnancy, however human studies are still limited.8, 9 It 
is unclear how diabetes in pregnancy impacts the developing kidneys in-utero. Given the increasing 
incidence of diabetes during pregnancy, it is critical that further investigations are carried out to 
understand the effects of hyperglycaemia during pregnancy on kidney development and long-term 
function.6, 11 
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We have previously demonstrated that an ultrasound measurement of the renal parenchymal 
thickness in fetuses and neonates presents a novel, non-invasive method to assess kidney growth 
and can provide a surrogate estimate of nephron numbers.12-14 The aim of this study was to use an 
ultrasound measurement of the fetal renal parenchymal thickness to evaluate whether diabetes 
during pregnancy affects the growth of the fetal kidneys. We hypothesised that the renal 
parenchymal thickness in fetuses from women with diabetes during pregnancy would differ from 
fetuses in the control group. 
8.3 Research Design and Methods 
8.3.1 Study design and recruitment 
This prospective, longitudinal, observational study was conducted between May 2017 and 
February 2019 at the Maternal-Fetal-Medicine Unit and Ultrasound Department of the Townsville 
University Hospital, Australia. The Townsville University Hospital is a large regional hospital that 
provides tertiary perinatal services to the large geographical area of North Queensland.15 
Recruitment was between May 2017 to October 2018. All neonates were born by March 2019 and 
data collection complete by December 2019.  
This study was part of a larger study assessing multiple factors which affect fetal kidney growth. 
Pregnant patients aged 18 years or older, who presented to the Townsville University Hospital 
were informed about the study and invited to participate by their treating obstetrician, midwife or 
sonographer at their second trimester obstetric ultrasound scan up until 28 weeks gestation. 
Inclusion criteria were an accurately dated singleton pregnancy based on last normal menstrual 
period (LNMP) and 1st trimester ultrasound, that correlated with each other within seven days, or 
if LNMP was uncertain, by 1st trimester ultrasound alone. Patients were excluded if they had a 




The subgroup of pregnant women with hyperglycaemia were diagnosed either with pregestational 
diabetes (type 1 or 2) or with gestational diabetes. Gestational diabetes was identified with a glucose 
tolerance test before 24 weeks, if they were assessed as high risk for gestational diabetes, or 
between 24 to 28 weeks as per routine management for all pregnant women. The diagnosis of 
gestational diabetes was based on the Australasian Diabetes in Pregnancy Society (ADIPS) 
guidelines,16 which are consistent with the International Association of Diabetes and Pregnancy 
Study Groups Consensus Panel,3 specifying if their plasma glucose levels met one or more of the 
following criteria:  
• Fasting of ≥5.1mmol/L; 
• 1-hour ≥10.0mmol/L following an oral 75g glucose load; and 
• 2-hour ≥8.5mmol/L following an oral 75g glucose load.  
Pregnant women with diagnosed diabetes were managed in a multidisciplinary diabetes clinic 
which included an endocrinologist or obstetric physician, maternal fetal medicine sub-specialist, 
diabetes educator, dietitian and midwife where they received specialist support for monitoring of 
glucose, diet and exercise. Patients generally attended the clinic every 1 to 4 weeks and were 
instructed to test their blood glucose levels four times a day: fasting and 2 hours after each meal. 
The aim was to maintain fasting glucose levels < 5.1mmol/L and < 7.0mmol/L 2 hours after 
meals for gestational as well as pregestational diabetes. If glycemic controls could not be met with 
appropriate diet, medications were added and adjusted to try and achieve these goals.16  
The control group was a cohort of low-risk pregnancies without underlying maternal diseases 
which may affect fetal growth (diabetes mellitus, heart disease, hypertension requiring treatment, 
kidney disease, pre-eclampsia), and who did not give birth prematurely before 32 weeks.  
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8.3.2 Sample size 
In order to determine sample size, a power analysis was carried out for a statistical power of 80% 
and a significance level of 0.05 (two-tailed).  Data from our previous study found the mean (SD) 
renal parenchymal thickness for neonates of normal birth weight was 9.4mm (± 1.1) and for low 
birth weight neonates it was 8.3mm (± 1.0) (p=0.01).12 Therefore, a sample size of 15 would be 
needed for each group. To allow for loss to follow-up, we aimed to recruit a minimum of 20 
participants for each group (40 in total). Ultrasound examinations were scheduled for each 
participant at least every four weeks. 
8.3.3 Study process 
Participants completed a questionnaire which included demographic, medical and obstetric data. 
The first ultrasound was most commonly performed between 16- and 26-weeks gestational age 
(GA); however, eight women had their first ultrasound at 28 weeks GA. Women were asked to 
attend ultrasound scans every four weeks from their first ultrasound until delivery. Some women, 
with high risk pregnancies, had additional clinically indicated ultrasounds. When their ultrasound 
examination was more than two weeks from the previous ultrasound recorded for the study, renal 
measurements were again performed for the study. After birth, perinatal data was collected from 
the mother and baby’s electronic medical record around onset of labour, model of delivery, 
gestational age at birth, birth weight, gender, condition of neonate and maternal medical history 
and medications. 
8.3.4 Ultrasound examination 
All examinations were performed by three Australian Accredited Medical Sonographers with more 
than two years post ultrasound qualification experience. Prior to commencement of the study, 
sonographers were trained to use a standardised protocol for renal measurements by authors DLW 
and SB. A follow-up audit, to ensure measurement consistency between sonographers, was 
conducted three months after commencement of the study. The sonographers were not blinded 
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to all clinical and biometric information as most studies included a diagnostic scan. A Voluson E8 
(GE Healthcare Ultrasound, Milwaukee, WI, USA) or an Epiq 7 (Philips Ultrasound, Bothell, WA, 
USA) were used for the ultrasound examinations. The highest frequency transducer possible (1-
5MHz), which matched the mother’s body habitus was selected. 
All measurements were performed on both kidneys. The images of the fetal kidneys were 
magnified so the kidney occupied the majority of the image. The renal parenchymal thickness was 
obtained from a midsagittal plane of the kidney by measuring from the inner aspect of the renal 
capsule to the sinus-pyramidal apex in both the anterior and posterior aspects (Fig 8.1a). The 
maximum kidney length was also measured in this midsagittal plane. In a transverse section of the 
fetal kidney, at the level of the renal pelvis, the maximum anteroposterior diameter (H) and 
transverse diameter (W) were measured (Fig 8.1b). Every measurement was performed twice, with 
the mean recorded. The kidney volume was calculated using the ellipsoid formula: KV = 0.523  




Figure 8.1 30 weeks gestational age (a) Measurement of the anterior (1) and posterior (2) 
fetal renal parenchymal thickness from the inner aspect of the renal capsule to the sinus-
pyramidal apex interface and of the kidney length (3). (b) Measurement of kidney 
transverse (1) and antero-posterior (2) dimensions. 
8.3.5 Statistical analyses 
Hadlock et al.18 fetal weight charts were used to plot the birth weight. Fetal weight charts are 
preferred to neonatal weight charts as neonatal charts do not represent a random sample of the 
population at a given GA, particularly those neonates born prematurely. It has been recommended 
that fetal growth be assessed against measurements of on-going pregnancies at that GA as opposed 
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to a birth weight of neonates born at a given GA.19, 20 R Statistical Language in R Studio (version 
1.2.1335)21, 22 was used for all analyses and graphics.  
Visual inspection of the histograms, normal Q-Q plots and box plots showed the maternal and 
birth data were approximately normally distributed. Each measurement is described as means +/- 
SD or N (%) and statistical significance was set as p<0.05.  
8.3.5.1 Modelling analysis 
As repeated measurements were made on each fetus, the effects of maternal diabetes on the 
relationship between parenchymal thickness and GA were analysed using random slopes linear 
mixed effects models. These allow for individual differences between fetuses in kidney size and 
growth rate. The nlme package (version 3.1-139).23 was used to fit the models and the ggplot2 
package24 was used to create the graphics. All measurements on each participant, for each visit, 
were included in the analysis with no outliers removed. Normality and homoscedasticity were 
assessed using visual inspection of residual plots.  
Fixed effects of gender and anterior vs posterior parenchymal thickness were tested in all the 
models but did not improve the fit. Whether or not to include them in the final model was 
determined by comparing alternative models of different complexity using likelihood ratio (LR) 
tests and Akaike’s Information Criteria (AIC). Three groups of models were fitted. 
8.3.5.2 Renal parenchymal thickness growth 
The relationship between the fetal renal parenchymal thickness and GA in fetuses of mothers with 
diabetes and the control group was analysed. Renal parenchymal thickness was the response 
variable and the fixed effects were GA, diabetes status (no diabetes or diabetes), kidney side (right 
or left) and an interaction between GA and diabetes status. To allow for curvature in the 
relationship between parenchymal thickness and GA, GA was included as a quadratic orthogonal 
polynomial. The diabetes status variable was dependent on which data set was used: it was either 
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no diabetes versus gestational diabetes, or no diabetes versus pregestational diabetes. The variable 
for GA was adjusted to 16 weeks = 0, so that the intercept term in the summary output would 
represent the parenchymal thickness value of the control group at 16 weeks, the lowest gestational 
age included in the study. 
Participant ID was treated as a random effect and the random slopes component used the 
orthogonal polynomial for the effect of GA. The fitted models showed greater residual variation 
as renal parenchymal thickness increased, so this was allowed for in the model. Details of the 
models fitted, with their outputs, are provided in Appendix C3.  
8.3.5.3 Abdominal circumference growth 
The relationship between the fetal abdominal circumference (AC) and GA was analysed with the 
AC as the response variable and the fixed effects were GA (again using a quadratic polynomial to 
allow for curvature), diabetes status, kidney side and an interaction between GA and diabetes 
status. As for models in the first group, participant ID and the GA polynomial were incorporated 
as random effects and the increase in residual variance with increasing AC was allowed for in the 
model.  
8.3.5.4 Fetal renal parenchymal thickness growth compared to AC growth  
The effects of hyperglycaemia during pregnancy on the relationship between the thickness of the 
fetal renal parenchyma and the AC were assessed. We assumed a power function of the form: 
y = axb 
was suitable to define this relationship, where y = parenchymal thickness and x = AC. Since y and 
x are both linear measurements, if they both grow at the same rate then the value of b should be 
1. To fit the model, the renal parenchyma and the AC were log transformed to convert the power 
function to the following linear equation: 
 
197 
log(y) = log(a) + b(log(x)) 
The response variable for these models was the log10-transformed parenchymal thickness and the 
fixed effects in each model were diabetes status, log10-transformed AC and an interaction between 
the two to examine whether the regression lines for each type of diabetes status had different 
slopes. A random intercept for each participant and a random slope for the effect of AC (log10) 
was used.  
8.4 Results 
Overall, 155 pregnant women were recruited. Fifty-five of the women had diabetes in pregnancy: 
46 gestational diabetes and 9 pregestational diabetes (type 1 n = 3 and type 2 n = 6). Although the 
number of women presenting with pregestational diabetes was small, it consisted of serial data 
which provided important, novel measurements and so was retained as a separate group in the 
analysis. Seventy-two women with low risk pregnancies were used as the control group. Twenty-
one women were excluded due to maternal disease classifying the pregnancy as high risk, six were 
excluded due to fetal abnormality and one was excluded as she failed to attend any ultrasound 
examinations (Fig 8.2). 
The characteristics of the mothers and babies are summarised in Table 8.1. Pregnancies that were 
complicated by either gestational diabetes or pregestational diabetes were associated with a 
significantly higher pre-pregnancy weight and BMI. Neonates of mothers with diabetes were born 





Figure 8.2 Flowchart of participant inclusion and exclusion process. 
A total of 690 ultrasound examinations were performed between 16- to 39-weeks GA with a mean 
(SD) number of scans per pregnancy of 5.4 ± 1.4. A single participant had only one scan. This 
participant had gestational diabetes and delivered preterm at 27 weeks GA. Some participants 




Characteristics of diabetic pregnancies and control pregnancies and their infants 





diabetes (N = 9) 
p value 
MATERNAL      
Maternal age (years) 29.1 ± 5.3 30.5 ± 4.7 31.2 ± 5.1 F2,124 = 0.216a 
Maternal height (cm) 164 ± 6.2 1.66 ± 6.6 165 ± 8.2 F2,124 = 0.233a 
Maternal pre-pregnancy weight (kg) 68.5 ± 15.9 87.0 ± 20.5 98.9 ± 26.7 F2,124 = <0.000*ab 
Maternal BMI (kg/cm2) (M, IQR) 25.5 ± 5.4 31.5 ± 6.7 36.1 ± 7.8 F2,124 = <0.000*ab 
Multiparous 33 (45.8%) 32 (69.9%) 7 (77.8%) 0.020*c 
MATERNAL – Diabetic groups only     
HbA1c (% (mmol/mol))  5.12 (32) ± 0.33 (N=33f) 6.91 (52) ± 1.28 F2,124 = <0.000*d 
Fasting GTT (for gestational diabetes only)  5.02 ± 0.69   
Treatment    0.284c 
• Diet only  10 (22%) 0 (0%)  
• Oral hyperglycemic agent (OHA)  9 (20%) 1 (11%)  
• Insulin  14 (30%) 5 (56%)  
• Insulin & OHA  13 (28%) 4 (33%)  
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diabetes (N = 9) 
p value 
NEONATAL     
GA at birth (weeks) 38.7 ± 1.5 37.9 ± 2.3  37.3 ± 1.2 F2,124 = 0.026ae 
Preterm 8 (11.1%) 5 (10.9%) 4 (44.4%) 0.040*c 
Birth weight (grams) 3189 ± 516 3288 ± 678 3560 ± 659 F2,124 = 0.184a 
Weight centile 37.6 ± 25.6 56.3 ± 29.7 73.6 ± 37.1 F2,124 = <0.000*ab 
Male 41 (56.9%) 20 (43.5%) 7 (77.8%) 0.126c 
Note: Means ± SD or N (%). GTT, glucose tolerance test; GA, gestational age. * = p<0.05; a one - way ANOVA; b Tukey individual pairwise comparison 
shows significant difference is between the control group and both groups of diabetes; c Fisher’s Exact Test; d Independent  




8.4.1 Renal parenchymal thickness growth 
There were 2556 renal parenchymal thickness measurements for the comparison between the 
gestational diabetes and the control groups and 1780 for the comparison of the pregestational 
diabetes to the control groups. At each examination four measurements of each fetus were 
completed, corresponding to one each by right or left kidney and anterior or posterior portion of 
the kidney. During modelling, no difference between the anterior or posterior parenchymal 
thickness or gender was found and therefore these were not included in the final model. Whether 
the measurement was from the left or the right kidney was included as a fixed effect in this, and 
all subsequent models, as the renal parenchymal measurement of the left kidney was found to be 
significantly thinner than the right (p=<0.05).  
The fetal renal parenchymal thickness for pregnancies with gestational diabetes was significantly 
thicker than the control group (LR Chisq=4.8, df=1, p=0.029) (Fig 8.3a). There was no significant 
interaction between diabetes and the GA, indicating that the parenchymal growth rate of the 
gestational diabetes group was not significantly different from the control group (Appendix C3 
part 2). The fetal renal parenchymal thickness of pregnancies with pregestational diabetes showed 
no significant differences from the control group, although the pregestational diabetes group was 
small (Fig 8.3b). The full output is provided in Appendix C3 part 2.  
The aim of the study did not include evaluating the impact of HbA1c levels and diabetic 
management of the different types of diabetes on renal growth, however, we did perform these 
analyses. HbA1c levels (LR Chisq=0.001, df=1, p=0.972) and diabetic management (diet only, 
OHA or insulin) (LR Chisq=2.79, df=3, p=0.424) were tested in the model, however there was 
no significant effect of either variable on renal parenchymal thickness. Although the mean HbA1c 
levels of mothers with pregestational diabetes was significantly higher than mothers with 
gestational diabetes (p=<0.0001), the number of cases is small so HbA1c impact in the model may 
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be underestimated. Analysis of the effect of these variables would require a larger study that is 
designed and powered for this purpose. 
 
Figure 8.3 Overall regression line for fetal renal parenchymal thickness by gestational 
age for (a) gestational diabetes and control groups and (b) pregestational diabetes and 
control. Shades denote 95% confidence interval. 
8.4.2 Abdominal circumference growth 
The interaction between diabetes type and GA was significant, with the results demonstrating that 
the growth rate of the fetal AC was higher for pregnancies with either gestational diabetes (LR 
Chisq=23.9, df=2, p=<0.0001) or pregestational diabetes (LR Chisq=12.8, df=2, p= 0.0015) (Fig 







Figure 8.4 Overall regression line for abdominal circumference by gestational age for 
control (black line), gestational diabetes (blue line) and pregestational diabetes (red line) 
groups. Shades denote 95% confidence interval. 
8.4.3 Fetal renal parenchymal thickness growth relative to AC growth 
The log10-transformed relationship between fetal renal parenchymal thickness and AC did not 
differ significantly between the groups of pregnancies with gestational diabetes and the control 
group (LR Chisq=1.37, df=1, p=0.242), and pregestational diabetes and the control group (LR 
Chisq=2.67, df=1, p=0.103) (Fig 8.5). There was some flattening of the slope of the pregestational 
group, however this did not reach significance. Similar findings were seen when the parenchymal 
growth relative to the AC growth was compared between the gestational and pregestational groups 




Figure 8.5 Relationship between log10 transformed fetal renal parenchymal thickness 
and abdominal circumference for (a) gestational diabetes and control groups and (b) 
pregestational diabetes and control groups. Shades denote 95% confidence interval. 
8.5 Discussion 
Diabetes in pregnancy is a high-risk condition for mothers and babies and the incidence is 
increasing globally.1, 2, 25 This is the first study, to our knowledge, that compared the growth of the 
fetal renal parenchyma in diabetic pregnancies to a control group of low-risk pregnancies. The 
longitudinal nature of our data and the use of mixed effects modelling is a strength of our study. 
Our findings demonstrated that the fetal renal parenchyma of pregnancies with gestational diabetes 
was significantly thicker than in the control group. However, there was no significant difference 
in fetal renal parenchymal thickness between the pregestational diabetes group when compared to 
the control group. 
Mothers with pregestational and gestational diabetes both had a significantly higher pre-pregnancy 
weight and BMI than the control group. Comparing the birth weight centiles of the neonates in 
lieu of GA allowed for the differences in GA at birth. Neonates born to mothers with gestational 
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and pregestational diabetes were significantly heavier when compared to the control group. The 
growth of the fetal AC in these groups was also significantly larger than the control group, 
supporting the findings of previous studies that mothers with diabetes have larger fetuses.26 
Glucose readily crosses the placenta, however insulin does not. Fetal overgrowth frequently occurs 
in diabetic pregnancies and this is referred to as the Pedersen hypothesis.27 
The Pedersen hypothesis provides an explanation for fetal overgrowth and is supported by other 
studies such as the HAPO trial.5, 27 The hypothesis states that maternal hyperglycaemia results in 
fetal hyperglycaemia and hypertrophy of fetal islet tissue leading to insulin hypersecretion, 
increased growth hormones and insulin-like growth factors (IGF), which promote fetal growth 
with increased deposition of fat and protein production.27 Diabetes in pregnancy is a leading cause 
for a large-for-gestational age (> 90th centile for GA) neonate with a disproportionate growth of 
the AC due to an increase in excessive fat and muscle in this region.1, 28 
If newborns of mothers with hyperglycaemia are larger and have organomegaly, due to fetal 
overgrowth, then it may be hypothesised that the kidneys should be proportionally bigger than 
kidneys from normo-glycemic mothers. This is consistent with our findings of a thicker fetal renal 
parenchyma in the gestational diabetes group when compared to the control group, however, when 
renal parenchymal growth was corrected for AC growth in these fetuses the difference 
disappeared. Thus indicating, that at the same AC both groups have a similar parenchymal 
thickness: the thicker renal parenchyma of fetuses of mothers with gestational diabetes was 
proportionally grown to the overall larger size of these fetuses.  
Few studies have investigated the impact of hyperglycaemia in pregnancy on the fetal kidneys. One 
longitudinal study demonstrated a significant increase in fetal kidney volume of fetuses of mothers 
with gestational diabetes.29 They did not report on any maternal or neonatal demographics. 
Another cross-sectional study measured the fetal kidney volume at one point in time between 32- 
34-weeks gestation and found no difference in the kidney volumes of fetuses of mothers with 
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gestational diabetes and those that did not.30 As opposed to our study, this study did not find any 
differences in maternal weight, BMI or parity between gestational diabetes group and their control 
group. No neonatal data, such as birth weight, was reported.30  
Studies of adults born to mothers with diabetes during pregnancy indicate that they are more likely 
to develop chronic kidney disease, hypertension, obesity and diabetes.9, 11 Animal studies of rodents 
have also demonstrated that the kidneys from offspring of mothers with diabetes have smaller 
kidney volumes, fewer nephrons and a greater proportion of damaged nephrons which is thought 
to be due to the toxic effects of hyperglycaemia.7, 31 It is important to consider that animal studies 
generally model severe hyperglycaemia in pregnancy which also frequently results in growth 
restriction.7, 8, 31 This does not reflect what usually occurs in humans.  
Participants in this study with gestational diabetes did not have severe hyperglycaemia at the time 
of diagnosis, which is supported by the fasting GTT and HbA1c. Over the last few decades there 
has been significant advances in the management of diabetes during pregnancy resulting in earlier 
diagnosis, better surveillance and improved management which may result in better outcomes in 
adulthood for these children.2 The findings from this study support the role for good glycemic 
control for healthy kidney development. Appropriately managed gestational diabetes results in 
normal fetal kidney growth, although larger than those of low risk pregnancies, with no discernible 
adverse effect to their growth pattern. This does not mean there is no impact, but rather that the 
impact is not significant enough to be detected by our current methods and it may emerge later in 
adulthood, which remains to be explored further. 
In the pregestational diabetes group, despite the overall larger birth weight of these babies 
compared to the control group, the fetal renal parenchyma was not significantly thicker than those 
in the control group. Relative to the size of the fetus, the renal parenchyma was not as thick as 
expected, and as was seen in the gestational diabetes group. When comparing the fetal renal 
parenchyma to AC growth of the pregestational diabetes group and the control group, there was 
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a flattening in the slope of the pregestational diabetes groups, however, this did not reach statistical 
significance. The findings suggest renal parenchymal growth slowed with increasing AC in the 
pregestational diabetes group compared to the control group and with a larger sample size this 
may reach statistical significance. When the fetal renal parenchyma to AC growth was compared 
between the gestational diabetes and pregestational diabetes groups, again the growth rate of the 
fetal renal parenchyma to AC of the pregestational group appears slightly slower than the 
gestational diabetes group, however, was not statistically significant.  
Maternal hyperglycaemia is more severe in pregestational compared to gestational diabetes and 
pregestational diabetes is associated with increased fetal abnormalities and adverse outcomes.2,5,25  
This suggests that the difference in the growth rate of the fetal renal parenchyma for the 
pregestational diabetes group may be due to the fetus being exposed to hyperglycaemia from 
conception to throughout their gestation and to higher glucose levels. Maintaining adequate 
glycemic control in pregestational diabetes is known to be more difficult during pregnancy.32 More 
severe hyperglycaemia in pregnancy may result in a reduced nephron endowment, which is 
reflected by a thinner than expected parenchyma, and may lead to an increased risk of kidney 
disease and hypertension in future life. Although the number of women with pregestational 
diabetes was small, the findings were interesting and warrant further investigation. If we were able 
to obtain a large cohort of untreated or poorly controlled women with diabetes in pregnancy, we 
might see the findings demonstrated in animal studies.  
8.5.1 Limitations 
There was a small number of women with pregestational diabetes, however, novel, longitudinal 
data was obtained which allowed our group to explore possible trends. There is also potential 
measurement bias as the sonographers were not blinded during the study. Sonographers are trained 
not to look at their measurements at the time they are performing them and three sonographers, 
rather than one, performed the examinations to reduce this bias.  
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8.5.2 Future research 
Larger studies evaluating the different subtypes of diabetes in pregnancy, timing of diagnosis, 
glycaemic control over the duration of the pregnancy and the effects of different treatments are 
needed to further improve our understanding of the impacts on fetal kidney development, both 
adverse and beneficial. Further studies utilising ultrasound to evaluate the renal parenchymal 
thickness of children and adults born to mothers with diabetes in pregnancy would be useful to 
gain additional information on long-term effects. 
8.6 Conclusion 
In-utero kidney development influences future kidney function and it is thought that diabetes in 
pregnancy may have an adverse effect on kidney development. Our study of gestational diabetes 
in pregnancy did not find any significant effect on the fetal renal parenchyma relative to the size 
of the fetus. However, in women with pregestational diabetes our finding of a relatively thinner 
renal parenchyma than expected suggests these fetuses may have fewer nephrons. Our study on 
the growth of the fetal renal parenchyma using ultrasound provides unique data to gain insight 
into the effect of maternal diabetes in kidney development. It is plausible that appropriate 
management and treatment of diabetes in pregnancy may mitigate some of the adverse impacts on 
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Chronic kidney disease (CKD) and hypertension are mostly preventable diseases.1, 2 The optimal 
way to truly tackle these problems is to start at the very beginning – where life begins. This thesis 
is concerned with the utility of antenatal ultrasound to examine methods to support the discovery 
of solutions to reduce the future risk of CKD and hypertension. The thesis presents a logical 
progression of studies undertaken to investigate novel measurements using antenatal ultrasound, 
of the fetal renal parenchyma and the fetal renal arteries. The reliability of these measurements was 
also assessed. These measurements were then further explored to investigate the effects of 
abnormal fetal growth and diabetes in pregnancy on the growth of the fetal renal parenchyma. 
Growth of the renal parenchymal thickness over the pregnancy should indirectly reflect nephron 
number.  This chapter will summarise the overall findings of this thesis, the applications to clinical 
practice and suggestions for future research.  
Ch 1: Introduction and background 
Ch 2: Systematic review 
Ch 3: Study design and methods 
Ch 4: Normal ranges of fetal renal parenchyma 
Ch 5: Normal ranges of fetal renal arteries 
Ch 6: Fetal renal parenchymal growth and fetal growth restriction 
Ch 7: Fetal renal parenchymal growth and fetal overgrowth 
Ch 8: Fetal renal parenchymal growth and diabetes in pregnancy 









9.1 Statistical Methods 
9.1.1 Study design 
This study was a prospective, longitudinal, cohort, observational study. As the aim was to assess 
the growth of the fetal kidneys, a longitudinal design was selected for several reasons. Longitudinal 
studies tend to be more efficient and have greater power than cross-sectional studies.3 Charts 
created from cross-sectional data can only be used for size not growth, even though, this incorrect 
use of cross-sectional data it is frequently encountered.4-6 There is active debate in the literature 
about the construction of fetal centile charts, as in the last decade there has been a push to improve 
the quality and methodological consistency of these charts.4, 7, 8 Large longitudinal cohort studies 
of healthy participants are the gold standard for the creation of standard charts.9 Fetuses grow at 
different velocities, and therefore the goal of performing multiple, serial measurements on the 
fetus during gestation is to quantify these variations in growth.  
The study was designed so that the participants would attend ultrasound examinations at 
approximately the same and equally spaced gestational ages. Yet, due to multiple different issues, 
such as family illness and transport, some examinations were missed or delayed, or at times 
additional examinations were required for clinical reasons. Women commenced the study at 
various gestational ages depending on when they presented to the hospital. This added 
heterogeneity and complexity to the data and meant that traditional statistical methods of 
comparisons would not be appropriate and would not utilise the full potential of the longitudinal 
data.  
9.1.2 Statistical analysis 
To maximise the potential of the longitudinal data, modern, advanced statistical methods were 
required for accurate assessment of the repeated measures and multiple variabilities within the 
data, and to produce high quality standardised charts for use in clinical practice. Mixed effects 
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models are emerging as the method of choice for the analysis of longitudinal data.10, 11 Mixed effects 
modelling is a sophisticated, powerful statistical method that analyses every data point and better 
accounts for the heterogeneity of the timing of the scans and missing data.10, 12 These models can 
simultaneously account for fixed and random effects that potentially contribute to the 
understanding of the data.10 To develop the charts from this study, methods of the recent large 
INTERGROWTH 21st Project for fetal growth, which produced international growth standards 
for fetuses, were employed.13 This resulted in charts with centiles that provide a good fit to the raw 
data and change smoothly with gestational age (GA) as recommended by the literature.4, 6, 8  
9.2 Renal Parenchyma Thickness: A Non-Invasive In-Vivo Method to Estimate 
Nephron Endowment 
It is a challenge to obtain a non-invasive in-vivo estimation of nephron number during fetal 
development. It is known that nephrons grow by branching outwards in concentric layers.14, 15 
Therefore, if there is an adverse interruption to their growth, fewer layers of nephrons develop 
and hence we expect that this would result in a thinner renal parenchyma. The uniqueness of the 
measurement of the renal parenchyma is its specificity and its simplicity. Specific, in that it is 
directly measuring the functional kidney tissue (layers of nephrons) and does not include the 
collecting system of the kidney. Simplistic, in that it is a single linear measurement which should 
have less variation and be more reliable than multiple renal measurements or renal volume sets 
which have traditionally been used to investigate renal development. Ultrasound is a non-invasive, 
non-ionising, relatively cheap imaging modality which is widely available, including in rural and 
remote areas, around the world.16 If found to be validated by other clinicians and populations, 
measurement of the renal parenchymal thickness could be easily learnt by sonographers and 




9.3 Standardised Charts for Normal Ranges of Renal Parenchymal Thickness 
Throughout Pregnancy 
Standard charts reflecting normal ranges of fetal renal parenchymal thickness, kidney length and 
kidney volume from 16 to 38 weeks were developed in the first study in order to address the need 
for a more sensitive method to evaluate fetal kidney growth and nephron number. These charts of 
normal ranges of renal parenchymal thickness, kidney length and kidney volume could be used in 
clinical practice. The charts require further validation in other populations and cohorts. This study 
revealed that the fetal renal parenchymal thickness increased with increasing GA up until 34 to 36 
weeks when the thickness of the parenchyma starts to plateau. This appropriately correlates with 
our understanding of nephrogenesis and its completion by 36 weeks’ gestation.17  
Renal parenchymal measurements can now be plotted on the graph that we have developed.18 
Deviation from the normal range presents a new criterion for the diagnosis of renal parenchymal 
pathologies and/or reduced nephron endowment. Providing multiple centiles allows the charts to 
be used as a potential screening tool (using the 10th and 90th centiles as lower and upper limits) or 
as a diagnostic tool (using the 3rd and 97th centiles as lower and upper limits). The fetal renal 
parenchymal thickness of participant 111, plotted in Figure 9.1, demonstrates slowing of growth 
of the renal parenchyma so that by 37 weeks GA the parenchyma was well below the 10th centile. 
This infant had fetal growth restriction (FGR) and was delivered at 37 weeks and 5 days with a 
birth weight of 2,225 grams. Charts, developed from this study, for fetal renal parenchymal 
thickness and those for fetal kidney length and volume, have been submitted for consideration for 
addition to Viewpoint 6 (GE Healthcare, Milwaukee, WI, USA), an advanced fetal imaging 
reporting system. Therefore, these fetal kidney charts could be utilised and verified by clinicians 




Figure 9.1 Standard chart of fetal renal Parenchymal Thickness with 3rd, 10th, 50th, 90th 
& 97th Centiles and the renal parenchymal thickness (red dots) for participant 111 
demonstrating slowing of growth of the renal parenchyma so that at 37 weeks GA the 
thickness of the renal parenchyma was well below the 10th centile. 
9.4 Reliability of the Measurements 
Fetal measurements are important to enable the correct prenatal diagnosis; however, clinicians 
need to have confidence in the validity of the measurement on which they base their clinical 
decisions. Therefore, it is important when developing a measuring technique to also assess its 
reliability. For this reason, a separate study was conducted to assess the reliability of the fetal renal 
measurements performed in the study. In this quality assurance study, all three sonographers were 
blinded to their own and each other’s measurements by concealing the measurement on the 
monitor. Following analysis, it was found that measurement of the renal parenchyma had excellent 
intraobserver and interobserver reliability. Excellent intraobserver and interobserver reliability was 
also demonstrated for the renal length, transverse and antero-posterior dimensions.18 
 
217 
In contrast to the fetal renal parenchymal measurements, measurements of the resistivity index 
(RI) and pulsatility index (PI) of the fetal renal arteries were only adequate for intraobserver 
reliability and poor for interobserver reliability. This finding is similar to other studies in the 
literature.19-21 A recent review of the reliability of ultrasound measurements in obstetrics and 
gynaecology studies found most studies had significant flaws in study design, interpretation and/or 
reporting which tended to result in overrating of the reproducibility.22 Fetal Doppler studies, in 
particular, often do not report reliability at all. This non-reporting of measurement reliability may 
be due to a concern that the measurement will not be considered for clinical use if there is poor 
reliability.20,  22 Points that remain to be considered, include, whether known physiological variations 
due to fetal movements, breathing and heart rate changes, be factored in when assessing the 
reliability of fetal Doppler.23-25 Additionally, new techniques being investigated may need 
refinement to improve their reliability and therefore should not be discounted based on early poor 
reliability studies.  It is essential to appreciate the reliability of the measurements that are being 
utilised in clinical practice. Once measurement of the fetal renal parenchyma was shown to have 
excellent reliability, we then wanted to assess if this measurement could be applied to detect 
adverse effects of FGR on the development of the fetal kidneys.  
9.5 Effects of Fetal Growth Restriction on Fetal Kidney Growth 
Having defined the normal ranges of fetal renal parenchymal thickness, the aim of the subsequent 
study was to utilise this novel measurement to determine the effect of FGR on the development 
of the renal parenchyma. It is widely accepted that FGR can affect nephron number and future 
kidney function, however, there is a lack of in-vivo, in-utero proof of this concept which was based 
on animal and ex-vivo studies.26-28 This study provided evidence of the negative effects of FGR on 
the renal parenchymal growth and therefore the development of the functional component of the 
fetal kidney. It demonstrated that measurement of the renal parenchyma was able to detect changes 
in parenchymal growth of the fetal kidney.  
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The findings from this study supported the theory that FGR has a direct adverse effect on 
nephrogenesis. Growth restricted fetuses had a significantly thinner parenchyma and a slower 
growth trajectory of the parenchyma than appropriately grown fetuses. Placental insufficiency is 
the most common cause of FGR, with the majority of FGR occurring in the 3rd trimester of 
pregnancy.29, 30 The 3rd trimester (28 weeks to term) is also when 60% of nephrons are formed. 17 
Therefore, it is likely that this deceleration in the growth of the renal parenchyma in FGR fetuses 
may stem from increasing placental insufficiency and slowing of fetal growth in the third trimester, 
at the time of maximum kidney growth. 
A key strength of our study was that a single birth weight centile cut-off (such as below the 10th 
centile) was not used as a proxy for FGR. Only fetuses that met an internationally recognised 
criteria for growth restriction were defined and included as FGR.31 These criteria for FGR 
incorporate a decline in overall growth as well as demonstrated changes in feto-maternal circulation 
on pulse Doppler. A fetus may be within the normal weight range, however, may still be growth 
restricted and the development of their kidneys may be compromised. This study attempted to 
analyse fetuses who were truly growth restricted and not just those who were small for gestational 
age. 
It could be argued that smaller babies have proportionally smaller kidneys and therefore there are 
no negative effects from FGR on kidney growth. By comparing the growth of the fetal head to 
the growth of the fetal renal parenchyma between FGR and appropriate-for-gestational age (AGA) 
fetuses, our study has shown that in growth restricted fetuses the renal parenchyma was 
significantly thinner than expected based on fetal head size alone. To our knowledge this 
comparison has not been done before and provides good evidence that FGR does have a 
detrimental effect on the renal development, as fetuses with the same head circumference had a 
significantly thinner renal parenchyma if they were truly growth restricted. A thinner fetal renal 
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parenchyma implies fewer nephrons and consequently a fetus who is at a higher risk of future 
decreased kidney function and disease.  
A reduced nephron number does not directly correlate with inevitable renal damage and future 
CKD, however the remaining nephrons will have an increased demand, making the kidneys more 
vulnerable to future kidney injury.32, 33 Some experts are advocating for life-long monitoring of 
kidney disease of all growth restricted, low birth weight and preterm infants along with those 
exposed to pre-eclampsia or diabetes.28 This would require the implementation of enormous 
resources and represent a significant health cost burden.  The renal parenchymal measurement 
could be employed to assist in more appropriately identifying infants at the highest risk of 
developing CKD and to provide a more complete picture of the infant’s renal function. Functional 
renal biomarkers could be evaluated after birth and combined with the information around 
possible nephron endowment from the renal parenchymal thickness to gain a more complete 
picture of renal function. More focused monitoring through a combination of postnatal renal 
ultrasound imaging and biomarkers could be applied. Early interventions such as healthy lifestyle 
programs providing information around nutrition and physical activity can also be concentrated 
on this group to try and reduce the occurrence of CKD and hypertension in later life.   
9.6 Effects of Fetal Overgrowth on Fetal Kidney Growth 
There is a paucity of studies generally on fetal well-being in the setting of fetal overgrowth not 
associated with diabetes. Most studies focus on delivery and birth trauma to the mother and 
infant.34, 35 No study had yet investigated the effects of fetal overgrowth on fetal kidney 
development.36 Renal parenchymal thickness was measured in both large-for-gestational age 
(LGA) and AGA fetuses to detect any possible effects of fetal overgrowth on the developing 
kidneys. The fetal renal parenchyma was found to be significantly thicker in LGA fetuses when 
compared to the AGA fetuses. The LGA infants were, however, significantly heavier at birth and 
had a higher birth weight centile. To account for this, the growth of the fetal renal parenchyma 
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was compared to the growth of the AC between the LGA and AGA groups. No difference was 
found in their growth trajectory, thus, indicating the growth in thickness of the renal parenchyma 
was in proportion to the larger size of the fetuses. 
Fetal overgrowth could not be demonstrated to have an adverse effect on the growth of the fetal 
renal parenchyma. This finding is not surprising as it has been demonstrated that there is a wide 
variation in nephron number in a normal population from autopsy studies.37, 38 The limitation of 
in-vivo studies is that it is not possible to determine the number of nephrons, this can only be 
estimated. Additionally, the quality of the nephrons and glomeruli cannot be assessed. Autopsy 
studies have demonstrated significant effects on glomeruli due to low birth weight and preterm 
birth,39, 40 however, these studies have not investigated nephron number and quality in fetal 
overgrowth. Animal and human autopsy studies are warranted to investigate fetal overgrowth and 
kidney development and to guide future clinical studies. Our study recruited a relatively small 
sample of LGA fetuses (16) and therefore, larger longitudinal studies following the infants into 
adulthood would be required to confirm any potential effects on renal parenchymal growth. LGA 
has been linked with childhood obesity and metabolic syndromes, which are strong risk factors for 
future CKD and hypertension.41-43 It is possible that programming of the kidneys might occur in 
early childhood rather than fetal life.44, 45 
Most of the literature on postnatal growth and risks of CKD and hypertension focus on infants 
affected by FGR, while there is little evidence on postnatal growth of infants born LGA.44, 46 A 
recent review based on human and animal studies showed that early and excessive weight gain of 
the child was associated with an increased risk of CKD and hypertension in adulthood and that 
many studies highlighted the potential role of early maternal nutrition in the development of future 
CKD.44 There were, however, some conflicting findings with 5 of 24 studies finding that increased 
growth in infancy and childhood appeared to be protective for developing CKD and 
hypertension.44 The etiology of fetal overgrowth and childhood obesity, and the links to future 
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kidney health is complex and involves many factors that likely interact and remain to be fully 
elucidated.41, 42, 46 One important factor is the role of diabetes in pregnancy. Most of the LGA 
infants in this study were born to mothers with diabetes in pregnancy. Therefore, the aim of the 
subsequent study was to investigate growth of the fetal renal parenchyma in pregnancies 
complicated by diabetes. 
9.7 Effects of Diabetes in Pregnancy 
Diabetes in pregnancy is a leading cause of LGA.34, 47 This study investigated the effect of 
hyperglycaemia during pregnancy on nephrogenesis by comparing the renal parenchyma of fetuses 
of mothers with diabetes to a control group of low risk pregnancies. There were two subgroups 
of pregnant women with diabetes: a larger group of women with gestational diabetes (46) and a 
smaller group of women with pregestational diabetes (type 1 or 2) (9).  
The fetal renal parenchyma was significantly thicker in fetuses of mothers with gestational diabetes 
compared to the control group of low-risk pregnancies, however, there was no significant 
difference in the growth trajectory of the renal parenchyma between the two groups.48 The infants 
of mothers with gestational diabetes were seen to be significantly bigger and therefore their 
parenchyma was proportionally thicker. This was surprising as animal studies and human studies 
of adults born to mothers with diabetes suggest a resultant reduced renal reserve and function.49-52 
It was therefore thought that we might have found the renal parenchymal to be relatively thinner 
due to adverse effects on nephrogenesis. The finding of no significant effect on the renal 
parenchymal in fetuses of mothers with gestational diabetes does not mean there is no effect, but 
rather no effect in-utero was detected using current methods. Another possible explanation for this 
result is that recent advances in management and treatment of diabetes in pregnancy over the last 
decade may be diminishing any adverse impacts hyperglycaemia may be having on the developing 
fetal kidneys. We are yet to carry out the long term follow up into adulthood of these infants. 
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Therefore, it is yet to be elucidated whether these improvements in management and treatment 
will result in a reduction in CKD and hypertension in the future.  
The findings were different in pregnancies complicated by pregestational diabetes. Infants of 
mothers with pregestational diabetes were also significantly larger than the control group, however, 
the fetal renal parenchyma was not found to be significantly thicker.48 It was expected that the 
renal parenchyma would be thicker in these fetuses considering their significantly larger size 
compared to the control group. A thinner than expected renal parenchyma may be due to 
hyperglycaemia adversely effecting nephrogenesis.  
Hyperglycaemia is known to be teratogenic to the kidneys during embryogenesis and is thought to 
effect nephrogenesis.53-55 Maternal hyperglycaemia is more severe in pregestational compared to 
gestational diabetes. The fetus is exposed to higher levels of maternal glucose from conception 
and throughout gestation and this is associated with increased fetal abnormalities and adverse 
outcomes.56, 57 One study showed an almost 30% increase in fetal abnormalities for each percentage 
rise in HbA1C on presentation58 and in yet another study, mothers with diabetes were found to 
have a three-fold increase in  fetal renal dysgenesis or agenesis.54 Our study demonstrated a trend 
towards a thinner than expected renal parenchyma in the pregestational diabetes group. 
Hyperglycaemia is present throughout the entire pregnancy in this group, whereas the gestational 
diabetes group, have less prolonged, milder hyperglycaemia and the hyperglycaemia predominantly 
presents during the third trimester. This hyperglycaemia throughout pregnancy in the 
pregestational diabetes group may be adversely affecting nephron endowment, however, the 
sample size of pregestational diabetic pregnancies was not large enough to make any concrete 
conclusions. The renal parenchymal measurement could be used in a larger study and correlated 
with maternal glucose levels to investigate if higher levels of hyperglycaemia present throughout 
the pregnancy affect the renal parenchymal growth.  
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This study offered unique information to gain a better understanding of the effects that diabetes 
in pregnancy may have on the developing fetal kidneys, however there are many unanswered 
questions and multiple valuable opportunities for further research.  
9.8 Fetal Renal Arterial Measurements 
This section of the thesis aimed at gaining more information on the role of blood flow to the fetal 
kidneys in fetuses with normal and abnormal fetal growth. In situations of chronic fetal hypoxia 
and/or nutrient deficiency, the fetus will preferentially shunt blood flow away from organs, such 
as the kidneys to more essential organs such as the brain, heart and adrenal glands.59, 60 This reduced 
perfusion to the fetal kidneys, due to preferential shunting, is thought to inhibit normal 
nephrogenesis.61, 62 We firstly established normal ranges of blood flow to the developing kidneys 
during pregnancy and then investigated to see if any alterations in the blood flow could be detected 
in situations of abnormal fetal growth. 
Charts of the normal ranges of the fetal renal artery RI and PI from 16 to 38 weeks gestation were 
developed. The RI and PI of the fetal renal arteries showed little variation during pregnancy. These 
charts may be used to detect physiological or pathological changes in the fetal renal blood flow. 
When the RI and PI of the fetal renal arteries were compared between FGR and AGA, as well as 
LGA and AGA fetuses there was no significant difference. It was thought that some reduction in 
the renal blood flow may have been detected in our FGR group to support the theory of 
preferential shunting away from the kidneys, however, no evidence of this was found.  
The findings indicate a lack of sensitivity in the measurements of RI and PI in the fetal renal artery. 
Blood flow to the fetal kidneys is relatively low, with only 3-5% of cardiac output directed to the 
kidneys compared to 15% after birth.63, 64 Changes to fetal renal blood flow may be too subtle to 
be detected using current methods. Perhaps analysing the fetal renal blood flow over a longer time, 
such as several minutes, may improve the sensitivity of the measurements and elucidate differences 
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in the blood flow.  The reliability of the RI and PI measurements from our study was poor, further 
indicating the low sensitivity of the measurement. However, blood flow in the fetal renal arteries 
was not the primary objective of this thesis and the study was not specifically powered to detect 
changes in blood flow. A larger study, particularly with a larger group of severe FGR fetuses and 
utilising emerging blood flow techniques, such as 3D volume flow, may demonstrate detectable 
changes in blood flow to these fetal kidneys compared to healthy fetuses. The true value of fetal 
renal artery Dopplers in clinical practice is still unanswered.  
9.9 Fetal Kidney Function and Amniotic Fluid 
Assessing fetal kidney function, non-invasively is challenging and complicated. From mid-
gestation, around 90% of amniotic fluid is provided through urination from the fetal kidneys, 
making it plausible to hypothesise that amniotic fluid levels reflect fetal kidney function.65 
Regulation of amniotic fluid is, however, a complex collaboration of many different fetal systems, 
not just the urinary tract, and the production of fetal urine is controlled by renal perfusion and 
tubular reabsorption.66,67  Furthermore, the kidneys have little function in-utero as the placenta 
performs most of the excretory functions that are performed by the postnatal kidneys.63 Therefore, 
perhaps we should be focusing on anatomical measurements rather than functional parameters in-
utero to predict future kidney function.  
In this thesis, amniotic fluid was tested as a fixed effect, in the mixed effects models comparing 
fetal renal parenchymal growth between FGR and AGA fetuses and LGA and AGA fetuses. There 
was, however, no significant effect. There was also no correlation between amniotic fluid levels 
and the RI and PI of the fetal renal arteries. Being unable to demonstrate any significant difference 
in amniotic fluid levels in abnormal fetal growth compared to normal fetal growth was 
disappointing but not surprising. It has been shown that amniotic fluid levels give some prognostic 
signs of fetal renal function, however, unfortunately these are not sensitive or specific enough to 
provide accurate quantification of fetal kidney function.67 Evaluation of amniotic fluid levels does 
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offer some information about the function of the fetal kidneys. For example, in cases of severe 
bilateral urinary tract abnormalities oligohydramnios may occur, or in chronic FGR there may be 
in a decline of amniotic fluid levels over time.63, 67 Currently we can only rely on invasive sampling 
of the amniotic or fetal blood to give any real quantification of fetal kidney function and the value 
of these procedures is controversial.68 Furthermore, the risks associated with these invasive tests 
should be considered. A systematic review in 2007 of 23 articles found that none of the analytes 
obtained from fetal urine could accurately predict poor postnatal kidney function.68 The challenge 
continues to find a non-invasive measure of fetal renal function. 
9.10 Limitations of the Study 
This was an observational study and therefore fundamentally subject to some selection bias. The 
participants were recruited through a mixed risk hospital service and therefore do not represent 
the whole community. Subsequentially, caution should be employed in extrapolating these results 
to different populations. 
Another limitation of the study was the inability to get the women to attend at the same gestational 
age and at set intervals. This is often a problem with clinical studies and can result in missing data 
and drop out of participants. Fortunately, only one participant failed to attend any ultrasound 
examinations. Most women were keen to attend and therefore if they were unable to come for an 
examination they attended at another time. This did add more heterogeneity to the data than was 
planned at the onset.  
Longitudinal studies are more efficient and powerful than cross-sectional studies and therefore 
require fewer participants, however, the sample size of some of the groups analysed were small. It 
was difficult to obtain a large group of infants born LGA and those with pregestational diabetes 
within the time allocated for recruitment. Study recruitment was initially set for a year - May 2017 
– April 2018. This was extended for a further six months until October 2018 to obtain a larger 
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cohort. Due to time constraints from grants and access to ultrasound equipment it was not possible 
to extend the recruitment further. 
A further limitation was the lack of blinding of the sonographers, which could have introduced 
possible measurement bias. Most ultrasound examinations included a diagnostic scan and 
therefore it was difficult to blind the sonographer to all clinical and biometric information. Having 
multiple sonographers undertaking the ultrasound examinations reduces some of the bias. 
Sonographers are also generally trained not to look at the measurements at the time that they are 
being performed. Additionally, the infants were not assigned to groups until after birth and the 
groups were based on birth weight and not the fetal birth weight calculated from the measurements 
by the sonographers. 
Antenatal ultrasound measurements of fetal structures require small-scale measurements. Due to 
maternal body habitus and/or fetal position during the scan, some measurements were not able to 
be obtained. Almost all linear kidney measurements were completed at every ultrasound 
examination, however, some renal Dopplers were not. The fetal renal arteries were the most 
technically difficult measurement to obtain as fetal movement and breathing also contributed to 
the ability to obtain a good quality Doppler signal.  
9.11 Conclusion 
The main aim of this thesis was to use antenatal ultrasound to assess the fetal renal parenchymal 
growth in a pregnant population and determine if abnormal growth or diabetes in pregnancy 
impacts fetal renal parenchymal thickness. Using mixed effects modelling, it was demonstrated 
that measurement of the fetal renal parenchyma could detect changes in kidney growth and provide 
an indirect estimate of nephron number. Measurement of the fetal renal parenchyma offers an 
enhanced, easy to perform, non-invasive single measurement to assess fetal kidney growth. 
 
227 
The standard charts developed in these studies will provide normal ranges of fetal renal 
parenchymal thickness, kidney length and kidney volume for use in clinical practice to identify 
alterations in fetal kidney growth. These charts will provide a useful resource for high-risk 
pregnancies. The thickness of the fetal renal parenchyma, when combined with other markers such 
as echogenicity of the parenchyma and the presence or absence of cysts will assist in the diagnosis 
of renal parenchymal pathologies. The standard charts describing the normal range of fetal renal 
artery RI and PI will also be a possible helpful resource in clinical practice. Presently, however, 
these charts and the findings from this research around fetal renal arteries, might be most valuable 
to guide and inform future research in this area and as an additional tool when investigating fetal 
renal development.  
The most significant finding from these studies was that measurement of the fetal renal 
parenchymal thickness could be used to detect changes in the growth of the renal parenchyma in 
situations of abnormal fetal conditions. Our work showed that FGR appears to adversely affect 
the growth of the fetal renal parenchyma. This implies that renal parenchymal thickness is 
providing an indirect estimate of nephron number – with a thinner renal parenchyma suggesting 
fewer layers of nephrons. 
Fetal renal parenchymal thickness presents a new marker that may indicate a reduced nephron 
number, which could be used in clinical practice to improve the identification of infants at a higher 
risk of future kidney disease and hypertension. Then suitable screening and support could be 
implemented early, such as performing postnatal renal ultrasounds and renal function tests, 
optimising childhood nutrition and facilitating involvement in programs to reduce the risk of 
obesity. We should also remember that maternal characteristics and health play a significant role 
in fetal growth and fetal development. Consequently, optimising maternal health before and during 
pregnancy, along with improving child health has the greatest potential economic and health 
community benefits to prevent adult CKD and hypertension. 
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This was the first study to investigate if fetal overgrowth affected fetal kidney growth and one of 
only a few studies into the effects of diabetes on fetal kidney growth. Although no significant 
changes to renal parenchymal thickness relative to the size of the fetus were definitively 
demonstrated in these circumstances, there were some interesting findings which should be 
evaluated in future research. The study of the effects of diabetes in pregnancy on the renal 
parenchymal thickness suggests the possibility that more severe levels of hyperglycaemia, present 
throughout pregnancy, may affect the growth of the parenchyma. It also provided some evidence 
that good management of glucose levels may counteract possible adverse effects on the renal 
parenchymal growth. Our work in this area also highlighted the many gaps in our understanding 
of the effects of fetal overgrowth and diabetes in pregnancy on the developing kidneys. 
We have demonstrated that the measurement of the fetal renal parenchyma shows promise as the 
most accurate, indirect method to estimate nephron numbers and that it can detect changes in fetal 
kidney growth. It could now be utilised in future studies to further increase our understanding of 
fetal renal development.   
9.12 Future Research 
Future investigations could emulate this study design with mixed effects modelling analysis of 
different populations and larger cohorts of FGR and LGA pregnancies to refine and validate 
measurement of the fetal renal parenchymal thickness across different populations of pregnant 
women. To really be able to elucidate the many complex factors that could impact the growth of 
the fetal kidneys in pregnancies complicated by diabetes, a large, dedicated study focusing on the 
effects of different types of diabetes, GA at diagnosis, adequacy of BSL control and types and 
timing of treatment would be valuable. This should be followed by a long-term study following 
the growth of the renal parenchymal thickness of infants, born to diabetic mothers, into adulthood. 
This should also include correlation with renal function tests. Only then can we truly start to 
demonstrate the long-term outcomes of the intrauterine environment on later life. 
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Although this study did not demonstrate any significant changes in the fetal renal blood flow in 
FGR fetuses this does still warrant refinement and improvement. Ultrasound imaging and, in 
particular, blood flow analysis, is rapidly improving with implementation of new techniques. 
Therefore, a study examining the renal arteries of growth restricted fetuses that is powered to 
detect a difference in blood flow and which investigates various different emerging Doppler 
techniques, such as volume flow measurements and 3D flow imaging, could be conducted and 
may be able to detect the subtle changes in renal perfusion that is thought to occur with FGR. 
Now we have renal parenchymal thickness as a marker of nephron endowment, it could be used 
in multiple different study settings to assess for any adverse changes to the renal parenchymal 
growth. For example, in the future if we discover interventions for the treatment of FGR, 
measuring the fetal renal parenchyma could be used to monitor the effects of the intervention on 
fetal kidney growth. Similar studies could be performed for treatments of diabetes in pregnancy.  
A natural progression of this work is to analyse how the renal parenchymal thickness, as a surrogate 
marker of nephron endowment, could be extended into the postnatal period and beyond. We have 
already completed pilot studies comparing the renal parenchyma of low birth and preterm neonates 
to normal birth weight term neonates and shown the usefulness of this measurement in the 
neonatal period. The preterm neonate in the neonatal intensive care unit usually suffers from a 
range of complex conditions and receives multiple different interventions. We know that 
nephrogenesis can be adversely impacted by preterm birth and growth restriction, however there 
are many other factors such as medications and types of ventilation which may also influence 
nephrogenesis. The renal parenchyma measurement could be used to assess effects of the various 
treatments on renal growth to assist in achieving optimal renal growth in this high-risk group.  
Extending on from this, is investigating the role that the renal parenchymal measurement could 
have in monitoring children and adults in cases of declining renal function, CKD or post kidney 
surgery. The renal parenchymal measurement is easily performed and uses ultrasound imaging 
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which is widely available. This makes the future applications of the renal parenchymal 
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PATIENT/PARTICIPANT INFORMATION SHEET and CONSENT FORM  
 
PROTOCOL NAME: The renal parenchyma – Evaluation of a novel 
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1 Introduction  
You are invited to take part in the FeRP research study. Before you decide whether to 
participate or not, it is important for you to understand why this research is being done 
and what it will involve. This information sheet tells you about the study. Please take 
the time to read through this and discuss it with others if you wish. Ask questions about 
anything you don’t understand or would like to know more about.  
 
This study is entirely voluntary (your choice). If you decide you want to take part in this 
study, you will be asked to sign the consent form. You will be given a copy of this 
information sheet and consent form to keep. 
 
Thank you for your interest and for taking the time to consider being involved. 
 
2 What is the purpose of this study? 
Abnormal fetal growth, such as growth restriction, overgrowth and preterm birth, have 
been found to affect the growth of the kidneys. Abnormal growth of the kidneys in the 
fetus is linked to high blood pressure and kidney disease later in life. Currently there is 
no easy, accurate method to assess the growth of the fetal kidneys. 
 
The purpose of this study is to investigate whether a new ultrasound measurement will 
improve our understanding of the growth of the kidneys and how abnormal fetal growth 
affects the kidney (renal) development. This study will also assess the blood flow to 
the kidneys and if abnormal fetal growth affects this blood flow. 
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This new measurement looks at the parenchyma of the kidney. The parenchyma is 
where the functional units of the kidney are. This study will measure how thick the 
parenchyma is and its blood flow in normally grown fetuses, growth restricted (small) 
fetuses and overgrown (large) fetuses and compare the measurements between these 
three groups. It is possible that the results of this study will help us find factors we can 
modify to improve fetal kidney growth.  
 
This study is being undertaken at the Townsville Hospital Ultrasound Department 
working in collaboration with James Cook University (JCU) and Monash University, 
Melbourne. At least 60 participants will be taking part in this study. 
 
The results of this study will be used by the principal researcher, Mrs Brennan, to obtain 
a Doctor of Philosophy (JCU).  
 
3 Who can participate? 
You can participate in this study if you are 18 years of age or older and are carrying 
one baby with a known due date. 
 
4 What does participation involve? 
The care for you and your pregnancy will be provided as normal by your doctors and 
midwives. If you agree to take part in this study, we will ask you to sign a consent form.  
 
You will need to have an ultrasound scan every four weeks from when you have your 
first scan after 16 weeks, until you deliver your baby. For example, if your first scan 
after 16 weeks was at 20 weeks, we would ask you to come for other scans for the 
research at 24, 28, 32, 36 and 40 weeks, whereas if your first scan was at 22 weeks it 
would be every four weeks from then (26, 30, 34, 38).  
 
Pregnant women, where the baby is not growing properly (too small or too large), may 
be referred by their doctor to have follow-up ultrasound scans every one to four weeks 
to watch the growth of the baby. If this is the case, you will already be coming for scans 
at least every four weeks and will not need extra scans. The ultrasound scan that your 
doctor referred you for will be the first priority. After this is done some extra kidney 
measurements on your baby will be done. This should only add about five minutes to 
the overall scan time.  
 
Pregnant women with a well grown baby, may only need one or two ultrasound scans 
normally between 16 to 40 weeks. If your doctor does not require a scan for clinical 
reasons, we will organise a scan for you every four weeks until you deliver your baby. 
This ultrasound scan will be similar to a routine growth scan. Measurements of baby, 
blood flow to your baby and the fluid around baby will be done and then the extra 
kidney measurements will be done. This scan should take around 20 to 30 minutes to 
be done. 
 
Before your first ultrasound for the study you will be asked to fill in a questionnaire 
telling us about your current pregnancy, your past pregnancies and your general 
health. We will also ask you for contact details in case we need to contact you after 
your baby is born. 
 
A member of the research team will collect information about your pregnancy and your 
baby from your medical notes. We may contact you after your baby is born, particularly 
if you did not deliver at Townsville Hospital. We may ask how baby is going and ask 
information around their birth, for example, your baby’s birth weight, sex and health.  
 
5 Does the participant have to take part in this study? 
Participation in this study is voluntary and is up to you if you wish to take part. If you 
decide to participate or not, it will not affect the care you will receive at any time and 
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will not affect your relationship with the staff caring for you. If you do decide to take 
part, you can still withdraw from the study at any time and you don’t have to give a 
reason. 
 
6 What are the possible benefits of taking part? 
There are no benefits to participating. 
 
7 What are the possible risks and disadvantages of taking part? 
Ultrasound is a part of routine obstetric care and there are no known risks to the mother 
or their baby. There are no disadvantages in taking part in this study. 
 
8 What will happen to the participant’s ultrasound results? 
All ultrasound images will be stored on Queensland Health Enterprise Picture Archiving 
and Communication System (ePACS) which is normal practice for all medical images 
and is part of the patient’s medical record. The scan will be reported by a radiologist or 
maternal-fetal-medicine specialist and this report is stored with images on ePACS as 
part of the patient’s record. 
 
10 Can the participant have other treatments during this study? 
Yes. You can receive whatever treatment you and your medical team think is suitable 
for your pregnancy. 
 
11 What if I join the study but then change my mind and want to withdraw? 
You can withdraw from the study at any time and you do not have to give a reason. 
Please let a member of the research team know and they will get you to complete a 
“Withdrawal of Consent” form. 
 
If you decide to no longer take part in the study no further information will be collected 
about you or your baby. You should be aware that data already collected will be kept 
and will form part of the study results. 
 
A decision to withdraw from the study will not affect the care you receive now or in the 
future and will not affect your relationship with the staff caring for you. 
 
12 What happens when the study ends? 
The results from this study will be analysed. They will then be presented at conferences 
and professional forums and written up and submitted to medical journals to publish. 
They will also be written up in the format of a PhD thesis. 
 
In any publication, presentation or report, information will be presented as summary 
data so no participant or their baby can be identified. Summary results of the data will 
also be provided to you by a letter from the researchers after publication, if you wish.  
 
13 What will happen to information about the participant? 
All information collected about participants during the study will be kept strictly 
confidential. No material that could potentially identify any participant or their baby will 
be used in any report of this study. Your personal details will be held securely within 
the Townsville Hospital and only members of the research team will have access to 
them.  
 
14 Will I be paid for taking part in this study? 
There is no payment or incentive for participating in this study. For participants who 
are asked to come for additional scans for the research, who would not have needed 
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15 Who is organising and funding the study? 
The study is being organised and funded by the Medical Imaging Ultrasound 
Department of the Townsville Hospital. The study will be the subject of funding 
applications in the future. Whether funding applications are successful or not, no 
money will be paid directly to any member of the research team. 
 
16 Who has reviewed the study? 
All research in Australia involving humans is reviewed by an independent group of 
people called a Human Research Ethics Committee (HREC). The ethical aspects of 
this study have been reviewed and approved by the HREC of the Townsville Hospital 
and Health Service Human Ethics Committee (EC00183). 
 
17 Further information and who to contact 
After you have read this information, a member of the research team will discuss the 
study with you again and answer any questions you may have. You will be given the 
chance to discuss participating in this study with whomever you wish, such as your 
partner, other family, friends or your doctors and midwives providing your care. If you 
would like to know more at any stage, please do not hesitate to contact the research 
contact person below. 
  
Research Contact Person: 
Name: Mrs Sonja Brennan 
 Position: Consultant Senior Sonographer 
 Phone:  
 Email:  
  
 
This project has been reviewed and approved by the Townsville Hospital and Health 
Service Human Research Ethics Committee. For concerns relating to the conduct of 
this project contact: 
 
HREC Chairperson 
 Phone: 07 4433 1440 




Thank you for taking the time to read this and consider being involved in the study. 
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FeRP Study - Fetal Renal Parenchyma  
 




How many weeks pregnant are you? -  Due Date: 
 
Mother’s height: _________cm               Mother’s weight (pre-pregnancy): ________kg 
 






Partner’s name: ________________________________________________________ 
 
Partner ‘s contact phone number: ___________________________________________ 
 
Other contact name and phone: ____________________________________________ 
 
Mother’s Medical History 
Please check yes or no Y N Please check yes or no Y N 
Diabetes   Epilepsy, seizures   
Thyroid disease   Blood clots   
High blood pressure   Chrohn’s or coeliac disease   
Heart disease   Rheumatoid arthritis, lupus   
Kidney disease   Autoimmune disease   
Liver disease, hepatitis   HIV or AIDS   
Lung problem, chronic asthma   Any malignancy/cancer   
Anaemia or blood disorder   Other medical condition   
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SECTION 2: Obstetric Details 
 
Previous pregnancies:  
 Date Outcome* Gestation 
age (e.g. 37 
weeks) 
Alive 









1         
2         
3         
4         
5         
6         




Did you have fertility treatment with this pregnancy?    No           Yes 
 
Have you had any previous ultrasounds on this pregnancy?    No           Yes 
If yes, please list when and where: _________________________________________ 
 
Have you smoked during this pregnancy?  
  No         Yes       If yes, how many per day ____________________________ 
 
Have you consumed alcohol during this pregnancy?  
  No         Yes       If yes, how many drinks per week______________________ 
 
Do you have gestational diabetes?     No           Yes 
If yes, is it controlled with  diet,  insulin, and/or  oral tablets  
 
 
Mother of Baby – Ancestry  Father of Baby – Ancestry 
 Aboriginal / Torres Strait Islander   Aboriginal / Torres Strait Islander 
 African       African 
 Asian       Asian 
 Caucasian      Caucasian 
 Indian        Indian  
 Middle Eastern      Middle Eastern 






Appendix C: Miscellaneous 
Appendix C1: Search Strategy 
Medline Ovid (R) 1946 to 7th Jan 2017: 
1    Ultrasonography (MeSH term exploded) –– “computer echotomography” OR 
“diagnostic ultrasound*” OR echography OR echotomography OR “medical sonography” 
OR “ultrasonic diagnoses” OR “ultrasonic diagnosis” OR “ultrasonic imaging” OR 
“ultrasonic tomography” OR “ultrasound imaging*” OR sonography  
2     Kidney* (MeSH term exploded) 
3     Renal (keyword) 
4     2 OR 3 
5     Fetus (MeSH term exploded) – “fetal structure*” OR “fetal tissue*” OR fetuses 
6     Prenatal (MeSH term exploded) – “antenatal diagnoses” OR antenatal diagnosis OR 
“antenatal screening*” OR “intrauterine diagnoses” OR “intrauterine diagnosis” OR 
“prenatal diagnoses” OR “prenatal diagnosis” OR “prenatal screening*” 
7     Foetus OR Foetal (keyword) 
8     5 OR 6 OR 7 
9     1 AND 4 AND 8 
10     Limit 9 to yr = “1996 – 2016” 









Analysis for: Is bigger better? Large for gestational age and 
kidney growth 
Part 1: Set up of libraries and data 





Load data sets 
LGA = read.csv("FINALLGAvsAGA.csv", header=T, sep=",") 
Factor variables 
LGA[,c("PtCode","AntPos", "SideRtLt", "Growth", "GendF1", "DM", "DMtype")]= 
  lapply(LGA[,c("PtCode","AntPos", "SideRtLt", "Growth", "GendF1", "DM", "D
Mtype")],factor) 
Re-name factors 
LGA$AntPos=factor(LGA$AntPos, labels=c("Ant", "Post")) 
LGA$SideRtLt=factor(LGA$SideRtLt, labels=c("Rt", "Lt")) 
LGA$Growth=factor(LGA$Growth, labels=c("AGA", "LGA")) 
LGA$GendF1=factor(LGA$GendF1, labels=c("F", "M")) 
LGA$DM=factor(LGA$DM, labels=c("N", "Y")) 
LGA$DMtype=factor(LGA$DMtype, labels = c("none", "T1", "T2", "GDM")) 
Remove all NAs from GAcont 
LGA.complete = LGA[!is.na(LGA$GAcont),] 
Change intercept so 16 starts at 0 
LGA.complete$GAcont=LGA.complete$GAcont-16 
  
Part 2: Renal parenchymal thickness (RPT) growth 
Model for RPT vs gestational age (GA) to compare appropriately for gestational age (AGA) to 
large for gestational age (LGA) 
Best model - Rerun with REML 
LGA11 = lme(RPT~ poly(GAcont,2)+Growth +SideRtLt, random= ~poly(GAcont,2)|P
tCode,  
            method = "REML", 
            na.action="na.omit",  
            weights = varPower(form=~fitted(.)), 
            data=LGA.complete, control = lmeControl(opt = "optim")) 
 
Anova(LGA11) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: RPT 
##                     Chisq Df Pr(>Chisq)     
## poly(GAcont, 2) 2630.0193  2  < 2.2e-16 *** 
## Growth             6.1236  1    0.01334 *   
## SideRtLt          17.8700  1  2.365e-05 *** 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
summary(LGA11) 
## Linear mixed-effects model fit by REML 
##  Data: LGA.complete  
##        AIC      BIC    logLik 
##   6457.323 6533.196 -3215.662 
##  
## Random effects: 
##  Formula: ~poly(GAcont, 2) | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##                  StdDev     Corr          
## (Intercept)       0.6337342 (Intr) p(GA,2 
## poly(GAcont, 2)1 17.7227171 0.741         
## poly(GAcont, 2)2 10.6686602 0.033  0.232  
## Residual          0.1560605               
##  
## Variance function: 
##  Structure: Power of variance covariate 
##  Formula: ~fitted(.)  
##  Parameter estimates: 
##     power  
## 0.8273603  
## Fixed effects: RPT ~ poly(GAcont, 2) + Growth + SideRtLt  
##                      Value Std.Error   DF   t-value p-value 
## (Intercept)        7.26745 0.0656708 2415 110.66486  0.0000 
## poly(GAcont, 2)1  91.70038 1.9062724 2415  48.10455  0.0000 
## poly(GAcont, 2)2 -12.20847 1.3739818 2415  -8.88547  0.0000 
## GrowthLGA          0.33871 0.1368743  116   2.47460  0.0148 
## SideRtLtLt        -0.12042 0.0284872 2415  -4.22730  0.0000 
##  Correlation:  
##                  (Intr) p(GA,2)1 p(GA,2)2 GrwLGA 
## poly(GAcont, 2)1  0.604                          
## poly(GAcont, 2)2  0.074  0.179                   
## GrowthLGA        -0.281 -0.002   -0.012          
## SideRtLtLt       -0.220  0.002   -0.001    0.000 
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -2.98110238 -0.62300863 -0.04924571  0.60903970  3.79301690  
##  
## Number of Observations: 2536 
## Number of Groups: 118 
 
intervals(LGA11) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                         lower        est.       upper 
## (Intercept)        7.13867397   7.2674509  7.39622789 
## poly(GAcont, 2)1  87.96228536  91.7003841 95.43848277 
## poly(GAcont, 2)2 -14.90277289 -12.2084677 -9.51416260 
## GrowthLGA          0.06761216   0.3387089  0.60980572 
## SideRtLtLt        -0.17628567  -0.1204238 -0.06456195 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                                              lower        est.      uppe
r 
## sd((Intercept))                         0.54912509  0.63373422  0.731379
9 
## sd(poly(GAcont, 2)1)                   14.81076354 17.72271712 21.207191
7 
## sd(poly(GAcont, 2)2)                    7.88602219 10.66866016 14.433171
4 
## cor((Intercept),poly(GAcont, 2)1)       0.59359263  0.74100829  0.840310
3 
## cor((Intercept),poly(GAcont, 2)2)      -0.09230832  0.03288405  0.157053
0 
## cor(poly(GAcont, 2)1,poly(GAcont, 2)2) -0.04379457  0.23156819  0.474230
6 
##  
##  Variance function: 
##           lower      est.     upper 
## power 0.7168314 0.8273603 0.9378892 
## attr(,"label") 
## [1] "Variance function:" 
##  
##  Within-group standard error: 
##     lower      est.     upper  
## 0.1256245 0.1560605 0.1938704 
 
  
Graph RPT vs GA for AGA and LGA  
 
Part 3: RPT growth compared to AC growth for AGA and 
LGA 
Power curves - log transform data so both intercept at 0 
log.LGA = mutate(LGA.complete, 
                logRPT=log(RPT), 
                logHC=log(HC), 
                logEFW=log(EFW), 
                logAC =log(AC), 
                logFL=log(FL)) 
 
Model for RPT growth compared to AC growth for AGA and LGA Best model- re-run with REML 
LGAgrowth4 = lme(logRPT ~ logAC*Growth + SideRtLt, random=~logAC|PtCode, 
                 method = "REML",na.action="na.omit", data=log.LGA, 
                 control = lmeControl(msMaxIter = 200)) 
 
Anova(LGAgrowth4) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: logRPT 
##                  Chisq Df Pr(>Chisq)     
## logAC        2667.6462  1  < 2.2e-16 *** 
## Growth          0.0050  1     0.9437     
## SideRtLt       18.5835  1  1.626e-05 *** 
## logAC:Growth    1.1204  1     0.2898     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
summary(LGAgrowth4) 
## Linear mixed-effects model fit by REML 
##  Data: log.LGA  
##         AIC       BIC   logLik 
##   -3180.477 -3127.963 1599.238 
##  
## Random effects: 
##  Formula: ~logAC | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##             StdDev    Corr   
## (Intercept) 0.8811569 (Intr) 
## logAC       0.1624066 -0.996 
## Residual    0.1178400        
##  
## Fixed effects: logRPT ~ logAC * Growth + SideRtLt  
##                     Value  Std.Error   DF   t-value p-value 
## (Intercept)     -3.217452 0.10623361 2411 -30.28657  0.0000 
## logAC            0.942259 0.01945883 2411  48.42322  0.0000 
## GrowthLGA        0.307815 0.29016680  116   1.06082  0.2910 
## SideRtLtLt      -0.020191 0.00468372 2411  -4.31085  0.0000 
## logAC:GrowthLGA -0.056041 0.05294316 2411  -1.05851  0.2899 
##  Correlation:  
##                 (Intr) logAC  GrwLGA SdRtLL 
## logAC           -0.997                      
## GrowthLGA       -0.366  0.365               
## SideRtLtLt      -0.022  0.000  0.000        
## logAC:GrowthLGA  0.366 -0.368 -0.997  0.000 
##  
## Standardized Within-Group Residuals: 
##          Min           Q1          Med           Q3          Max  
## -4.029098804 -0.645188691 -0.005399481  0.644233639  3.469127118  
##  
## Number of Observations: 2532 
## Number of Groups: 118 
 
intervals(LGAgrowth4) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                       lower        est.       upper 
## (Intercept)     -3.42577045 -3.21745183 -3.00913320 
## logAC            0.90410140  0.94225916  0.98041692 
## GrowthLGA       -0.26689686  0.30781505  0.88252696 
## SideRtLtLt      -0.02937537 -0.02019083 -0.01100630 
## logAC:GrowthLGA -0.15985947 -0.05604066  0.04777815 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                             lower       est.      upper 
## sd((Intercept))         0.7107334  0.8811569  1.0924454 
## sd(logAC)               0.1315787  0.1624066  0.2004572 
## cor((Intercept),logAC) -0.9978904 -0.9964768 -0.9941188 
##  
##  Within-group standard error: 
##     lower      est.     upper  
## 0.1144578 0.1178400 0.1213222 
 
  
Graph for RPT(log10) vs AC(log10) for LGA and AGA 
 
Part 4: Renal arteries RI and PI for AGA and LGA 
Model for for RI vs GA for AGA and LGA 
LGAri8=lme(RI~ poly(GAcont,2)*Growth +SideRtLt, random= ~poly(GAcont,2)|PtC
ode,  
           method = "REML", 
           na.action="na.omit", 
           data= LGA.complete, weights = varPower(form=~fitted(.)), 
           control = lmeControl(opt = "optim")) 
 
Anova(LGAri8) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: RI 
##                          Chisq Df Pr(>Chisq)     
## poly(GAcont, 2)        52.1052  2  4.847e-12 *** 
## Growth                  0.6980  1  0.4034493     
## SideRtLt               11.7396  1  0.0006119 *** 
## poly(GAcont, 2):Growth  5.5377  2  0.0627326 .   
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
summary(LGAri8) 
## Linear mixed-effects model fit by REML 
##  Data: LGA.complete  
##        AIC       BIC  logLik 
##   -8750.42 -8663.678 4390.21 
##  
## Random effects: 
##  Formula: ~poly(GAcont, 2) | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##                  StdDev     Corr          
## (Intercept)      0.01744079 (Intr) p(GA,2 
## poly(GAcont, 2)1 0.91954104 -0.061        
## poly(GAcont, 2)2 0.82465751  0.197 -0.358 
## Residual         0.02618637               
##  
## Variance function: 
##  Structure: Power of variance covariate 
##  Formula: ~fitted(.)  
##  Parameter estimates: 
##     power  
## -2.320179  
## Fixed effects: RI ~ poly(GAcont, 2) * Growth + SideRtLt  
##                                 Value  Std.Error   DF  t-value p-value 
## (Intercept)                 0.8844856 0.00212007 2283 417.1971  0.0000 
## poly(GAcont, 2)1            0.0339716 0.10829763 2283   0.3137  0.7538 
## poly(GAcont, 2)2           -0.6740581 0.10012551 2283  -6.7321  0.0000 
## GrowthLGA                  -0.0041984 0.00556876  116  -0.7539  0.4524 
## SideRtLtLt                  0.0048392 0.00141237 2283   3.4263  0.0006 
## poly(GAcont, 2)1:GrowthLGA  0.5938162 0.30120248 2283   1.9715  0.0488 
## poly(GAcont, 2)2:GrowthLGA  0.1381872 0.28087357 2283   0.4920  0.6228 
##  Correlation:  
##                            (Intr) pl(GA,2)1 pl(GA,2)2 GrwLGA SdRtLL p(GA
,2)1: 
## poly(GAcont, 2)1           -0.122                                             
## poly(GAcont, 2)2            0.257 -0.372                                      
## GrowthLGA                  -0.337  0.046    -0.098                            
## SideRtLtLt                 -0.336  0.004     0.003    -0.001                  
## poly(GAcont, 2)1:GrowthLGA  0.046 -0.360     0.134    -0.152 -0.007           
## poly(GAcont, 2)2:GrowthLGA -0.093  0.133    -0.356     0.303  0.002 -0.3
59    
##  
## Standardized Within-Group Residuals: 
##           Min            Q1           Med            Q3           Max  
## -2.9284721597 -0.6184383751 -0.0006439879  0.5772429722  3.3180871580  
##  
## Number of Observations: 2406 
## Number of Groups: 118 
 
intervals(LGAri8) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                                   lower         est.        upper 
## (Intercept)                 0.880328118  0.884485577  0.888643035 
## poly(GAcont, 2)1           -0.178400441  0.033971600  0.246343640 
## poly(GAcont, 2)2           -0.870404566 -0.674058077 -0.477711588 
## GrowthLGA                  -0.015228021 -0.004198390  0.006831241 
## SideRtLtLt                  0.002069543  0.004839202  0.007608861 
## poly(GAcont, 2)1:GrowthLGA  0.003157034  0.593816192  1.184475350 
## poly(GAcont, 2)2:GrowthLGA -0.412606899  0.138187196  0.688981292 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                                              lower        est.       upp
er 
## sd((Intercept))                         0.01461665  0.01744079  0.020810
58 
## sd(poly(GAcont, 2)1)                    0.77876821  0.91954104  1.085760
46 
## sd(poly(GAcont, 2)2)                    0.66542578  0.82465751  1.021992
27 
## cor((Intercept),poly(GAcont, 2)1)      -0.29404119 -0.06053193  0.179796
29 
## cor((Intercept),poly(GAcont, 2)2)      -0.04700223  0.19724996  0.419245
28 
## cor(poly(GAcont, 2)1,poly(GAcont, 2)2) -0.57158388 -0.35799004 -0.098960
07 
##  
##  Variance function: 
##           lower      est.     upper 
## power -3.467513 -2.320179 -1.172845 
## attr(,"label") 
## [1] "Variance function:" 
##  
##  Within-group standard error: 
##      lower       est.      upper  
## 0.02275063 0.02618637 0.03014096 
 
 
Model for for PI vs GA for AGA and LGA Best model for PI - re-run using REML 
LGApi1=lme(PI~ poly(GAcont,2)*Growth +SideRtLt, random= ~poly(GAcont,2)|PtC
ode,  
           method = "REML", 
           na.action="na.omit", 
           data= LGA.complete, weights = varPower(form=~fitted(.)), 
           control = lmeControl(opt = "optim")) 
 
Anova(LGApi1) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: PI 
##                          Chisq Df Pr(>Chisq)     
## poly(GAcont, 2)        17.5720  2  0.0001529 *** 
## Growth                  0.0046  1  0.9457488     
## SideRtLt                1.7249  1  0.1890689     
## poly(GAcont, 2):Growth  3.5370  2  0.1705875     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
summary(LGApi1) 
## Linear mixed-effects model fit by REML 
##  Data: LGA.complete  
##        AIC      BIC    logLik 
##   903.0603 989.8024 -436.5301 
##  
## Random effects: 
##  Formula: ~poly(GAcont, 2) | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##                  StdDev    Corr          
## (Intercept)      0.1505377 (Intr) p(GA,2 
## poly(GAcont, 2)1 6.6174758  0.197        
## poly(GAcont, 2)2 6.7811936  0.250 -0.154 
## Residual         0.1147190               
##  
## Variance function: 
##  Structure: Power of variance covariate 
##  Formula: ~fitted(.)  
##  Parameter estimates: 
##     power  
## 0.9811413  
## Fixed effects: PI ~ poly(GAcont, 2) * Growth + SideRtLt  
##                                Value Std.Error   DF   t-value p-value 
## (Intercept)                 2.272742 0.0174594 2283 130.17335  0.0000 
## poly(GAcont, 2)1           -0.116593 0.7830765 2283  -0.14889  0.8817 
## poly(GAcont, 2)2           -3.145205 0.7938186 2283  -3.96212  0.0001 
## GrowthLGA                   0.012254 0.0461858  116   0.26532  0.7912 
## SideRtLtLt                  0.013685 0.0104199 2283   1.31334  0.1892 
## poly(GAcont, 2)1:GrowthLGA  3.892908 2.1714894 2283   1.79274  0.0731 
## poly(GAcont, 2)2:GrowthLGA  0.477373 2.2255649 2283   0.21450  0.8302 
##  Correlation:  
##                            (Intr) pl(GA,2)1 pl(GA,2)2 GrwLGA SdRtLL p(GA
,2)1: 
## poly(GAcont, 2)1            0.081                                             
## poly(GAcont, 2)2            0.273 -0.213                                      
## GrowthLGA                  -0.345 -0.031    -0.104                            
## SideRtLtLt                 -0.296  0.005     0.003    -0.001                  
## poly(GAcont, 2)1:GrowthLGA -0.028 -0.361     0.077     0.077 -0.007           
## poly(GAcont, 2)2:GrowthLGA -0.098  0.076    -0.357     0.315  0.001 -0.1
92    
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -2.57339146 -0.61952610 -0.01784109  0.62608968  4.88878722  
##  
## Number of Observations: 2406 
## Number of Groups: 118 
 
intervals(LGApi1) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                                   lower        est.       upper 
## (Intercept)                 2.238504413  2.27274227  2.30698012 
## poly(GAcont, 2)1           -1.652208764 -0.11659292  1.41902292 
## poly(GAcont, 2)2           -4.701885721 -3.14520452 -1.58852331 
## GrowthLGA                  -0.079222896  0.01225387  0.10373063 
## SideRtLtLt                 -0.006748613  0.01368487  0.03411836 
## poly(GAcont, 2)1:GrowthLGA -0.365390927  3.89290772  8.15120636 
## poly(GAcont, 2)2:GrowthLGA -3.886967508  0.47737339  4.84171428 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                                               lower       est.     upper 
## sd((Intercept))                         0.127250024  0.1505377 0.1780871 
## sd(poly(GAcont, 2)1)                    5.410884667  6.6174758 8.0931287 
## sd(poly(GAcont, 2)2)                    5.538414956  6.7811936 8.3028425 
## cor((Intercept),poly(GAcont, 2)1)      -0.102719046  0.1971167 0.4641159 
## cor((Intercept),poly(GAcont, 2)2)      -0.008724587  0.2496544 0.4767835 
## cor(poly(GAcont, 2)1,poly(GAcont, 2)2) -0.408234892 -0.1543860 0.1216252 
##  
##  Variance function: 
##           lower      est.    upper 
## power 0.6012455 0.9811413 1.361037 
## attr(,"label") 
## [1] "Variance function:" 
##  
##  Within-group standard error: 
##      lower       est.      upper  
## 0.08394216 0.11471897 0.15677988 
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Analysis for: The effect of diabetes during pregnancy on fetal 
renal parenchymal growth 
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Load data sets 
DM=read.csv("DM2.csv") 
Subset out only gestational diabetes (GDM) vs Control 
GDM = subset(DM, (DMtype=="0"|DMtype=="3"), 
             select =c(PtCode,GAcont, RPT, AntPos, SideRtLt, 
                       GendF1, DM,DMtype, BMI, 
                       HC, AC, FL, EFW, Length, Trans, AP, RVol)) 
Subset out Pregestational vs control 
DM_pregest=subset(DM, (DMtype=="0"|DMtype=="1"|DMtype=="2"), 
                  select =c(PtCode,GAcont, RPT, AntPos, SideRtLt, 
                            GendF1,DM,DMtype, BMI, 
                            HC, AC, FL, EFW, Length, Trans, AP,RVol)) 
Remove NAs from gestational age variable (GAcont) 
GDM.complete = GDM[!is.na(GDM$GAcont),] 
PreGD.complete = DM_pregest[!is.na(DM_pregest$GAcont),] 
Change intercept so 16 starts at 0 
GDM.complete$GAcont=GDM.complete$GAcont-16 
PreGD.complete$GAcont=PreGD.complete$GAcont-16 
Part 2: Renal parenchymal thickness (RPT) growth 
Model for RPT vs gestational age (GA) to compare GDM to control 
Best model is GDM5 - re-run with REML 
GDM5 = lme(RPT~ poly(GAcont,2)*DM +SideRtLt, random= ~poly(GAcont,2)|PtCode
,  
           method = "REML", 
           na.action="na.omit",  
           weights = varPower(form=~fitted(.)), 
           data=GDM.complete) 
 
summary(GDM5) 
## Linear mixed-effects model fit by REML 
##  Data: GDM.complete  
##        AIC      BIC    logLik 
##   6471.402 6559.054 -3220.701 
##  
## Random effects: 
##  Formula: ~poly(GAcont, 2) | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##                  StdDev     Corr          
## (Intercept)       0.6812192 (Intr) p(GA,2 
## poly(GAcont, 2)1 16.5691877  0.765        
## poly(GAcont, 2)2  9.3826482 -0.062  0.325 
## Residual          0.1625385               
##  
## Variance function: 
##  Structure: Power of variance covariate 
##  Formula: ~fitted(.)  
##  Parameter estimates: 
##     power  
## 0.8069518  
## Fixed effects: RPT ~ poly(GAcont, 2) * DM + SideRtLt  
##                          Value Std.Error   DF  t-value p-value 
## (Intercept)            7.08178  0.084664 2433 83.64605  0.0000 
## poly(GAcont, 2)1      90.65337  2.276828 2433 39.81564  0.0000 
## poly(GAcont, 2)2     -13.61145  1.585395 2433 -8.58553  0.0000 
## DMY                    0.21158  0.134046  116  1.57839  0.1172 
## SideRtLtRt             0.09999  0.028430 2433  3.51715  0.0004 
## poly(GAcont, 2)1:DMY   1.66424  3.678743 2433  0.45239  0.6510 
## poly(GAcont, 2)2:DMY   3.64535  2.532931 2433  1.43918  0.1502 
##  Correlation:  
##                      (Intr) pl(GA,2)1 pl(GA,2)2 DMY    SdRtLR p(GA,2)1: 
## poly(GAcont, 2)1      0.662                                             
## poly(GAcont, 2)2     -0.007  0.253                                      
## DMY                  -0.614 -0.418     0.004                            
## SideRtLtRt           -0.166 -0.001     0.001     0.000                  
## poly(GAcont, 2)1:DMY -0.409 -0.619    -0.157     0.675  0.000           
## poly(GAcont, 2)2:DMY  0.004 -0.159    -0.626    -0.002  0.000  0.283    
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -2.92995204 -0.62816629 -0.02979786  0.60368922  3.77055641  
##  
## Number of Observations: 2556 
## Number of Groups: 118 
 
Anova(GDM5) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: RPT 
##                        Chisq Df Pr(>Chisq)     
## poly(GAcont, 2)    3214.5919  2  < 2.2e-16 *** 
## DM                    4.7581  1  0.0291613 *   
## SideRtLt             12.3703  1  0.0004362 *** 
## poly(GAcont, 2):DM    2.0734  2  0.3546233     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
intervals(GDM5) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                             lower         est.       upper 
## (Intercept)            6.91575875   7.08177902   7.2477993 
## poly(GAcont, 2)1      86.18864533  90.65336689  95.1180885 
## poly(GAcont, 2)2     -16.72031887 -13.61145480 -10.5025907 
## DMY                   -0.05391847   0.21157653   0.4770715 
## SideRtLtRt             0.04424309   0.09999278   0.1557425 
## poly(GAcont, 2)1:DMY  -5.54955261   1.66424052   8.8780336 
## poly(GAcont, 2)2:DMY  -1.32157292   3.64535093   8.6122748 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                                               lower        est.      upp
er 
## sd((Intercept))                         0.590506901  0.68121923  0.78586
66 
## sd(poly(GAcont, 2)1)                   13.743157960 16.56918774 19.97633
90 
## sd(poly(GAcont, 2)2)                    6.968197009  9.38264818 12.63369
66 
## cor((Intercept),poly(GAcont, 2)1)       0.624526414  0.76487260  0.85736
55 
## cor((Intercept),poly(GAcont, 2)2)      -0.305239552 -0.06174329  0.18933
13 
## cor(poly(GAcont, 2)1,poly(GAcont, 2)2)  0.006599854  0.32502800  0.58360
85 
##  
##  Variance function: 
##           lower      est.     upper 
## power 0.6964282 0.8069518 0.9174754 
## attr(,"label") 
## [1] "Variance function:" 
##  
##  Within-group standard error: 
##     lower      est.     upper  








Model for RPT vs GA to compare pregestational diabetes to control 
Pregest5 is best model 
Pregest5 = lme(RPT~ poly(GAcont,2)*DM +SideRtLt, random= ~poly(GAcont,2)|Pt
Code,  
           method = "ML", 
           na.action="na.omit",  
           weights = varPower(form=~fitted(.)), 
           data=PreGD.complete, control = lmeControl(opt = "optim")) 
 
summary(Pregest5) 
## Linear mixed-effects model fit by maximum likelihood 
##  Data: PreGD.complete  
##        AIC      BIC    logLik 
##   4572.846 4655.112 -2271.423 
##  
## Random effects: 
##  Formula: ~poly(GAcont, 2) | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##                  StdDev     Corr          
## (Intercept)       0.6528489 (Intr) p(GA,2 
## poly(GAcont, 2)1 13.8865035 0.792         
## poly(GAcont, 2)2  9.3562617 0.054  0.062  
## Residual          0.1323798               
##  
## Variance function: 
##  Structure: Power of variance covariate 
##  Formula: ~fitted(.)  
##  Parameter estimates: 
##     power  
## 0.9186026  
## Fixed effects: RPT ~ poly(GAcont, 2) * DM + SideRtLt  
##                          Value Std.Error   DF  t-value p-value 
## (Intercept)            7.16355  0.082494 1694 86.83697  0.0000 
## poly(GAcont, 2)1      74.09936  1.945246 1694 38.09254  0.0000 
## poly(GAcont, 2)2     -11.36670  1.527425 1694 -7.44174  0.0000 
## DMY                    0.15105  0.241291   79  0.62600  0.5331 
## SideRtLtRt             0.04942  0.033856 1694  1.45976  0.1445 
## poly(GAcont, 2)1:DMY  -3.67667  5.743090 1694 -0.64019  0.5221 
## poly(GAcont, 2)2:DMY  -6.56468  4.748648 1694 -1.38243  0.1670 
##  Correlation:  
##                      (Intr) pl(GA,2)1 pl(GA,2)2 DMY    SdRtLR p(GA,2)1: 
## poly(GAcont, 2)1      0.664                                             
## poly(GAcont, 2)2      0.084  0.053                                      
## DMY                  -0.328 -0.227    -0.029                            
## SideRtLtRt           -0.204 -0.001     0.001     0.000                  
## poly(GAcont, 2)1:DMY -0.225 -0.339    -0.018     0.690  0.000           
## poly(GAcont, 2)2:DMY -0.027 -0.017    -0.322     0.084  0.000  0.093    
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -2.97657950 -0.60539159 -0.04743634  0.60957532  3.45017476  
##  
## Number of Observations: 1780 
## Number of Groups: 81 
 
Anova(Pregest5) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: RPT 
##                        Chisq Df Pr(>Chisq)     
## poly(GAcont, 2)    1743.1681  2     <2e-16 *** 
## DM                    2.2975  1     0.1296     
## SideRtLt              2.1393  1     0.1436     
## poly(GAcont, 2):DM    2.1839  2     0.3356     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
intervals(Pregest5) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                             lower         est.      upper 
## (Intercept)            7.00207071   7.16355368  7.3250366 
## poly(GAcont, 2)1      70.29152683  74.09935556 77.9071843 
## poly(GAcont, 2)2     -14.35664100 -11.36669862 -8.3767562 
## DMY                   -0.32828476   0.15104714  0.6303790 
## SideRtLtRt            -0.01685129   0.04942112  0.1156935 
## poly(GAcont, 2)1:DMY -14.91880103  -3.67667474  7.5654516 
## poly(GAcont, 2)2:DMY -15.86017844  -6.56467642  2.7308256 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                                             lower        est.      upper 
## sd((Intercept))                         0.5503656  0.65284892  0.7744156 
## sd(poly(GAcont, 2)1)                   11.0924388 13.88650351 17.3843627 
## sd(poly(GAcont, 2)2)                    6.1301555  9.35626170 14.2801651 
## cor((Intercept),poly(GAcont, 2)1)       0.6232270  0.79234828  0.8906695 
## cor((Intercept),poly(GAcont, 2)2)      -0.2519524  0.05375325  0.3497042 
## cor(poly(GAcont, 2)1,poly(GAcont, 2)2) -0.2987676  0.06164774  0.4066725 
##  
##  Variance function: 
##           lower      est.    upper 
## power 0.7826365 0.9186026 1.054569 
## attr(,"label") 
## [1] "Variance function:" 
##  
##  Within-group standard error: 
##     lower      est.     upper  
## 0.1014177 0.1323798 0.1727946 
 
Graph of RPT vs GA for Pregestational diabetes and Control groups  
 
Part 3: Abdominal circumference (AC) growth 
Model for AC vs GA to compare GDM to control 
Best model GDMac5 - change to REML 
GDMac5 = lme(AC~ poly(GAcont,2)*DM, random= ~poly(GAcont,2)|PtCode,  
             method = "REML", 
             na.action="na.omit",  
             weights = varPower(form=~fitted(.)), 
             data=GDM.complete, control=lmeControl(opt = "optim")) 
 
summary(GDMac5) 
## Linear mixed-effects model fit by REML 
##  Data: GDM.complete  
##        AIC      BIC    logLik 
##   15483.06 15564.88 -7727.531 
##  
## Random effects: 
##  Formula: ~poly(GAcont, 2) | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##                  StdDev      Corr          
## (Intercept)       12.0236330 (Intr) p(GA,2 
## poly(GAcont, 2)1 297.1461245  0.735        
## poly(GAcont, 2)2 270.8745754  0.100 -0.104 
## Residual           0.2655375               
##  
## Variance function: 
##  Structure: Power of variance covariate 
##  Formula: ~fitted(.)  
##  Parameter estimates: 
##    power  
## 0.490408  
## Fixed effects: AC ~ poly(GAcont, 2) * DM  
##                         Value Std.Error   DF   t-value p-value 
## (Intercept)           245.706   1.42850 2434 172.00296  0.0000 
## poly(GAcont, 2)1     3260.539  36.71709 2434  88.80165  0.0000 
## poly(GAcont, 2)2     -166.129  33.42844 2434  -4.96970  0.0000 
## DMY                     9.195   2.29021  116   4.01512  0.0001 
## poly(GAcont, 2)1:DMY  238.257  58.82853 2434   4.05003  0.0001 
## poly(GAcont, 2)2:DMY  117.386  53.86519 2434   2.17925  0.0294 
##  Correlation:  
##                      (Intr) pl(GA,2)1 pl(GA,2)2 DMY    p(GA,2)1: 
## poly(GAcont, 2)1      0.684                                      
## poly(GAcont, 2)2      0.118 -0.137                               
## DMY                  -0.624 -0.427    -0.074                     
## poly(GAcont, 2)1:DMY -0.427 -0.624     0.085     0.686           
## poly(GAcont, 2)2:DMY -0.073  0.085    -0.621     0.123 -0.132    
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -3.32175728 -0.56120251  0.01299609  0.51433392  3.20138174  
##  
## Number of Observations: 2556 
## Number of Groups: 118 
 
Anova(GDMac5) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: AC 
##                        Chisq Df Pr(>Chisq)     
## poly(GAcont, 2)    13784.137  2  < 2.2e-16 *** 
## DM                     0.877  1      0.349     
## poly(GAcont, 2):DM    23.889  2  6.495e-06 *** 
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
intervals(GDMac5) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                            lower        est.     upper 
## (Intercept)           242.905279  245.706484  248.5077 
## poly(GAcont, 2)1     3188.538568 3260.538553 3332.5385 
## poly(GAcont, 2)2     -231.680475 -166.129336 -100.5782 
## DMY                     4.659417    9.195459   13.7315 
## poly(GAcont, 2)1:DMY  122.897879  238.257045  353.6162 
## poly(GAcont, 2)2:DMY   11.759209  117.385557  223.0119 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                                               lower        est.        u
pper 
## sd((Intercept))                         10.56390163  12.0236330  13.6850
7169 
## sd(poly(GAcont, 2)1)                   256.10223685 297.1461245 344.7678
5683 
## sd(poly(GAcont, 2)2)                   232.86153898 270.8745754 315.0929
7714 
## cor((Intercept),poly(GAcont, 2)1)        0.61063628   0.7349709   0.8239
4200 
## cor((Intercept),poly(GAcont, 2)2)       -0.05730062   0.1000135   0.2524
8144 
## cor(poly(GAcont, 2)1,poly(GAcont, 2)2)  -0.27543722  -0.1041160   0.0736
1516 
##  
##  Variance function: 
##          lower     est.    upper 
## power 0.342002 0.490408 0.638814 
## attr(,"label") 
## [1] "Variance function:" 
##  
##  Within-group standard error: 
##     lower      est.     upper  
## 0.1168555 0.2655375 0.6033959 
 
Model for AC vs GA to compare pregestational diabetes to control 
Best model Pregac5 - change to REML 
Pregac5 = lme(AC~ poly(GAcont,2)*DM, random= ~poly(GAcont,2)|PtCode,  
              method = "REML", 
              na.action="na.omit",  
              weights = varPower(form=~fitted(.)), 
              data=PreGD.complete, control = lmeControl(msMaxIter = 200)) 
 
summary(Pregac5) 
## Linear mixed-effects model fit by REML 
##  Data: PreGD.complete  
##        AIC      BIC    logLik 
##   10582.36 10659.07 -5277.182 
##  
## Random effects: 
##  Formula: ~poly(GAcont, 2) | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##                  StdDev       Corr          
## (Intercept)      1.252347e+01 (Intr) p(GA,2 
## poly(GAcont, 2)1 3.006259e+02  0.746        
## poly(GAcont, 2)2 2.443911e+02  0.106 -0.137 
## Residual         6.987270e-04               
##  
## Variance function: 
##  Structure: Power of variance covariate 
##  Formula: ~fitted(.)  
##  Parameter estimates: 
##   power  
## 1.56092  
## Fixed effects: AC ~ poly(GAcont, 2) * DM  
##                          Value Std.Error   DF   t-value p-value 
## (Intercept)           247.8149   1.48815 1691 166.52535  0.0000 
## poly(GAcont, 2)1     2671.7814  36.64231 1691  72.91520  0.0000 
## poly(GAcont, 2)2     -135.2711  30.04207 1691  -4.50272  0.0000 
## DMY                    19.8031   4.47122   79   4.42902  0.0000 
## poly(GAcont, 2)1:DMY  367.9845 109.37263 1691   3.36450  0.0008 
## poly(GAcont, 2)2:DMY   66.3260  91.72530 1691   0.72309  0.4697 
##  Correlation:  
##                      (Intr) pl(GA,2)1 pl(GA,2)2 DMY    p(GA,2)1: 
## poly(GAcont, 2)1      0.710                                      
## poly(GAcont, 2)2      0.125 -0.157                               
## DMY                  -0.333 -0.236    -0.042                     
## poly(GAcont, 2)1:DMY -0.238 -0.335     0.053     0.712           
## poly(GAcont, 2)2:DMY -0.041  0.051    -0.328     0.134 -0.148    
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -3.93730036 -0.54228041  0.00563303  0.58062035  3.39023834  
##  
## Number of Observations: 1776 
## Number of Groups: 81 
 
Anova(Pregac5) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: AC 
##                        Chisq Df Pr(>Chisq)     
## poly(GAcont, 2)    6236.2808  2  < 2.2e-16 *** 
## DM                    6.9224  1   0.008512 **  
## poly(GAcont, 2):DM   12.8479  2   0.001622 **  
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
intervals(Pregac5) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                           lower       est.      upper 
## (Intercept)           244.89610  247.81491  250.73373 
## poly(GAcont, 2)1     2599.91234 2671.78139 2743.65044 
## poly(GAcont, 2)2     -194.19467 -135.27112  -76.34758 
## DMY                    10.90337   19.80311   28.70285 
## poly(GAcont, 2)1:DMY  153.46455  367.98451  582.50447 
## poly(GAcont, 2)2:DMY -113.58104   66.32603  246.23309 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                                              lower        est.       upp
er 
## sd((Intercept))                         10.6512565  12.5234744  14.72478
03 
## sd(poly(GAcont, 2)1)                   249.4033068 300.6258717 362.36855
03 
## sd(poly(GAcont, 2)2)                   204.0064095 244.3910908 292.77023
91 
## cor((Intercept),poly(GAcont, 2)1)        0.6021273   0.7456422   0.84248
02 
## cor((Intercept),poly(GAcont, 2)2)       -0.1490315   0.1060003   0.34780
96 
## cor(poly(GAcont, 2)1,poly(GAcont, 2)2)  -0.4050833  -0.1365864   0.15359
91 
##  
##  Variance function: 
##          lower    est.    upper 
## power 1.370619 1.56092 1.751221 
## attr(,"label") 
## [1] "Variance function:" 
##  
##  Within-group standard error: 
##        lower         est.        upper  
## 0.0002456354 0.0006987270 0.0019875774 
 





DM3[,c("PtCode","AntPos", "SideRtLt", "GendF1","DM", "DMtype", "DMGr", "GTT
Scale","Treat")]= 
  lapply(DM3[,c("PtCode","AntPos", "SideRtLt", "GendF1", "DM", "DMtype", "D
MGr", "GTTScale","Treat")],factor) 
 
##Change factor names 
DM3$AntPos=factor(DM3$AntPos, labels=c("Ant", "Post")) 
DM3$SideRtLt=factor(DM3$SideRtLt, labels=c("Rt", "Lt")) 
DM3$GendF1=factor(DM3$GendF1, labels = c("F", "M")) 
DM3$DM=factor(DM3$DM, labels = c("N", "Y")) 
DM3$DM_type=factor(DM3$DMtype, labels=c("None", "T1", "T2", "GDM")) 
DM3$DMGr=factor(DM3$DMGr, labels=c("control", "GDM", "Pregest")) 
DM3$Treat=factor(DM3$Treat, labels=c("none", "Diet", "OHA", "Insulin")) 
 
##Remove all NAs from GAcont 
DM3.complete = DM3[!is.na(DM3$GAcont),] 
 
##Change intercept so 16 starts at 0 
DM3.complete$GAcont=DM3.complete$GAcont-16 
 
Graph of AC vs GA for gestational and pregestation diabetes and Control groups  
 
Part 4: RPT growth compared to AC growth for GDM 
and pregestational diabetes 
Model for RPT growth compared to AC growth for GDM and control 
##Power curves - log transform data so both intercept at 0 
log.DM = mutate(DM, 
                logRPT=log(RPT), 
                logHC=log(HC), 
                logEFW=log(EFW), 
                logAC =log(AC), 
                logFL=log(FL)) 
Subset out GDM vs control from log.DM 
log_GDM=subset(log.DM, (DMtype=="0"|DMtype=="3"), 
               select =c(PtCode,GAcont, RPT, AntPos, SideRtLt, 
                         GendF1, DM,DMtype, DMGr, BMI,HC, AC, FL, EFW,  
                         Length, Trans, AP,RVol, logRPT, logHC, logEFW,  
                         logAC, logFL)) 
Power curve RPT to AC for GDM vs control 
GDMgrowth3 best model - change to REML 
GDMgrowth3 = lme(logRPT ~ logAC*DM + SideRtLt, random=~logAC|PtCode, 
             method = "REML",na.action="na.omit", data=log_GDM, 
             control = lmeControl(msMaxIter = 200)) 
 
summary(GDMgrowth3) 
## Linear mixed-effects model fit by REML 
##  Data: log_GDM  
##         AIC       BIC   logLik 
##   -3261.793 -3209.195 1639.897 
##  
## Random effects: 
##  Formula: ~logAC | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##             StdDev    Corr   
## (Intercept) 0.8622425 (Intr) 
## logAC       0.1593078 -0.996 
## Residual    0.1167751        
##  
## Fixed effects: logRPT ~ logAC * DM + SideRtLt  
##                 Value  Std.Error   DF   t-value p-value 
## (Intercept) -3.444753 0.12602929 2435 -27.33295  0.0000 
## logAC        0.980422 0.02311627 2435  42.41265  0.0000 
## DMY          0.231434 0.20008793  116   1.15666  0.2498 
## SideRtLtRt   0.017114 0.00461955 2435   3.70467  0.0002 
## logAC:DMY   -0.042936 0.03671102 2435  -1.16957  0.2423 
##  Correlation:  
##            (Intr) logAC  DMY    SdRtLR 
## logAC      -0.997                      
## DMY        -0.630  0.628               
## SideRtLtRt -0.018  0.000  0.000        
## logAC:DMY   0.628 -0.630 -0.997  0.000 
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -3.98164034 -0.65163417  0.01276083  0.63774356  3.48621096  
##  
## Number of Observations: 2556 
## Number of Groups: 118 
Anova(GDMgrowth3) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: logRPT 
##              Chisq Df Pr(>Chisq)     
## logAC    2878.0506  1  < 2.2e-16 *** 
## DM          0.0161  1  0.8990371     
## SideRtLt   13.7246  1  0.0002117 *** 
## logAC:DM    1.3679  1  0.2421746     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
intervals(GDMgrowth3) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                    lower        est.       upper 
## (Intercept) -3.691888511 -3.44475280 -3.19761709 
## logAC        0.935092672  0.98042226  1.02575185 
## DMY         -0.164865690  0.23143367  0.62773303 
## SideRtLtRt   0.008055243  0.01711390  0.02617256 
## logAC:DMY   -0.114924115 -0.04293606  0.02905200 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                             lower       est.      upper 
## sd((Intercept))         0.6965259  0.8622425  1.0673862 
## sd(logAC)               0.1292732  0.1593078  0.1963206 
## cor((Intercept),logAC) -0.9977837 -0.9963207 -0.9938949 
##  
##  Within-group standard error: 
##     lower      est.     upper  
## 0.1134394 0.1167751 0.1202089 
 
Graph of RPT vs AC for GDM and Control groups 
 
Model for RPT growth compared to AC growth for pregestational and control 
Subset out pregest vs control 
log_pregest=subset(log.DM, (DMtype=="0"|DMtype=="1"|DMtype=="2"), 
                   select =c(PtCode,GAcont, RPT, AntPos, SideRtLt, 
                             GendF1, DM,DMtype, DMGr, BMI, 
                             HC, AC, FL, EFW, Length, Trans, AP,RVol, 
                             logRPT, logHC, logEFW, logAC, logFL)) 
 
Best model 3 - change to REML 
pregestgrowth3 = lme(logRPT ~ logAC *DM +SideRtLt, random=~logAC|PtCode, 
                     method = "REML",na.action="na.omit", 
                     data=log_pregest, 
                     control = lmeControl(opt = ("optim"))) 
 
summary(pregestgrowth3) 
## Linear mixed-effects model fit by REML 
##  Data: log_pregest  
##         AIC      BIC   logLik 
##   -2220.764 -2171.45 1119.382 
##  
## Random effects: 
##  Formula: ~logAC | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##             StdDev    Corr   
## (Intercept) 0.9798013 (Intr) 
## logAC       0.1815529 -0.997 
## Residual    0.1179587        
##  
## Fixed effects: logRPT ~ logAC * DM + SideRtLt  
##                 Value Std.Error   DF   t-value p-value 
## (Intercept) -3.434973 0.1382659 1692 -24.84324  0.0000 
## logAC        0.979359 0.0254353 1692  38.50398  0.0000 
## DMY          0.646008 0.4068848   79   1.58769  0.1164 
## SideRtLtRt   0.010171 0.0055981 1692   1.81684  0.0694 
## logAC:DMY   -0.121865 0.0746864 1692  -1.63169  0.1029 
##  Correlation:  
##            (Intr) logAC  DMY    SdRtLR 
## logAC      -0.998                      
## DMY        -0.340  0.339               
## SideRtLtRt -0.020  0.000  0.000        
## logAC:DMY   0.340 -0.341 -0.998  0.000 
##  
## Standardized Within-Group Residuals: 
##          Min           Q1          Med           Q3          Max  
## -3.910485269 -0.657655213 -0.007770504  0.635791145  3.149876796  
##  
## Number of Observations: 1776 
## Number of Groups: 81 
 
Anova(pregestgrowth3) 
## Analysis of Deviance Table (Type II tests) 
##  
## Response: logRPT 
##              Chisq Df Pr(>Chisq)     
## logAC    1629.0077  1    < 2e-16 *** 
## DM          0.3648  1    0.54585     
## SideRtLt    3.3009  1    0.06924 .   
## logAC:DM    2.6624  1    0.10274     
## --- 
## Signif. codes:  0 '***' 0.001 '**' 0.01 '*' 0.05 '.' 0.1 ' ' 1 
 
intervals(pregestgrowth3) 
## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                     lower        est.       upper 
## (Intercept) -3.7061636482 -3.43497340 -3.16378316 
## logAC        0.9294706538  0.97935852  1.02924638 
## DMY         -0.1638757797  0.64600815  1.45589208 
## SideRtLtRt  -0.0008090544  0.01017082  0.02115070 
## logAC:DMY   -0.2683527862 -0.12186527  0.02462225 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                             lower       est.      upper 
## sd((Intercept))         0.7626885  0.9798013  1.2587191 
## sd(logAC)               0.1420963  0.1815529  0.2319656 
## cor((Intercept),logAC) -0.9986405 -0.9974975 -0.9953956 
##  
##  Within-group standard error: 
##     lower      est.     upper  
## 0.1139383 0.1179587 0.1221210 
 
Graph of RPT vs AC for pregestational diabetes and Control groups 
 
  
Model for RPT growth compared to AC growth for GDM and pregestational 
Subset out only diabetes patients (no control) 
DMOnly=subset(log.DM, (DMGr=="Pregest"|DMGr=="GDM"), 
               select =c(PtCode,GAcont, RPT, AntPos, SideRtLt, 
                         GendF1, DM, DMtype, DMGr, BMI,HC, AC, FL, EFW,  
                         Length, Trans, AP,RVol, 
                         logRPT, logHC, logEFW,logAC, logFL)) 
Best model 3 - change to REML 
GDMvsPDGgrowth3 = lme(logRPT ~ logAC *DMGr + SideRtLt, random=~logAC|PtCode
, 
                      method = "REML",na.action="na.omit", data=DMOnly, 
                      control = lmeControl(opt = ("optim"))) 
 
summary(GDMvsPDGgrowth3) 
## Linear mixed-effects model fit by REML 
##  Data: DMOnly  
##         AIC       BIC   logLik 
##   -1494.217 -1448.596 756.1084 
##  
## Random effects: 
##  Formula: ~logAC | PtCode 
##  Structure: General positive-definite, Log-Cholesky parametrization 
##             StdDev    Corr   
## (Intercept) 0.6914525 (Intr) 
## logAC       0.1270452 -0.994 
## Residual    0.1166929        
##  
## Fixed effects: logRPT ~ logAC * DMGr + SideRtLt  
##                       Value Std.Error   DF   t-value p-value 
## (Intercept)       -3.233875 0.1333902 1122 -24.24372  0.0000 
## logAC              0.940781 0.0243450 1122  38.64365  0.0000 
## DMGrPregest        0.393306 0.3287192   53   1.19648  0.2368 
## SideRtLtRt         0.021284 0.0067941 1122   3.13267  0.0018 
## logAC:DMGrPregest -0.075308 0.0597792 1122  -1.25977  0.2080 
##  Correlation:  
##                   (Intr) logAC  DMGrPr SdRtLR 
## logAC             -0.996                      
## DMGrPregest       -0.406  0.404               
## SideRtLtRt        -0.025  0.000  0.000        
## logAC:DMGrPregest  0.405 -0.407 -0.996  0.000 
##  
## Standardized Within-Group Residuals: 
##         Min          Q1         Med          Q3         Max  
## -3.34878388 -0.66269527 -0.02239424  0.67312143  3.46624600  
##  
## Number of Observations: 1180 
## Number of Groups: 55 
 
anova(GDMvsPDGgrowth3) 
##             numDF denDF   F-value p-value 
## (Intercept)     1  1122 29501.614  <.0001 
## logAC           1  1122  1742.650  <.0001 
## DMGr            1    53     0.400  0.5297 
## SideRtLt        1  1122     9.814  0.0018 




## Approximate 95% confidence intervals 
##  
##  Fixed effects: 
##                          lower        est.       upper 
## (Intercept)       -3.495597641 -3.23387526 -2.97215288 
## logAC              0.893014244  0.94078117  0.98854810 
## DMGrPregest       -0.266021708  0.39330556  1.05263282 
## SideRtLtRt         0.007953113  0.02128373  0.03461435 
## logAC:DMGrPregest -0.192599328 -0.07530774  0.04198385 
## attr(,"label") 
## [1] "Fixed effects:" 
##  
##  Random Effects: 
##   Level: PtCode  
##                              lower       est.      upper 
## sd((Intercept))         0.47303760  0.6914525  1.0107156 
## sd(logAC)               0.08749299  0.1270452  0.1844773 
## cor((Intercept),logAC) -0.99739637 -0.9938017 -0.9852807 
##  
##  Within-group standard error: 
##     lower      est.     upper  
## 0.1118062 0.1166929 0.1217931 
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A B S T R A C T
Purpose: To determine the role of ultrasound imaging in evaluating fetal kidney growth.
Methods: MEDLINE, CINAHL and EMBASE databases were electronically searched for studies between 1996 and
January 2017 and limited to English language. Studies were included if they reported on an ultrasound tech-
nique to assess fetal kidney growth and they were not a case report or case series. There was independent
selection of studies by two reviewers in consensus with one other reviewer. Data were extracted by one reviewer
in consensus with two other reviewers.
Results: A total of 1785 articles were identified. The full text of 39 of these were assessed for eligibility for
inclusion. Twenty-eight studies were then included in the review. Standard two dimensional (2D) fetal renal
measurements are easy to perform, however, this review identified that most studies had some methodological
limitations. The disadvantage with 2D and three dimensional (3D) fetal renal volumes are that they include the
entire kidney and good reproducibility of 3D volumes has not yet been demonstrated. Currently there is limited
research on fetal kidney growth in the setting of abnormal fetal growth. Research focussing directly on fetal
kidney parenchyma and blood flow is scarce.
Conclusions: Some nomograms of 2D and 3D fetal kidney size and volume have been developed. Kidney length is
the most popular single fetal kidney measurement; however, it does not seem to be a good indicator of growth. In
IUGR fetuses, kidney length remained similar to appropriately grown fetuses whereas AP and TS dimensions
were significantly decreased. New ultrasound techniques focusing on the parenchyma of the kidney and per-
fusion to the kidney should be explored as they may provide more meaningful information on kidney devel-
opment in the fetus and future kidney function.
1. Introduction
It is well established that an adverse intrauterine environment can
affect fetal kidney development resulting in possible hypertension and
chronic kidney disease later in life [1,2]. Intrauterine growth restriction
(IUGR) can result in significant reductions in nephron number [3]
which may ultimately result in decreased renal function [4]. Although
most studies concentrate on IUGR and low birth weight infants, over-
growth or large for gestational age (LGA) are also emerging as factors
that can disrupt normal fetal kidney development and increase risks for
hypertension and chronic kidney disease [5]. The normal development
of the fetal kidneys can be crucial to an individual’s long-term health
outcomes.
The human kidney develops through three successive embryonic
stages. Transient development and regression of the primary (prone-
phros) and secondary (mesonephros) fetal kidneys occurs between day
23 and day 112 [6]. These primitive fetal kidneys have no impact on
fetal renal function. The definitive, tertiary fetal kidney is the meta-
nephros and this is the permanent functional kidney. It begins devel-
oping on day 30 leading to the formation of nephrons − the functional
units within the kidney [6,7]. Fetal kidneys are unlike most other or-
gans in that the maximum cell proliferation occurs in the third trime-
ster. Nephrogenesis continues up until 34–36 weeks gestation with
approximately 60% of nephrons formed in the third trimester [8].
Assessment of the fetal kidneys is an essential part of an obstetric
ultrasound. Accurate information regarding kidney size is crucial to
http://dx.doi.org/10.1016/j.ejrad.2017.09.017
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identifying kidney abnormalities and detecting changes in fetal kidney
growth. Ultrasound imaging is safe, cost effective and widely available
to evaluate fetal kidney size, echotexture and perfusion. A variety of
two and three-dimensional ultrasound techniques have emerged and
advanced to evaluate kidney development. The aim of this review was
to systematically review the literature to determine what role ultra-
sound plays in evaluating fetal kidney growth. Current ultrasound
imaging techniques and accuracy will be reviewed.
2. Method
A systematic review of observational studies was conducted using a
protocol designed a priori and following the PRISMA guidelines for
systematic reviews. Author SB developed and conducted the search
strategy using medical subject headings (MeSH) and keywords and this
was reviewed by author YK (Appendix A). MEDLINE (ovid); CINAHL
and EMBASE electronic databases were electronically searched in Au-
gust 2016 and again in January 2017; for publications from the year
1996 onwards. The literature search was limited to the English lan-
guage. The reference lists of relevant articles were hand-searched for
additional relevant studies.
Human observational ultrasound studies that were not a case report
or case series were included. Only studies reporting on an ultrasound
technique assessing fetal kidney growth were included. Studies that
only assessed fetal pelvic renal dilatation were excluded.
Only studies published from the last 20 years (from 1996) were
included as it was felt that the significant advances in ultrasound
techniques and improvements in diagnosis and definition in prenatal
imaging made these older studies less relevant. Also excluded were
unpublished studies, non-peer-reviewed, conference abstracts, letters to
the editor and opinion articles. If data from a single study population
was reported more than once, the publication containing the most
complete information was included.
Study selection was performed in two sequential steps, firstly as-
sessing articles by title and abstract and secondly by full text of the
article. Two reviewers (SB and YK) independently screened the titles
and abstracts of all identified citations and potentially eligible studies
were selected. The full text of these potentially eligible studies was
screened by the same two reviewers. Any discrepancies between the
reviewers were resolved by consultation with a third reviewer (DW).
A data extraction sheet was developed. Only pre-specified outcomes
of interest in the review were collected. Review author SB extracted the
data from the studies and the second review author YK checked the
extracted data. Any disagreements were resolved by discussion with a
third reviewer (DW). Fig. 1 outlines study selection process. A narrative
synthesis, including tables, was done on the extracted data to explain
and summarise the characteristics and findings of the included studies.
3. Results
A total of 1785 articles were identified and after review of the title
and abstract, the full text of 39 of these were assessed for eligibility for
inclusion (Fig. 1). Four papers from the Generation R study reported the
same renal data [9–12] and therefore these data were only considered
once using the paper by Verburg et al. [9] as it contained the most
relevant and complete data assessing fetal kidney measurements. Fi-
nally, 28 studies were reviewed.
Relevant characteristics of these included studies are presented in
Tables 1–3. Most studies were prospective in design with only 2 of the
28 studies retrospective [13,14]. A cross-sectional design was utilised
by 21 studies while 7 studies had a longitudinal design. Selected studies
were divided into three groups depending on the ultrasound technique
used to assess the kidneys. Some studies reported on more than one
ultrasound technique (Tables 1–3).
Generally, the study time and duration, how participants were re-
cruited and missing participants and data was poorly reported.
Calculation of estimated gestational age (GA) was most commonly
achieved using the last normal menstrual period (LNMP) correlated
with a first or early second trimester ultrasound (18 studies) [13–30].
Six studies used ultrasound dating only [9,31–35], one used only an
accurate LNMP [36] and three did not report how GA was determined
[37–39].
Overall ultrasound features of the studies and measurement
methods were well described. Most studies focussed on the mid-second
trimester to third trimester [9,13,14,16,18–31,33–35,37–39], as ima-
ging the fetal kidneys well under 20 weeks can be difficult [33,40]. The
three studies that reported data below 14 weeks GA used transvaginal
scanning [15,17,36]. The GA range assessed was very variable between
studies. Two studies showed only a snap shot in time with a GA range of
15 days (around 34 weeks) [34] and 4 weeks (28–32 weeks) [9]. One
study measured the fetal kidneys at 23 weeks and again at 32 weeks
[18]. Studies covering the longest GA ranges were Chitty and Altman
[20] 16–42 weeks, van Vuuren et al. [32] 16–42 weeks and Hsieh et al.
[25] 15–40 weeks. The GA range was unclear in one study [23].
3.1. Differences between right and left kidneys and gender
Overall the evidence strongly supported no significant difference
between right and left fetal kidney size (17 of the 18 studies) for all
ultrasound measurements regardless of the technique used
[13,15,16,17,19,23–26,28–33,35,38]. Six of the seven studies that ex-
amined gender differences found no significant difference between fetal
kidney measurements [17–19,23,29,30]. Only one study demonstrated
a difference in size between right and left kidneys and males and fe-
males [9]. This was a large study, however, it had a small four-week
gestational window (28.4–32.6 weeks) when each fetus was measured
once. The study revealed right kidneys had a larger transverse and
antero-posterior dimension when compared to left kidneys, resulting in
larger calculated renal volumes. No difference, however, was found
between kidney lengths. All kidney measurements were smaller in fe-
males than males [9].
3.2. Standard two dimensional (2D) measurements
Nineteen studies reported on a standard two-dimensional (2D) ul-
trasound measurement [9,13,15–23,29,31,32,34,36–39]. Standard two-
dimensional (2D) measurements of the fetal kidneys was the earliest
and simplest method utilised to assess kidney size at different gesta-
tional ages [41,42]. Most reviewed studies involved a low risk, un-
complicated pregnancy to obtain normal fetal kidney nomograms
Fig. 1. Study selection process.
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[16–20,23,32,36,38].
A longitudinal design was used by four studies that reported on 2D
measurements [19,22,32,37], with the best quality longitudinal study
being Van Vuuren et al. [32]. This study of 96 participants measured all
three dimensions of the kidney and clearly defined how GA was de-
termined. Good longitudinal data was obtained every two weeks. Par-
ticipants were divided into two groups. Each group came every four
weeks, however, one group started at 16 weeks and the other at 18
weeks. Reference charts were constructed for kidney length, antero-
posterior diameter, transverse diameter and volume [32]. In the other
longitudinal studies, one did not report how GA was determined [37],
another only measured kidney length [19] and the third study had a
small sample size of ten normal pregnancies [22].
Overall, evidence from the selected studies using standard 2D ul-
trasound measurements suggest fetal kidney growth correlates posi-
tively with GA. The velocity of kidney growth is highest between 26
and 34 weeks in appropriately grown fetuses. This was termed the
“critical period” for fetal kidney growth [37] and was supported by
other studies [9,34]. Kidney size was linked positively with fetal weight
and size [9,18,38].
Few studies used standard 2D methods to investigate fetal kidney
growth in abnormal fetal growth. Compared to appropriately grown
fetuses, kidneys of IUGR fetuses demonstrated significant reductions in
transverse and antero-posterior dimensions [31]. This is particularly
marked during the critical kidney growth period (26–34 weeks). No
significant difference was demonstrated between the renal lengths of
IUGR fetuses compared to appropriately grown fetuses.
3.3. Renal volumes − calculated from two dimensional (2D) measurements
Kidney volume calculations should technically be a better estimate
of overall kidney size and shape than single linear measurements
[43,44]. Traditionally fetal renal volumes were calculated using 2D
ultrasound measures. Three orthogonal kidney diameters are applied to
the volume formula of an ellipsoid shape to obtain a volume estimate
(length x transverse x antero-posterior x 0.523) [45]. The ellipsoid
formula was used to calculate renal volumes in nine studies
[9,18,20–22,32–34,38]. Findings from the studies of appropriately
grown fetuses in normal pregnancies demonstrated fetal kidney volume
increases exponentially until birth [32] or with some slowing of growth
velocity after 36 weeks [20].
Studies assessing fetal renal 2D volumes during abnormal fetal
growth were scarce. One such study was a large study, however was
cross-sectional in design and examined a very narrow GA window of
28.4 weeks to 32.6 weeks (median age 30.4 weeks) [9]. Their findings
suggested that IUGR, placental insufficiency and fetal redistribution of
blood flow result in decreased fetal kidney volumes, around the critical
kidney growth period of 26–34 weeks. Smaller kidney volumes were
also associated with reduced amniotic fluid suggesting an association
with fetal kidney function [9]. Another cross-sectional study of IUGR
fetuses reported considerable reductions in the kidney volumes of IUGR
fetuses [21]. When corrected for fetal weight, there was a 15% reduc-
tion of kidney volume for IUGR fetuses compared to appropriately
grown fetuses [21].
No studies were found evaluating fetal kidney growth in large for
gestational age (LGA) fetuses. Fetal kidney growth in hyperglycaemic
pregnancies was investigated by one study [33]. This longitudinal study
compared 2D kidney volumes of normoglycaemic pregnancies with
hyperglycaemic pregnancies. Often fetuses of hyperglycaemic mothers
are LGA due to organomegaly and increased fat deposition from the
increased glycogen to the fetus [33], however, the relationship between
fetal size and kidney size was not reported. This study demonstrated
maternal hyperglycaemia was associated with alterations in fetal
kidney volume. The median fetal kidney volumes of hyperglycaemic
pregnancies were significantly larger than the 75th percentile for nor-
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examination.
3.4. Renal volumes − three dimensional (3D)
Three dimensional (3D) techniques were used to calculate fetal
kidney volumes in six studies. One of two methods were used to obtain
3D volumes: the multiple parallel plane method (multiplanar) or the
rotational Virtual Organ Computer-aided AnaLysis (VOCAL) method.
The older multiplanar technique is utilised in the four earlier studies,
between 2000 and 2008 [24–27] and involves manually tracing mul-
tiple adjacent sequential planes of the organ. VOCAL is the newer, more
automated volumetric tool employed by the two later 3D studies (2009
and 2013) [28–35].
Most of the included 3D studies focused on constructing reference
curves for 3D fetal kidney volumes correlating to GA. Only one of these
studies was longitudinal in design and able to truly assess growth,
unfortunately this study had the narrowest gestational range of be-
tween 24–34 weeks [26]. All studies reporting on 3D kidney volumes
demonstrated substantial differences of reported “normal” values. For
example, two similarly designed studies published the same year, from
the same country, using the same equipment reported at 35 weeks a
kidney volume of 7.9 mL as the 50th centile in one study [24] and
below the 5th centile for the other [25]. Even when reviewing two
studies using the newer VOCAL method, one study reported the 50th
centile of the right kidney at 34 weeks as 21.8 cm3 [35] and the other
reported 11.7 cm3 as their 50th centile at 34 weeks [28]. These con-
siderable variations are highly unlikely to be due to different popula-
tion characteristics. In clinical practice, it would be impossible to know
which reference curves to use and these results should therefore be used
with caution.
3D ultrasound assessment of abnormal fetal kidney growth was
evaluated in only one study. This study compared 3D fetal renal vo-
lumes between IUGR fetuses and appropriately grown fetuses [27].
Volumes in IUGR fetuses were significantly smaller when compared to
appropriately grown fetuses [27]. This evidence is not strong as this one
cross-sectional study measured volumes only once in 28 IUGR fetuses
and the considerable variation in normal 3D fetal kidney volumes is
likely to also be an issue in measurements of abnormally grown fetuses.
3.5. Other ultrasound techniques
Five studies investigated other ultrasound techniques to assess fetal
renal growth or size, with a focus on the kidney parenchyma
[13,14,29,30,39]. The kidney parenchyma has more recently become
an emphasis of investigation as it contains the nephrons. In a hydro-
nephrotic kidney, the length, transverse and antero-posterior dimen-
sions and kidney volume may be normal or above normal. However, the
parenchyma may be thinner than normal and the kidney may have
impaired function [46].
The study by Devriendt et al. [39] measured cortical thickness (from
the outer renal capsule to the external limit of the pyramids) and me-
dullary thickness (the pyramid from the papilla to its base) of the
parenchyma separately and demonstrated that these measures in-
creased with GA. There was poor reproducibility with an inter-observer
variability of 16.5% for cortical thickness and 28.6% for medullary
thickness [39]. This was likely due to the various and changing shape of
the renal pyramids, making accurate and reproducible placement of the
callipers difficult.
In contrast, Hadar et al. [30] conducted a study measuring the en-
tire kidney parenchyma from the renal capsule to the sinus-pyramidal
interface and indicated there was a gradual linear growth of the par-
enchyma with increasing GA [30]. Both the anterior and posterior
parenchyma thicknesses were measured in transverse and longitudinal
planes. Their findings demonstrated that measuring parenchymal
thickness on longitudinal sections was more reliable and reproducible
than transverse measurements and had significantly better intra and
inter-observer variability than Devriendt et al. [39] at 0.6% and 8.8%
for anterior parenchyma and 3.5% and 2.4% for posterior parenchyma
respectively [30]. Supporting the consistency of this study [30] is that
measurements were completed while performing the ultrasound rather
than measured offline, by a reader, from archived images, as was done
in the study by Devriendt et al. [39].
The echogenicity of the parenchyma was subjectively evaluated and
compared to kidney size by one study [29]. This study reported a sig-
nificantly higher biparietal diameter/kidney length ratio in those fe-
tuses with hyperechogenicity of the kidney parenchyma and proposed
this parenchymal hyperechogenicity is an indicator of depression of
fetal renal perfusion. These results should be interpreted with caution
as their standard deviation for fetal kidney length was large at 5.4 mm
and the study had other technical issues, including a non-validated
technique to assess fetal hypoxia [29].
Kidney parenchymal area was measured in two other studies
[13,14]. Unfortunately, they were retrospective in design and the entire
area of the kidney in transverse and longitudinal was measured. These
two studies in fact did not measure renal parenchyma and actually
measured kidney area. Both used their data to develop nomograms of
kidney area.
4. Discussion
After reviewing 28 studies using ultrasound to assess fetal kidney
development, this systematic review revealed several ultrasound tech-
niques to evaluate fetal kidney growth. These techniques had a wide
variety of sensitivity and reproducibility. Identification of abnormal
kidney morphology or growth is aided by availability of normal fetal
kidney biometry charts. Unfortunately, this review identified most
studies had some methodological limitations.
There is limited data on actual kidney growth. Some studies re-
ported kidney growth as an outcome, however, they were cross-sec-
tional in design [13,14,24,25,30,38]. It is common for size and growth
to be confused and used interchangeably. A limitation of cross-sectional
studies is they are not appropriate to evaluate growth and can only be
used to produce kidney size reference curves [47]. Only one cross-
sectional study recognised this limitation [20]. Longitudinal studies can
overcome this limitation as the same fetal kidneys are measured at
multiple time periods during the pregnancy. A large, longitudinal study
of kidney size and volume would provide reference curves for kidney
size and growth [47].
In IUGR fetuses, AP and TS dimensions were significantly decreased,
but kidney length remained similar to appropriately grown fetuses. The
kidney shape changes to long and skinny or “sausage-shaped” as de-
scribed by Konje et al. [31] and suggests the thinning of the kidney
could be due to fewer layers of nephrons. Lampl et al. [22] investigated
effects of maternal smoking during pregnancy on fetal kidney growth,
proposing maternal smoking affected growth patterns, resulting in long
thin “sausage-shaped” kidneys late in the third trimester. Un-
fortunately, the number of participants with recorded birth outcomes
was small (6 smokers and 21 non-smokers) and thus the results deemed
insufficient to suggest any meaningful outcomes [22].
Kidney length is the most popular single fetal kidney 2D measure-
ment used in current clinical practice and in the selected studies. It was
not, however, seen to be a good indicator of growth. This may make
kidney length more useful for estimating GA, where dates are uncertain
[16,19,23] and highlights its lack of sensitivity in assessing alterations
in fetal kidney growth.
Kidney volume calculations estimate overall kidney size and shape.
2D volumes are simpler and quicker than 3D volume calculations and
can be done with any basic ultrasound equipment. 3D volume calcu-
lations require higher-level ultrasound equipment with additional 3D-
specific transducers and proprietary software. The disadvantage of
calculating fetal kidney volumes from 2D measurements is it erro-
neously assumes that the kidney is an ellipsoid shape. Compared to the
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gold standard of fluid displacement, an in vitro study demonstrated
using the ellipsoid formula underestimated actual renal volumes by
24% [48].
3D ultrasound volume calculations are not dependant on an as-
sumed geometric shape and therefore are thought to more precisely
estimate volumes of irregular shaped organs [49]. Large variations
between reported results for these 3D studies is likely due to metho-
dological inconsistencies. It is apparent from the selected studies that
there is substantial variation in data collection, analysis and presenta-
tion of 3D volumes. This is mostly due to ultrasound machines having
proprietary file formats that prevent viewing and analysis of data sets
outside the specific machine brand. Universal standardisation of 3D file
formats and software, regardless of equipment used, is overdue.
All studies describe the technique utilised to acquire 3D data sets
and subsequent 3D volume calculations, however, the studies lack ex-
plicit image landmarks for volume acquisition and calliper placement
for volume measurement. This is necessary for any ultrasound mea-
surement to provide accurate and reproducible results. This is even
more crucial when calculating 3D volumes as several planes need to be
consistently demarcated and any error in calliper placement is multi-
plied over the volume [50].
By far the biggest issue compromising the evidence from all the
reviewed 3D volume studies is the lack of acceptable reproducibility
data. Two studies did not report any intra or inter-observer variability
[24,25]. The other four reported either only intra-observer variability,
when there was one operator [26,27], or both intra and inter-ob-
servability, if there was more than one operator [28,35]. Surprisingly
all four studies only assessed reproducibility on the analysis and mea-
surement of the already obtained 3D data set. Errors introduced during
acquisition of the 3D data set can be a considerable source of error.
Factors such as the depth of the kidney, the number and orientation of
the slices and movement of the patient, the fetus or the probe all affect
spatial accuracy and can significantly influence the 3D kidney volume
obtained [26]. It is important to assess the variability of the post-pro-
cessed images; however, it is illogical for all studies to ignore the
variability associated with 3D data acquisition.
Additionally, it was not clear in most studies how many operators
had obtained the 3D data sets and no information on their qualifications
and skill level. It was also unclear if the same person acquiring the data
was analysing the data. These omissions may considerably influence the
quality of the results. In most clinical settings ultrasound scans are
performed by multiple operators and variability is unavoidable. This
needs to be accounted for, or at least, it needs to be reported along with
what quality assurance steps were taken to try and maintain some
consistency and standardisation of measurements.
3D ultrasound equipment and software is expensive and not as
readily available as 2D ultrasound equipment. 3D imaging has a higher
workload than 2D measurements: longer acquisition times, followed by
time for post processing the volume of interest. The quality of the ac-
quired image significantly affects the 3D outcome. All studies report
that performing the 3D acquisition requires a “quiet” fetus which can
take substantial time to achieve [24]. In summary, the reviewed 3D
ultrasound studies had no acceptable evidence of true intra or inter-
observer variability and therefore good reliability and reproducibility
of 3D volumes has not yet been demonstrated.
Hyperechogenicity of the fetal kidneys may be associated with
disruption of kidney growth and changes in kidney function. Suranyi
et al. [29] investigated the echogenicity of the parenchyma and fetal
kidney size to establish a correlation with fetal hypoxia. Their findings,
however, are questionable for several reasons. Hyperechogenicity of the
kidney medullae was subjectively established by comparing the echo-
genicity of the kidney to the liver or spleen. The authors stated that
kidney hyperechogenicity was a sensitive sign of fetal hypoxia and they
appear to use this to determine severity of fetal hypoxia [29]. Renal
parenchymal echogenicity and corticomedullary differentiation are re-
ported in the literature, however, are yet to be validated [39]. In 2003,
as it is today, fetal medullary hyperechogenicity is not a validated or
clinically used method to establish the presence or absence of fetal
hypoxia.
During fetal hypoxia, blood flow is redistributed away from the
kidneys to more essential organs [51]. Suranyi et al. [29] propose that
this reduced kidney perfusion possibly delays fetal kidney development
resulting in hypoplasia of the kidney and a hyperechogenic appearance.
The role of the kidney parenchyma and blood flow in assessing fetal
kidney growth and future renal function has not yet been well eval-
uated. Preliminary data from term neonates [52] and children [53]
indicates parenchymal thickness may be a more reliable investigative
method to define normal and abnormal kidney development. More re-
search is needed to validate these propositions.
Magnetic resonance imaging (MRI) is being increasingly utilised to
image the fetal kidneys and provides excellent delineation of anatomy
[54]. Fetal kidney measurements and volumes have been described
with MRI [55,56]. There are still some safety concerns around MRI for
the fetus, such as biological effects and acoustic noise [54]. MRI is more
expensive than ultrasound, is limited by fetal movement, has several
contraindications and has similar problems to ultrasound with regards
to maternal obesity. Ultrasound imaging provides real-time images, is
non-invasive and relatively inexpensive and is still the modality of
choice for routine evaluation of fetal kidney growth [54,57].
4.1. Limitations
The search was restricted to English language and studies published
from the last 20 years (from 1996) as it was felt that the significant
advances in ultrasound imaging made these older studies less relevant.
The major limitation of this systematic review is most of the included
studies were of a cross-sectional design rather than longitudinal. Widely
variable gestational age ranges were analysed. Most studies involved
low-risk, uncomplicated pregnancies as most studies were establishing
normal ranges.
5. Conclusions
Following a review of 28 studies investigating fetal kidney growth
using ultrasound, we can conclude that the collective results provide
some normal ranges of 2D and 3D fetal kidney size and volume.
However, there are few large, good quality, longitudinal studies. There
is also a paucity of research into the effects of abnormal fetal growth,
particularly overgrowth, on fetal kidney development. Kidney length is
the most popular single fetal kidney measurement; however, it does not
seem to be a good indicator of growth. In IUGR fetuses, kidney length
remained similar to appropriately grown fetuses whereas antero-pos-
terior and transverse dimensions were significantly decreased.
Currently there is no easily reproducible, sensitive method for mea-
suring changes in fetal kidney growth. New ultrasound techniques
concentrating on the parenchyma of the kidney and the perfusion to the
kidney may provide improved information on fetal kidney develop-
ment.
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Appendix A. Medline Ovid (R) 1946 to 7th Jan 2017
1 Ultrasonography (MeSH term exploded) –– “computer echotomography” OR “diagnostic ultrasound*” OR echography OR echotomography OR
“medical sonography” OR “ultrasonic diagnoses” OR “ultrasonic diagnosis” OR “ultrasonic imaging” OR “ultrasonic tomography” OR
“ultrasound imaging*” OR sonography
2 Kidney* (MeSH term exploded)
3 Renal (keyword)
4 2 OR 3
5 Fetus (MeSH term exploded) – “fetal structure*” OR “fetal tissue*” OR fetuses
6 Prenatal (MeSH term exploded) – “antenatal diagnoses” OR antenatal diagnosis OR “antenatal screening*” OR “intrauterine diagnoses” OR
“intrauterine diagnosis” OR “prenatal diagnoses” OR “prenatal diagnosis” OR “prenatal screening*”
7 Foetus OR Foetal (keyword)
8 5 OR 6 OR 7
9 1 AND 4 AND 8
10 Limit 9 to yr = “1996–2016”
11 Limit 10 to English language
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AbstrAct
Introduction Disorders of fetal growth, such as 
intrauterine growth restriction (IUGR) and large for 
gestational age (LGA), have been found to have a profound 
effect on the development of the fetal kidney. Abnormal 
kidney development is associated with hypertension and 
chronic kidney disease later in life. This study will use 
a novel ultrasound measurement to assess the renal 
parenchymal growth and kidney arterial blood flow in the 
fetus to evaluate the development of the fetal kidneys 
and provide an indirect estimate of nephron number. 
Measurements in normally grown, IUGR and LGA fetuses 
will be compared to determine if changes in renal 
parenchymal growth can be detected in utero.
Methods and analysis This longitudinal, prospective, 
observational study will be conducted over 12 months 
in the Ultrasound Department of the Townsville Hospital, 
Australia. The study will compare fetal renal parenchymal 
thickness (RPT) and renal artery Doppler flow between 
IUGR fetuses and appropriately grown fetuses, and LGA 
fetuses and appropriately grown fetuses between 16 
and 40 weeks. The fetal RPT to renal volume ratio will 
also be compared, and correlations between RPT, renal 
parenchymal echogenicity, fetal Doppler indices and 
amniotic fluid levels will be analysed.
Ethics and dissemination This study was approved by 
the Townsville Health District Human Research Ethics 
Committee. The study results will form part of a thesis 
and will be published in peer-reviewed journals and 
disseminated at international conferences.
IntroductIon
Chronic kidney disease is an increasing 
contributor to the global burden of disease, 
with hypertension now the leading risk 
factor.1 Recognition of the risk factors and 
implementation of preventive strategies is 
crucial to reducing hypertension and kidney 
disease. Abnormalities in fetal growth, such as 
intrauterine growth restriction (IUGR), have 
a profound effect on the kidney develop-
ment.2 3 The association between an adverse 
intrauterine environment and chronic kidney 
disease later in life is now compelling.4–6 
During early fetal life, there is transient 
development and regression of the primary 
(pronephros) and secondary (mesonephros) 
fetal kidneys between day 23 and day 112 of 
embryonic life.7 The permanent functional 
tertiary fetal kidney is the metanephros which 
begins developing on day 30.7 Nephrogenesis 
involves the formation of the functional units 
of the kidney called nephrons and continues 
up to 36 weeks’ gestational age.8 9 It is essential 
that appropriate nephrogenesis is achieved in 
utero as the number and quality of nephrons 
directly influences lifetime kidney function.10
IUGR can result in a significant reduc-
tion in nephron number; however, large for 
gestational age (LGA), particularly related to 
maternal hyperglycaemia, is also associated 
with abnormal fetal kidney development and 
an increased risk of hypertension and chronic 
kidney disease.11 A better understanding 
of the relationship between abnormal 
fetal growth and nephrogenesis is needed. 
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Protocol
strengths and limitations of this study
 ► This will be the first study to use a novel ultrasound 
measurement of the fetal renal parenchyma and 
measurements of renal blood flow to assess fetal 
kidney growth.
 ► Fetal kidney growth will be assessed not only in 
normally grown but also in growth-restricted and 
large-for-gestational-age fetuses.
 ► This is a prospective, longitudinal, rather than cross-
sectional, ultrasound study and should enhance our 
understanding of how fetal kidneys grow.
 ► This study is the first of a series of studies 
investigating kidney growth, and although renal 
function and renal parenchymal thickness of the 
infants are not included in this study, follow-up of 
the infants will be included in future studies.
 ► Due to fetal position and/or maternal habitus, not all 
kidney measurements may be obtainable at every 
scan.
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Figure 1 Measurement of kidney length (1) and the anterior 
(2) and posterior (3) fetal renal parenchymal thickness from 
the inner aspect of the renal capsule to the sinus–pyramidal 
apex interface.
Presently, the only accurate method of calculating human 
nephron number is during an autopsy.12 A non-invasive 
measure of nephron endowment is needed.
Ultrasound is the primary imaging modality for evalu-
ating fetal kidneys. We conducted a systematic review on 
the evaluation of fetal kidney growth using ultrasound 
which revealed that there are few good-quality, longitu-
dinal studies.13 The most commonly reported ultrasound 
measurement was renal length; however, renal length 
alone was not found to be very sensitive to evaluate disrup-
tions in fetal kidney growth in the presence of fetal growth 
restriction.13 Few studies analysed the effects of IUGR on 
fetal kidney growth, and no studies have, to date, analysed 
if LGA has an effect on fetal kidney growth. Results from 
two-dimensional (2D) and three-dimensional (3D) renal 
volume (RV) calculations were disappointing. Volumes 
calculated from 2D measurements underestimate RVs by 
as much as 24%.14 Substantial variations were reported 
for ‘normal’ 3D kidney volumes, and good reliability 
and reproducibility has not yet been demonstrated. 
Currently, there is no easily repeatable, sensitive method 
of measuring changes in fetal kidney growth.13
Measuring the renal parenchyma with ultrasound is 
a novel method to assess fetal kidney development and 
predict future renal function. Measuring just the renal 
parenchyma will measure only the important func-
tional part of the kidney which contains the nephrons 
(figure 1). One small cross-sectional study measured fetal 
renal parenchyma in normally grown fetuses15; however, 
no studies have evaluated the fetal renal parenchyma in 
abnormally grown fetuses. Preliminary data from term 
neonates16 and children17 indicate that the parenchymal 
thickness may be a more reliable investigative method 
to define normal and abnormal kidney development. 
Methods such as measuring the parenchymal thickness, 
RV to parenchymal thickness ratio, renal artery Dopplers 
and echogenicity of the renal parenchyma are potential 
non-invasive methods to evaluate nephron endowment 
and future renal function.
The aim of this study is to use ultrasound to assess the 
fetal renal parenchymal growth in a pregnant population 
demonstrating either normal or abnormal growth and 
determine if abnormal fetal growth influences fetal renal 
parenchymal thickness (RPT). Non-invasive ultrasound 
techniques are used. The results could help identify 
factors that adversely affect kidney development so that 
they could be modified by public health interventions 
and education programmes. This may promote improved 
fetal nephron number and quality at birth and reduce 




 ► Determine normal RPT of fetuses from 16 to 40 weeks’ 
gestation from a group of normally grown fetuses.
 ► Determine the effects of IUGR and LGA on RPT in a 
group of abnormally grown fetuses.
Secondary objectives
 ► Assess the relationship between RPT and renal artery, 
umbilical artery and middle cerebral artery Doppler 
indices, and amniotic fluid levels.
 ► Assess the relationship between renal parenchymal 
echogenicity, renal artery Doppler flow and IUGR or 
LGA.
study design and setting
This is a prospective, longitudinal, observational study 
being conducted over 12 months, commencing in May 
2017, in the Ultrasound Department of the Townsville 
Hospital, Australia.
Participants
Patients who are referred for a diagnostic second 
trimester ultrasound scan will be recruited for this study. 
Pregnant women of 18 years or older, with an accurately 
dated singleton pregnancy of 16 weeks’ gestation or 
more, will be included. Pregnant women with uncertain 
dates, multiple pregnancy or any known major congenital 
fetal abnormality or chromosomal fetal abnormality will 
be excluded.
recruitment and consent of participants
Pregnant patients 18 years of age or older, who present 
to the Medical Imaging Department at the Townsville 
Hospital for an obstetric ultrasound, will be invited to 
participate. In addition, mixed risk patients may also be 
informed about the study by their treating obstetrician, 
midwife or sonographer. Detailed written information 
will be given to the patient and written consent obtained.
study process
Figure 2 outlines the flow schedule of the participants. 
The first ultrasound scan will be performed from 16 
weeks and then follow-up ultrasounds will be performed 
at least every 4 weeks from the first ultrasound scan. Some 
women, particularly with high-risk pregnancies, will 
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Figure 2 Flow chart of study participants.
require more than one clinically indicated ultrasound. 
For example, women with a growth-restricted fetus may 
need to be monitored by ultrasound monthly or more 
frequently. However, the control group of healthy women, 
with appropriately grown fetuses, may only require one to 
two clinically indicated scans between 16 and 40 weeks’ 
gestation. To obtain good longitudinal data, particularly 
for the control group, the women will be asked to attend 
for additional research scans every 4 weeks until delivery.
ultrasound examinations
Australian Accredited Medical Sonographers with at 
least 2 years’ postultrasound qualification experience 
will perform all ultrasound examinations. A high-level 
ultrasound machine with pulse wave and colour Doppler 
flow will be used, and the highest frequency transducer 
possible, matching the mother’s body habitus, will be 
selected. When a woman attends for a clinically indicated 
scan, this will be the priority, and then the additional fetal 
renal measurements required for the research study will 
be performed thereafter.
Where possible, the fetal kidneys should be measured 
with the fetal spine up (anterior) or as close as possible to 
this position. The image is magnified so that the kidney 
occupies most of the image and both kidneys can be 
identified. A midsagittal scan of both kidneys along their 
longest length will be recorded and the longest length (L) 
of both kidneys measured. The parenchymal thickness 
will be measured in two directions: from the posterior 
aspect of the kidney to the pelvis (posterior parenchyma) 
and from the anterior border of the kidney to the pelvis 
(anterior parenchyma) (figure 1). A transverse section of 
the fetal abdomen at the level of each renal pelvis will 
be imaged. The maximum anteroposterior diameter (H) 
and transverse diameter (W) will be measured for both 
kidneys.
Bilateral fetal renal artery Dopplers will be performed 
in the coronal view of the kidneys. Colour flow should be 
used to identify the renal artery entering the kidney. A 
low wall filter of between 30 and 60 Hz will be used, and 
a sample gate of size 2–3 mm will be placed in the mid 
trunk of the renal artery. Using an angle as close to 0° as 
possible, a pulse wave signal will be obtained. The average 
of three consecutive waveforms will be used to calculate 
the resistivity index (RI) and pulsatility index (PI).
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Table 1 After baby’s birth, perinatal data to be collected 
from the mother and baby’s electronic medical record
Birth data to be 
collected









Gender Maternal medical 
history:






 ► Renal disease
Base excess  ► Hypertension
Lactate Demographic, medical 
and obstetric history 
from participant 
questionnaire
The following routinely performed obstetric measure-
ments will also be recorded for the study:
 ► Single deepest pool amniotic fluid measurement;
 ► Umbilical artery Doppler;
 ► Middle cerebral artery Doppler (where clinically indi-
cated or 30 weeks’ gestation and over);
 ► Ductus venous, where clinically indicated;
 ► Biometries—head circumference (HC), biparietal 




Perinatal data will be collected from the mother and 
baby’s electronic medical record (table 1).
Primary outcome measure
 ► RPT: anterior and posterior thickness in longitudinal 
plane.
Secondary outcome measures
 ► RV: calculated using the formula 
RV=length×width×height×0.523;
 ► Fetal growth biometries: HC, BPD, AC and FL;
 ► Amniotic fluid: single deepest pool;
 ► Umbilical artery Doppler flow: RI and PI calcu-
lated from the average of at least three consecutive 
waveforms;
 ► Middle cerebral artery Doppler flow: RI and PI calcu-
lated from the average of at least three consecutive 
waveforms;
 ► Renal parenchymal echogenicity: subjectively assessed 
by the sonographer as either normal echogenicity, 
more hyperechoic than normal or more hypoechoic 
than normal;
 ► Renal artery Doppler flow: RI and PI calculated from 
the average of at least three consecutive waveforms.
sample size
Optimal sample size has been calculated based on a 
statistical power of 80% and a significance level of 0.05 
(two-tailed). Data from a previously published study16 
have demonstrated that the RPT was 9.4 mm (±1.1 mm) 
for normal birth weight neonates and 8.3 mm (±1.0 mm) 
for low birth weight neonates at term. Therefore, it is esti-
mated that a sample size of 45 will be needed (15 intra-
uterine growth-restricted fetuses, 15 LGA fetuses and 15 
appropriate for gestational age (AGA)). Allowing for 
the possibility of loss to follow-up, 20 participants will be 
recruited for each group resulting in a total of 60 partici-
pants, each having an ultrasound scan every 4 weeks.
data analysis
After the ultrasound examination is complete, and the 
baby is born, all data will be collated and divided into 
three groups: AGA, IUGR and LGA. Comparisons of 
RPT and renal artery Dopplers between IUGR and AGA 
fetuses, and LGA and AGA fetuses between 16 and 40 
weeks will be analysed. RV will be compared with RPT in 
each fetal group to obtain an RPT to RV ratio. Correla-
tion between RPT, renal parenchymal echogenicity, fetal 
Doppler indices and amniotic fluid levels will be carried 
out, and intraobserver and interobserver variability will 
be assessed.
Statistical analysis will be performed using IBM SPSS 
Statistics, V.24.0. The normality of the variables will be 
determined by the Kolmogorov-Smirnov test. Renal 
measurements will be expressed as means±SDs for 
continuous, normally distributed data and as a median 
(IQR) for continuous, non-normally distributed data. 
Paired/unpaired t-tests will be used to compare means 
of normally distributed data and Mann-Whitney or 
Kruskal-Wallis tests for non-normally distributed data. 
A value of P<0.05 will be considered statistically signifi-
cant. Univariate and multivariate analysis will be carried 
out to determine the association between RPT and 
other variables. Intraobserver variability will be deter-
mined by calculating the differences between the two 
measurements made by the same sonographer. Interob-
server variability will be assessed by calculating the 
differences between two measurements carried out on 
the same patient by different sonographers.
Data management
Data collection commenced in May 2017 and is planned 
to finish in December 2018 once the birth data of all 
participants are obtained. Participant data will be deiden-
tified and assigned a number code to ensure confidenti-
ality for each woman and baby.
Electronic data will be stored and saved on a pass-
word-protected computer. Hard (paper) copies of the 
consent form, questionnaire and data sheets from the 
ultrasound examination will be stored in a locked filing 
cabinet in the principal researcher’s office. This office 
is a secure room within the ultrasound department of 
the Townsville Hospital. Only the principal researcher 
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and members of the research team will have access to 
the data.
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Abstract
Objective: The objective of this study was to develop new standard growth charts
for fetal renal parenchymal thickness, length, and volume to define normal ranges for
use in clinical practice and to assess the reliability of these measurements.
Methods: This was a prospective, longitudinal study of 72 low-risk singleton preg-
nancies undergoing serial ultrasound examinations at least every four weeks. Multiple
renal measurements were performed on both kidneys at each scan. The renal paren-
chymal thickness was measured in the mid-sagittal plane. Standard charts were
developed and the intra and interobserver reliability for the renal measurements was
analysed.
Results: Standard charts were developed for fetal renal parenchymal thickness,
length, and volume.
Conclusion: We present novel charts, which demonstrate the growth of the fetal
renal parenchyma during pregnancy. They will be useful in clinical practice to identify
any alterations from these normal ranges, which may be an important criterion for
assisting prenatal diagnosis of renal pathologies and future studies in the prediction
of kidney function.
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Abstract
Chronic kidney disease continues to be under recognised and is associated with a significant
global health burden and costs. An adverse intrauterine environment may result in a depleted
nephron number and an increased risk of chronic kidney disease. Antenatal ultrasound was
used to measure the foetal renal parenchymal thickness (RPT), as a novel method to estimate
nephron number. Foetal renal artery blood flow was also assessed. This prospective,
longitudinal study evaluated the foetal kidneys of 102 appropriately grown and 30 foetal
growth-restricted foetuses between 20 and 37 weeks gestational age (GA) to provide vital
knowledge on the influences foetal growth restriction has on the developing kidneys. The foetal
RPT and renal artery blood flow were measured at least every 4 weeks using ultrasound. The
RPT was found to be significantly thinner in growth-restricted foetuses compared to appropri-
ately grown foetuses [likelihood ratio (LR)= 21.06, P≤ 0.0001] and the difference increases
with GA. In foetuses with the same head circumference, a growth-restricted foetus was more
likely to have a thinner parenchyma than an appropriately grown foetus (LR= 8.9, P= 0.0028),
supporting the principle that growth-restricted foetuses preferentially shunt blood towards the
brain. No significant difference was seen in the renal arteries between appropriately grown and
growth-restricted foetuses. Measurement of the RPT appears to be a more sensitive measure
than current methods. It has the potential to identify infants with a possible reduced nephron
endowment allowing for monitoring and interventions to be focused on individuals at a higher
risk of developing future hypertension and chronic kidney disease.
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